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Basal Cell Carcinoma (BCC) is the most common type of skin cancer; its 
development is associated with mutational inactivation of the PTCH1 tumour 
suppressor gene leading to deregulation of the Hedgehog pathway through increased 
expression of the downstream GLI (GLI1 and GLI2) transcription factors. The high 
expression of GLI1 and GLI2 has also been shown to be maintained through a 
positive feedback mechanism in human keratinocytes, but this has partly relied upon 
mRNA expression and has not been fully explored at the protein level. Moreover, 
expression analysis in human BCCs has largely relied upon in situ hybridization or 
RT-PCR and no studies have investigated co-expression of the GLI1 and GLI2 
proteins. 
Whereas an active mutant of GLI2 (GLI2N) has been shown to increase 
endogenous GLI1 protein expression in normal human keratinocytes, preliminary 
evidence suggests that ectopic GLI1 suppresses endogenous GLI2 protein 
expression, which refutes the presence of a positive GLI feedback loop. In human 
BCC samples, there was a relatively high degree of heterogeneity in the expression 
pattern of GLI1 and GLI2 with the various antibodies employed and this was also 
affected by how the tissue was processed i.e. frozen versus formalin-fixed. 
Surprisingly, many BCCs displayed strong epidermal GLI1 expression that was 
decreased in the basal layer and tumour islands. In most tumours GLI1 and GLI2 
showed areas of co-expression, but this was not uniform and in many areas one 
protein was more abundant than the other. Moreover, there was no clear difference in 
the expression level of GLI1 or GLI2 between BCC subtypes (aggressive versus non-
aggressive). Finally, one antibody (GLI1 H-300) detected strong GLI1 expression in 
mesenchymal cells surrounding tumour islands (in frozen samples) but this did not 
correlate with epithelial Sonic Hedgehog ligand expression, suggesting a lack of 
paracrine Hedgehog signalling in BCC biology. In summary, this project has shown 
that GLI regulation and expression are more complex than previous studies have 
suggested and that research in this field is hampered by a lack of consistency and 
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1.1 The skin 
1.1.1 Structure of the skin  
Skin is the largest organ of the body and performs a vital role in acting as barrier 
against the outside world, as it prevents the ingress of harmful chemicals and 
pathogenic organisms. The skin is composed by three layers: the epidermis, dermis, 
and the subcutaneous layer (fat layer) (Fig. 1.1 a).  
The epidermis is a stratified structure mainly composed by keratinocytes; scattered 
throughout the epidermis there are also melanocytes, responsible for skin 
pigmentation, Langerhans' cells, which are part of the immune system and Merkel 
cells which have sensory roles (Freinkel and Woodley, 2001). The epidermis is a 
continually renewing epithelia in a basal to superficial direction: the end point is 
terminally differentiated and metabolically inactive keratinocytes known as 
corneocytes which are periodically shed from the skin surface. The dermis is a thick 
layer of fibrous and elastic tissue (made mostly of collagen, elastin, and fibrillin) that 
gives the skin its flexibility and strength, but is also involved in the regulation of the 
body temperature. The subcutaneous layer helps insulate the body from heat and cold 
and serves as an energy storage area where fat cells are held together by fibrous 
tissue.  
Hair follicles (see section 1.2) are skin appendages that consist of downward growths 
of epidermal tissue into the dermis in which hair is produced. In the deep dermis 
there are also sebaceous glands that connect to the surface of the skin through sweat 
ducts: the hair follicle and associated sebaceous gland are named the ‘pilosebaceous 
unit’. 
1.1.2 Layers of the epidermis 
The epidermis is divided into layers (basal, spinous, granular and cornified)(Fig. 1.1 
b) which can be distinguished histologically and correspond to distinct stages in the 
differentiation of the keratinocyte (Freinkel and Woodley, 2001). 
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The basal layer is a single layer of cells located at the dermal-epidermal junction. 
Keratinocytes proliferation takes place exclusively in the basal layer and the cells 
generated undergo a differentiation process as they are displaced outwards until they 
reach the outer surface of the epidermis where they are shed. Maintenance of 
epidermal homeostasis depends upon a fine balance between cell proliferation in the 
basal layer and cell death in the stratum corneum. Keratinocyte regeneration is 
maintained by stem cells resident in the basal cell layer: these cells divide 
asymmetrically to generate a transient-amplifying cell which gives rise to a basal 
keratinocyte and a stem cell to maintain the stem cell pool. In addition to the basal 
layer, skin epidermal stem cells are also found in the hair follicle bulge and at the 
base of the sebaceous glands (Watt et al., 2006). Next to the basal layer is the 
spinous layer which consists of multiple rows of keratinocytes in which the synthesis 
of characteristic keratins, proteins and lipids takes place. Lamellar granules are also 
synthetised; these lipid-rich structures are later discharged into the intercellular space 
and contribute to the water-proof qualities of the epidermis. On top of the spinous 
layer sits the granular layer; granular keratinocytes are characterized by keratohyalin 
granules composed of proteins profilaggrin, locrin and keratins intermediate 
filaments. The stratum lucidum is an additional epidermis layer only found in thick 
skin (the palms of the hands and the soles of the feet) that helps reduce friction forces 
between the stratum corneum and stratum granulosum. During the transition from the 
granular to the cornified layer keratinocytes become metabolically inactive losing 
their organelles and nuclei, while lipids are released into the extracellular space. 
Corneocytes are composed by 80% keratins which linked with lipids provide a 
waterproof barrier. When corneocytes reach the surface of the epidermis they 
become less tightly associated with each other as desmosomes undergo proteolytic 
degradation and are eventually shed into the environment. The process of 
differentiation in the epidermis is also known as keratinisation: all keratinocytes 
contain cytoplasmic keratin filaments, the nature of which is dependent upon their 
location within the epidermis. The keratins serve a structural role and are classified 
as either acidic (type I, keratins K10 to K20) and basic (type II, keratins K1 to K9). 
Keratins assemble into filaments as obligate heteropolimers, meaning a member of 
each family (acidic and basic) must be coexpressed and form a filament structure 
(Freinkel and Woodley, 2001). Basal keratinocytes contain bundles of K5 and K14, 
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while K1 and K10 are newly synthesized in the spinous keratinocytes. In 
hyperproliferative epidermis, such as during wound healing, K1 and K10 are 
downregulated while K6 is induced. Keratin K2e is a marker of late epithelial 
differentiation.  
Keratinocytes in the epidermis are connected to each others through protein adhesion 
structures named desmosomes; keratinocytes in the basal layer are anchored to the 
basement membrane via hemidesmosomes. Attachment of the epidermis to the 
underlying dermis is mediated by adhesive interactions between the basal 
keratinocytes and the basement membrane, which contains a layer of proteins 
including laminins, collagens and fibronectin. These extracellular matrix proteins 
serve as ligands for integrin receptors expressed on basal keratinocytes, which 














Figure 1.1: Anatomy of the skin and structure of the epidermis  
 
Diagram of the skin, showing the epidermis, dermis, and subcutaneous layer (a) and section 
of epidermis highlighting the different cell layers present in the epidermis (b).  
(Modified from http://www.cancer.gov/cancertopics/pdq/treatment/skin/Patient and Alonso 















1.2 The Hair Follicle  
Hair follicles are mammalian skin appendages that produce hairs, whose functions 
include thermoregulation, sensory information collection and social communication 
(Stenn and Paus, 2001; Botchkarev and Paus, 2003) (Fig. 1.2a). The hair follicle 
develops during embryogenesis and consists of three concentric cylinders: the central 
one is the hair fiber, the middle one constitutes the inner root sheath (IRS) and the 
outermost one the outer root sheath (ORS) (Stenn and Paus, 2001). At the base of the 
hair follicle is located a region containing specialized dermal cells, named the dermal 
papilla. Hair follicles contain two major types of cell: dermal papilla cells, derived 
from the mesenchyme, and epithelial cells of the root sheaths and hair fiber, derived 
from the epithelium (Hardy, 1992). The sebaceous gland buds from the upper outer 
root sheath; sebocytes secrete lipid-rich sebum into the hair canal that empties out to 
the skin surface.  
All mature follicles undergo successive cycles consisting of phases of active growth 
(anagen), followed by regression (catagen) and inactivity (telogen) (Fig. 1.2 b). 
During each anagen phase a new hair fiber is produced, while in the catagen phase 
the follicle partially degenerates and the hair moves it towards the skin surface for 
subsequent shedding. Telogen is a phase of relative quiescence before the follicle 
receives new signals that would determine its re-entry into anagen. 
At a molecular level, the Sonic Hedgehog (SHH) (see section 1.4), WNT/-catenin 
(WNT) (see section 1.9) and Bone Mophogenic Protein (BMP) signalling pathways 
are involved in both hair follicle morphogenesis and adult hair cycle. BMP factors 
together with WNT and SHH activating signals stimulates hair-follicle induction 
during embryogenesis (Botchkarev and Paus, 2003). Hedgehog signalling (HH) is 
required for hair morphogenesis during embryonic development: in Sonic Hedgehog 
(SHH) knockout mice no mature hair follicles are present as formation of the dermal 
papilla fails to occur (St-Jacques et al., 1998; Chiang et al., 1999). Overexpression of 
a stabilized form of -catenin (which mimics activated WNT signalling) induces de- 
novo formation of hair follicles in the skin of transgenic mice (Gat et al., 1998). 
Also, transient activation of -catenin signaling in adult mouse epidermis is 
sufficient to induce new hair follicles and growth of existing follicles (Lo Celso et 
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al., 2004). Reciprocally, loss of -catenin expression in mice does not allow hair 
follicle development (Huelsken et al., 2001). As SHH expression is absent in -
catenin knockout mice, SHH signaling has been proposed to act downstream of 
WNT signalling in hair follicle development (Huelsken et al., 2001). Hedgehog 
signaling also plays a key role in adult hair follicle growth (Sato et al., 1999; Wang 
et al., 2000b) in association with the WNT signalling pathway. Whereas SHH 
signaling is responsible for the downgrowth of the follicular epithelium to form a 
follicle, WNT/-catenin signaling has a key role in initiating formation of the hair 
bud (in adult mice skin the hair follicle is unable to enter anagen following β-catenin 




























Figure 1.2: Hair follicle structure and hair cycle 
Schematic representation of a hair follicle (a) and of hair follicle morphogenesis and hair 





1.3 Basal Cell Carcinoma 
1.3.1 Incidence and aetiology 
Basal Cell Carcinoma (BCC) is the most common malignant cancer that affects the 
Caucasian population and its incidence rate is on the increase (Crowson, 2006). 
Although rarely metastatic, it is capable of extensive local growth and its surgical 
extirpation can have adverse cosmetic effect since they are most common on the 
head and neck region (Miller, 1995). Known risk factors for BCC development 
include ultraviolet light, exposure to arsenic or ionizing radiation, and a 
compromised immune system (Crowson, 2006). The molecular mechanisms 
underlying BCC development, which involve deregulation of the Hedgehog pathway, 
were deduced from studies of a rare hereditary disorder, Gorlin’s syndrome, which is 
characterized by hundreds of these tumours (Gorlin, 1995; Hahn et al., 1996b).  
1.3.2 Classification 
Basal Cell Carcinomas can be broadly classified into three subtypes on the basis of 
their histological appearance: Nodular, Micronodular, Superficial, and Morpheic / 
Infiltrative, the latter being the less frequent but most aggressive type (Crowson, 
2006) (Fig. 1.3). 
Nodular BCC, the most common subtype, begins as a papule or nodule on or within 
the skin, which grows slowly and has a pearly translucence. These BCCs are 
characterized by discrete nests of basaloid cells; tumour cells tend to align more 
densely in a palisading pattern at the periphery of the nests. Nodular BCCs can 
become very large and destroy deeper structures. Micronodular BCCs are 
histologically similar to Nodular BCCs, manifesting as tumour nests of basaloid 
cells, although they tend to be smaller and widely dispersed. Superficial BCC lesions 
appear as flat wrinkled superficial ulcerations, often larger than 1 cm in diameter. 
Histologically they appear as aggregates of basaloid cells located within and just 
underneath the epidermis. Morphoeic and Infiltrative BCCs appear as plaques with 
irregular contours and small irregular  islands of tumour cells embedded in a heavily 
collagenized fibrous stroma (Halpern and Hanson, 2004). Histologically they present 














Figure 1.3: Histological analysis of Basal Cell Carcinomas belonging to different 
subtypes 
Haematoxylin and eosin staining of nodular (a), superficial (b), micronodular (c) and 








1.3.3 Origin of Basal Cell Carcinoma  
The molecular mechanisms underlying Basal Cell Carcinoma development, which 
involve deregulation of the Hedgehog pathway (see section 1.7), were deduced from 
studies of a rare hereditary disorder, Gorlin’s syndrome, which is characterized by 
hundreds of these tumours (Gorlin, 1995; Hahn et al., 1996b). Since mutations 
affecting the Hedgehog pathway result in the development of BCC and SHH activity 
in the skin is mostly confined to hair follicles, it has been hypothesized that cells of 
the hair follicle may be an important target for BCC carcinogenesis; alternatively, 
BCC may also originate from the basal layer of interfollicular epidermis that, as a 
result of oncogenic mutation, are able to re-enter into the into the cell cycle. 
Different theories regarding the cell of origin of BCCs are present in the literature. 
BCCs have been proposed to derive from basal keratinocytes of the interfollicular 
epidermis which are positive for the expression of keratin 5 and keratin 14 and 
negative for differentiation markers (Miller, 1995; Crowson, 2006) this is consistent 
with the role of SHH pathway in skin, which is implicated in the maintenance of the 
epidermal stem cell population present in the epidermal basal layer and in the hair 
follicle bulge (Blanpain and Fuchs, 2006). Due to the role of SHH signaling in the 
hair follicle morphogenesis and cycle, these tumours may also be derived from 
undifferentiated cells of the outer root sheath of the hair follicle (Blanpain and Fuchs, 
2006)Blanpain and Fuchs, 2006; Crowson, 2006; Hutchin et al., 2005).   
Upon wounding, follicular stem cells migrate and contribute to the healed wound 
epithelium; using different genetic mouse models of BCC, it has been shown that 
oncogene-expressing follicular stem cells promote the formation of BCCs after 
wounding (Kasper et al., 2011; Wong and Reiter, 2011). The neuroepithelial stem 
cell marker nestin, which is expressed in the hair follicle papilla, is also present in the 
stroma of BCCs, suggesting a similarity between the BCC stroma and the 
mesenchyme surrounding of the hair follicle (Sellheyer and Krahl, 2011). Recently, 
some papers have tried to identify the cell of origin of BCC by taking advantage of 
mouse models expressing HH pathway components in specific skin regions. In 
Youssef et al. (Youssef et al., 2010),  an activated form of SMO (SMOM2, see 
section 1.4) is conditionally expressed in either hair follicle bulge stem cells, hair 
follicle transit amplifying cells or basal epidermal cells (from which all other 
 35 
epidermal layer are generated). No BCC originating from bulge stem cells and their 
progenies were observed, while constitutive SMOM2 activation in basal 
keratinocytes leaded to tumour formation; BCC are therefore proposed to arise from 
interfollicular epidermis. Another recent publication uses a constitutively active form 
of GLI2 (GLI2ΔN, see section 1.8) and argues that tumor phenotype depends on the 
cell targeted and the level of oncogenic HH signaling, as well as the hair cycle 
proliferation phase (Grachtchouk et al., 2011). GLI2ΔN is proposed to be a more 
potent activator of HH signalling than SMOM2; GLI2ΔN induction in hair follicle 
stem cells gives rise to nodular BCCs, while its expression in interfollicular 
epidermis results in superficial BCCs. Nodular BCCs skin tumors arise from a subset 
of hair follicle stem cells that expresses the Lrg5 marker; moreover, GLI2ΔN 
induction during the anagen phase of the hair cycle enhances its tumorigenic 
properties. In Ptch1 heterozygous mice X-ray induced BCC develop from hair 
follicle bulge stem cells (Wang et al., 2011). Selective deletion of p53 enhances 
tumor formation from the hair follicle bulge and also leads to BCC development 
from the intefollicular epidermis; the latter event is due to increased SMO expression 
in interfollicular epidermis as a result of p53 loss. This could also partly explain the 
discrepancies with the result of Youssef et al., where BCCs are observed in 
interfollicular epidermis as a result of targeted expression of SMO, which is not 
expressed at a significative level in interfollicular skin of Ptch1 + / - mice. PTCH1 
may have non HH-related functions (Barnes et al., 2001) which are required for BCC 
formation from the hair follicle but not from the intefollicular epidermis in the 
presence of mutated SMO. Although expression of downstream HH pathway 
components result in murine BCC development, Ptch1 + / - mouse model are 
proposed to be a more relevant model of human BCC tumorigenesis as nearly 90% 






Treatment options for BCC include surgical excision, Moh’s micrographic surgery, 
curettage and electrodesiccation, cryosurgery, treatment with chemicals that interfere 
with DNA synthesis (5-Fluorouracil) or that modulate the immune response 
(Imiquimod) (Ceilley and Del Rosso, 2006). Recently, synthetic SMO inhibitors 
have been tested for the treatment of human BCC but have shown limited efficacy so 





















1.4 The Hedgehog signalling pathway 
The Hedgehog (HH) signaling pathway is one of the most fundamental signal 
transduction pathways in embryonic development and it is conserved from flies to 
humans (Hooper and Scott, 1989; Goodrich et al., 1996; Hahn et al., 1996a). 
Hedgehog was initially identified as a segment polarity gene that controls Drosophila 
embryonic pattern during a large-scale screen for mutations that impair the 
development in the fruit fly (Nussleinvolhard and Wieschaus, 1980)  
The pathway takes its name from its polypeptide ligand, called Hedgehog (HH) in 
Drosophila. Three vertebrate homologs of the Drosophila hedgehog gene have been 
identified: Sonic Hedgehog (SHH), Desert Hedgehog (DHH), and Indian Hedgehog 
(IHH) (Echelard et al., 1993). SHH is the most broadly expressed member of this 
family and most likely responsible for all the major effects on development of the 
brain, spinal cord, axial skeleton, and limbs (Chiang et al., 1996). IHH has been 
implicated in regulation of cartilage differentiation in the growth of long bones 
(Lanske et al., 1996; St-Jacques et al., 1999). DHH exerts its effect mainly in the 
developing germline and in Schwann cells of the peripheral nervous system (Bitgood 
et al., 1996; Mirsky et al., 1999). Sonic Hedgehog ligand (SHH) is the most widely 
expressed Hedgehog ligand (Chiang et al., 1996); it encodes a 45 kDa protein that 
undergoes autocatalytic cleavage and modification to give a 20 kDa active N-
terminal fragment covalently bound to cholesterol (Porter et al., 1996).  
The Patched gene (PTCH) was originally identified in Drosophila: in humans it 
consists of 23 exons and encodes a glycoprotein with 12 membrane-spanning 
domains (Hooper and Scott, 1989; Nakano et al., 1989) and two large extracellular 
loops that are required for Hedgehog ligand binding (Marigo et al., 1996) (Stone et 
al., 1996). There are two Patched genes in humans: Patched 1 (PTCH1) is the major 
receptor molecule for all three forms of Hedgehog ligand, and mutations in this gene 
are associated with a wide variety of birth defects and development of specific 
tumours. (Hahn et al., 1996a; Goodrich et al., 1997). Patched 2 (PTCH2) is a close 
homolog of Patched, which function is still unclear (Smyth et al., 1999). From here 
onward Patched1 (PTCH1) will be referred as PTCH unless otherwise specified. 
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Smoothened (SMO) is a 115 kDa protein containing seven membrane spanning 
domains which shows structural similarity to serpentine G-protein coupled receptors 
(Alcedo et al., 1996; vandenHeuvel and Ingham, 1996). 
The Hedgehog signal is received and transduced via a receptor complex consisting of 
PTCH1 and SMO. The exact nature of the interaction between PTCH1 and SMO is 
still unclear, but it involves change in the cellular localization and stability of PTCH1 
and SMO upon Hedgehog ligand binding (Denef et al., 2000). Under physiological 
condition PTCH1 localisation to the cellular cilia inhibits Hedgehog signaling by 
excluding SMO (Rohatgi et al., 2007); upon ligand binding SMO translocates to the 
cilia, where it activates the transduction cascade leading to the activation of the GLI 
transcription factors (Fig. 1.4). The net effect of pathway stimulation is the activation 
of members of the GLI family of zinc finger transcription factors (Kasper et al., 
2006) (see section 1.8). In the absence of ligand, GLI proteins are linked to the 
cytoskeleton by interaction with a multiprotein complex that includes Fused (Fu) and 
Suppressor of fused (SuFu) (Murone et al., 2000). Upon ligand binding GLI proteins 
are translocated into the nucleus (Kogerman et al., 1999; Sheng et al., 2006) where 
they activate transcription of target genes, including genes involved in cell 
proliferation (e.g. cyclin D), apoptosis (Bcl2, c-Flip), invasion (Snail), and 
maintenance of the stem cell pool (Sox-9) (Duman-Scheel et al., 2002; Mill et al., 
2003; Aberger and Frischauf, 2006; Kasper et al., 2006). GLI target genes include 
PTCH1 itself (Nilsson et al., 2000). A negative feedback loop of PTCH1 on GLI1 
has recently been described (Rahnama et al., 2006). This effect is observed even in 
the presence of the Hedgehog pathway inhibitor cyclopamine. Moreover, PTCH1 C-
terminal region (proposed to play a role in HH/SMO signalling) is dispensable for 
this inhibition, indicating this effect is independent of canonical Hedgehog signaling. 
Recent evidence indicates that Hedgehog pathway remains active in a subset of cells 
in the adult (stem cells) (Ruiz i Altaba et al., 2002) and contribute to tissue 
homeostasis in some organs, including the skin. Aberrant reactivation of Hedgehog 
pathway in adult tissue has been linked with development of different types of cancer 








Figure 1.4: The Hegdehog signalling pathway 
Diagram of the Hedgehog signalling pathway main components in the absence (left) or in the 












1.5 Hedgehog signalling in cancer 
Hedgehog signalling deregulation due to mutation in the pathway components has 
been shown to cause formation of Basal Cell Carcinoma (BCC), a nonmelanoma skin 
cancer, and of medulloblastomas, a primitive neuroectodermal tumour of the brain 
(di Magliano and Hebrok, 2003); mutations in Hedgehog pathway components have 
been found both in familial and sporadic cases of BCC. 
Interestingly, Hedgehog signalling seems to be required also for the growth and 
maintenance of other types of cancer, including pancreas, prostate, lung and 
digestive tract (Berman et al., 2003; Watkins et al., 2003; Karhadkar et al., 2004; 
Nolan-Stevaux et al., 2009) which are caused by mutations in different pathways 
(Thayer et al., 2003; Watkins et al., 2003; Karhadkar et al., 2004; Sarangi et al., 
2009; Zhao et al., 2009). This discovery could have important therapeutic 
implication as Hedgehog signalling inhibitors could be an alternative approach for 
tumours that are difficult to treat by conventional means. 
1.5.1 Antagonists of Hedgehog signalling 
Screens of different molecules have led to the identification of several diverse 
antagonists of Hedgehog signalling, some of which may have potential therapeutic 
application. The first Hedgehog signalling antagonist discovered was cyclopamine, a 
steroidal alkaloid found in lily (Veratrum californicum). When pregnant sheep ate 
lilies, this resulted in severe holoprosencephaly in developing embryos, also referred 
as ‘cyclopia’; the relevant chemical from the lily was then named 'cyclopamine'. 
Holoprosencephaly (HPE) is a developmental disorder characterized by an absence 
of midline facial structures and development of fused nasal chambers at a location 
overlying a cyclopic eye. As holoprosencephaly is also a characteristic feature of 
SHH-/- knockout mice (Chiang et al., 1996) and  human HPE is associated with loss 
of function mutation at the human SHH locus (Belloni et al., 1996), it was suggested 
that cyclopamine works by repressing the Hedgehog pathway (Cooper et al., 1998) 
acting on the SMO protein (Taipale et al., 2000). Cyclopamine inhibits the growth of 
human medulloblastoma and glioma cell lines (Dahmane et al., 2001) and also of 
mouse embryonic fibroblasts (MEFs) lacking a functional copy of PTCH1 (Taipale 
et al., 2000): therefore, cyclopamine has been proposed as treatment for tumour 
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displaying aberrant activation of the Hedgehog pathway. KAAD-cyclopamine (3-
keto, N-aminoethyl-aminocaproyl-dihydrocinnamoyl-cyclopamine) is a potent 
synthetic cyclopamine derivative (Taipale et al., 2000) while SANT-1 (4-Benzyl-
piperazin-1-yl)-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethylene)-amine is a 
synthetic SMO antagonist. The use of cyclopamine and its derivative as cancer 
therapeutics is hindered by their teratogenic effects. A recently developed synthetic 
inhibitors of SMO, GDC-0449, has given promising preliminary results in the 
treatment of medulloblastoma and metastatic BCC (Von Hoff et al., 2009; Yauch et 
al., 2009). However, other anti-SMO inhibitors appear to be effective in reducing 
BCC tumour growth in mouse models but have shown limited success in the 
treatment of human BCCs (Williams et al., 2003; Tang et al., 2011). 
1.5.2 Paracrine Hedgehog signalling in cancer 
The interaction between tumour cells and stromal cells has been shown to be linked 
to the tumorigenic process and to play a fundamental role in tumour invasion. 
Recently, Hedgehog signalling has been proposed to regulate tumour growth by 
acting in a paracrine manner (Fig. 1.5). In mouse xenotrasplantation models of 
pancreatic and colorectal cancer the effect of Hedgehog ligands is not predominantly 
exerted in tumour cells; instead, the proteins are secreted to activate the Hedgehog 
pathway in non-malignant stromal cells (Yauch et al., 2008). This closely resemble 
the typical role of Hedgehog signalling in development, which is mediated by 
paracrine effects on mesenchymal cells (Ingham and McMahon, 2001). HH ligand 
produced by cancer cells activates the pathway in tumour stroma, which in turn 
affects tumour development, possibly by secretion of chemokines and growth-
promoting factors. Specific inhibition of Hedgehog signaling with Hedgehog 
pathway antagonist or by genetic deletion of SMO in the stroma of mice results in 
growth inhibition of HH ligand-expressing xenografts (Yauch et al., 2008). 
Additional evidence for paracrine Hedgehog signalling in cancer came from mouse 
models of pancreatic cancer (Nolan-Stevaux et al., 2009; Tian et al., 2009). 
Inhibition of Hedgehog signalling in the stroma has been shown to alter the secretion 
of factors, such as insulin-like growth factor receptor and WNT signalling pathway 
components, that are linked to cancer pathogenesis (Yauch et al., 2008; Scales and 
de Sauvage, 2009). Moreover, in a mice model of pancreatic cancer tumour-
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associated fibroblasts expressed GLI1 and also stained positive for vascular 
endothelial growth factor (VEGF) (Bailey et al., 2009). A better understanding of 
paracrine Hedgehog signaling mechanism in cancer can therefore be useful to 




Figure 1.5: Proposed autocrine and paracrine mode of Hedgehog signalling in 
cancer 
Requirement for autocrine Hedgehog signalling has been reported in epithelial tumours (a); 
recent publications also highlight a paracrine mode of Hedgehog action in cancer (b), in 
which the stromal compartment contributes to tumour formation via mechanisms that 

















1.6 Role of tissue stroma in cancer  
Epithelial cells are surrounded by the stroma, which is composed by the extracellular 
matrix (ECM) as well as cellular components such as fibroblasts and cells belonging 
to the immune and vascular systems.  
Cancer cells can modify their adjacent stroma through the expression of growth 
factors that promote angiogenesis and alter ECM protein expression, leading to 
increased inflammatory cell recruitment and also activating surrounding fibroblasts 
(Tlsty and Coussens, 2006). Activated fibrobroblasts play a prominent role in cancer 
progression via secretion of ECM components, growth factors, chemokine and 
proteases. The growth factors secreted by fibroblasts belongs to different families, 
including the fibroblast growth factor (FGF) family, the insulin-like growth factor 
(IGF) family, the epithelial growth factor (EGF) family, hepatocyte growth factor 
(HGF), the vascular endothelial growth factor family (VEGF) and the transforming 
growth factor (TGF-) family (Bhowmick et al., 2004). During malignant tumour 
progression cells acquire the ability to invade the surrounding tissues; specifically, 
keratinocytes are able to cross the basement membrane barrier by promoting 
extracellular matrix degradation and activating cell motility mechanisms (Liotta and 
Kohn, 2001). Degradation of basement membranes components is achieved by 
secretion of matrix metalloproteinase (MMP), while cytoskeletal changes favour 
migratory movement.  
The microenvironment of a tumour is constituted of a heterogenous population of 
stromal cells, extracellular matrix components and secreted factors, which make it 









1.7 Hedgehog signalling in Basal Cell Carcinoma 
Insight into the molecular mechanism underlying Basal Cell Carcinoma (BCC) 
development came from the study of Gorlin-Goltz’s syndrome, also known as 
Nevoid Basal Cell Carcinoma Syndrome (NBCCS) (Gorlin, 1995). Gorlin’s 
syndrome is an autosomal dominant condition that results in a variety of 
developmental and skeletal defects and is associated with an increased risk for some 
types of cancers, most notably BCCs, but also fibrosarcomas and 
rhabdomyosarcomas. Gorlin-Goltz’s syndrome maps to chromosome 9q22.3; the 
majority of sporadic BCCs display loss of heterozigosity on chromosome 9q22 
suggesting that inactivation of a tumour suppressor in this location is an important 
step in BCC formation (Gailani et al., 1996a). Tumour suppressor genes normally 
exert a negative control on cell growth, and inactivation of both homologues is 
required for a tumorigenic effect (Weinberg, 1995). In accordance with Knudson’s 
two hits hypothesis of tumorigenesis, heritable mutations in the human homologue of 
the Drosophila Patched gene were identified in patients with NBCCS syndrome and 
somatic loss of heterozygosity in the tumour suppressor Patched gene resulted in 
BCC development (Hahn et al., 1996b; Johnson et al., 1996). The Patched gene was 
originally identified as a gene regulating segmentation and polarity during 
Drosophila development (Hooper and Scott, 1989; Nakano et al., 1989). The 
transmembrane receptor PTCH1 is part of the Hedgehog pathway and it is conserved 
in eukaryotic organisms (Goodrich et al., 1996; Hahn et al., 1996a), where this 
pathway plays a role in development and tissue homeostasis. Mutations in the 
Patched gene (Gailani et al., 1996b; Gailani and Bale, 1997; Aszterbaum et al., 1998) 
and other components of the Hedgehog pathway were subsequently identified also in 
sporadic BCCs. The mutational spectrum of Patched in sporadic BCCs suggests that 
environmental factors other than ultraviolet B (UVB), the predominant carcinogenic 
component of sunlight, may play a role in tumorigenesis. UVB typically causes 
formation of photodimers that result in G·C to A·T transitions opposite dipyrimidine 
sites (Quinn, 1997). Mutations in p53 occur in ~50% of BCCs (Ziegler et al., 1993); 
less frequently occurring mutations in the Ras family of proto-oncogenes 
(Vanderschroeff et al., 1990) are often of the type caused by UVB.  However, only 
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about 50% of the Patched mutations in sporadic BCCs have the typical UVB 
signature (Gailani and Bale, 1997). 
Activation of SMO, similar to PTCH1 inactivation, result in transcription of 
Hedgehog target genes; activating mutations in the SMO gene (SMOM1, SMOM2) 
have been detected in of sporadic BCCs (Xie et al., 1998) SMOM2 mutation 
(Trp535Leu), which maps in the seventh transmembrane domain of SMO, has been 
detected in almost all BCCs lacking PTCH1 mutations. In contrast to wild-type 
SMO, the mutant form has been shown to result in BCC-like tumours in transgenic 
mice expressing this mutant gene under the control of an epidermal promoter (Yang 
et al., 2008). Other rare mutations in the Hedgehog pathway that causes BCC are 
Sonic Hedgehog ligand (SHH) activating mutations and possibly gain-of-function 
mutation in GLI proteins (Khavari, 2006). 
1.7.1 Other signaling pathways implicated in Basal Cell Carcinoma 
pathogenesis 
Hedgehog and WNT signalling have been shown to interact both in normal 
development (Mullor et al., 2001) and in vitro oncogenic cell transformation (Li et 
al., 2007). Cross talk between the Hedgehog and WNT pathways has also been 
suggested to be implicated in Basal Cell Carcinoma pathogenesis. In a mouse model 
of skin cancer activation of WNT signalling pathway has been shown to be required 
for the development of follicular hamartomas, a type of benign tumour associated 
with deregulated Hedgehog signalling (Yang et al., 2008). Constitutive activation of 
Hedgehog signaling by targeted expression of an oncogenic form of SMO (SMOM2) 
in the skin induces WNT signalling, and this induction is required for tumour 
development, as expression of the secreted WNT pathway inhibitor Dkk1 in the skin 
prevents tumour formation. In mice where activation of the secreted WNT inhibitor 
Dkk1 could be achieved in the skin compartment tumour formation was abolished. 
These results suggest WNT signaling inhibition as a potential therapeutic target in 
BCC, although further studies are required to address the importance of this 
interaction in human neoplasia.  
TGF pathway components (see section 1.10) have been shown to be present in the 
epithelial and stromal components of BCCs (Schmid et al., 1996; Furue et al., 1997; 
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Verhaegh et al., 1997; Gambichler et al., 2007) and to promote invasion by acting on 
the stroma (Marsh et al., 2008), although their precise role in the development of this 
epithelial tumour remains to be fully elucidated. TGF has been shown to induce 
GLI1 and GLI2 expression in keratinocytes and fibroblasts even in the presence of 
cyclopamine, suggesting this activation is not be dependent on canonical Hedgehog 























1.8 GLI proteins and their role in Basal Cell Carcinoma 
The GLI family of transcription protein control transcriptional programs in response 
to Hedgehog pathway activation. Following ligand binding GLI proteins translocate 
into the nucleus (Fig 1.6); three vertebrate Gli genes - Gli1, Gli2 and Gli3  have been 
identified (Kinzler et al., 1988; Ruppert et al., 1988). They regulate defined 
transcriptional programs in a context-dependent and cell-type specific manner.  
GLI1, GLI2, and GLI3 encode transcription factors that share five highly conserved 
tandem cysteine-histidine C2-H2 zinc fingers motif (F/YXCX2-4CX3FX5LX2HX3-
4HX5) and a consensus histidine-cysteine linker sequence between zinc fingers 
(Ruppert et al., 1988). The GLI1 and GLI3 proteins recognize a conserved 
GACCACCCA sequence in the promoters of target genes (Kinzler and Vogelstein, 
1990; Ruppert et al., 1990; Vortkamp et al., 1995), and GLI2 recognizes a nearly 
identical GAACCACCCA motif (Tanimura et al., 1998). Full length GLI proteins 
have been speculated to have activator as well as repressor functions, the latter as a 
result of carboxyl-terminal cleavage by the proteasome (Ruiz i Altaba et al., 2002). 
In the absence of Hedgehog signalling proteolytic processing leads to the formation 
of a GLI3 repressor form (GLI3-R) which represses GLI factor transcriptional 
activity (Wang et al., 2000a).  
GLI1 was originally identified as a gene that was amplified in human glioma 
(Kinzler et al., 1987) and subsequently shown to be a transcription factor that binds 
DNA in a sequence-specific manner (Kinzler and Vogelstein, 1990). GLI1 has been 
classified as an oncogene on the basis of its ability to transform cells in cooperation 
with adenovirus E1A (Ruppert et al., 1991). To date, different GLI1 isoforms have 
been described: GLI1N, which encodes an N-terminal truncated protein generated 
by skipping exons 2 and 3 (Shimokawa et al., 2008) and tGLI1, an in-frame deletion 
spanning the entire exon 3 and part of exon 4 (Lo et al., 2009). GLI1N is a less 
potent transcriptional activator compared to full-length GLI1; the expression ratio of 
the two GLI1 isoforms is greatly variable in tumour cell lines. tGLI1 has been 
discovered during the analysis of human glioblastoma multiforme samples and has 
been shown to confer enhanced migratory properties to cells. Moreover, other two 
GLI1 isoforms have been described by transfecting full length GLI1 into glioma cells 
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(Altaba, 1999; Stecca and Ruiz i Altaba, 2009), one deleted at the amino-terminal 
(positions 1 – 231) and the other missing a large portion at the carboxyl-terminal 
(position 515 to the end of the protein) (see also section 4.3.5 and Figure 4.53). 
GLI2N is a constitutively active form of GLI2 lacking the amino-terminal repressor 
domain (which was identified in 2005); this truncated form of GLI2 was thought to 
represent the whole protein but has been revealed to be a much more potent 
transcriptional activator than the full length GLI2 in vitro (Roessler et al., 2005). In 
the absence of HH ligand, full length GLI2 is a weak transcriptional activator; in 
response to Hedgehog signalling, proteolytic removal of the amino terminal repressor 
domain, or its inactivation, appears to be required for full GLI2 activator function 
(Roessler et al., 2005). Four different GLI2 isoforms have been described: alpha (), 
beta (), gamma () and delta (), whose transcripts are generated by combinations of 
two independent alternative splicing sites (Tanimura et al., 1998). Alternative 
splicings result in a 51-base deletion of the coding frame in the beta () and delta () 
isoforms, and a 1,231-base deletion in the gamma () and delta () isoforms. 
GLI3 has been reported to be phosphorylated by protein kinase A (PKA), casein 
kinase 1 (CK1), and glycogen synthase kinase 3β (GSK3β) and targeted for 
ubiquitination by β-TrCP ubiquitin ligase, in order to be converted into a truncated 
transcriptional N-terminal repressor (Wang et al., 2000a; Pan et al., 2006b). GLI2 
contains PKA and GSK3β phosphorylation sites, but appears to be inefficiently 
processed in vivo in mouse (Pan et al., 2006b). However, using a biochemical 
approach in different cell lines, several protein fragments smaller than full-length 
GLI2 have been detected, similarly to what has also been observed for GLI1 (Altaba, 
1999; Aza-Blanc et al., 2000). GLI2 has also been shown to be phosphorylated by 
PKA, CK1 and GSK3β in C-terminal activation domain (Pan et al., 2006a; Riobo et 
al., 2006b) and targeted for ubiquitination and proteasome mediated full protein 
degradation by β-TrCP ubiquitin ligase (Bhatia et al., 2006; Pan et al., 2006b). GLI1 
has also been shown to be degraded via the proteasome in vivo in mice (Huntzicker 




Figure 1.6: Components of the Hedgehog pathway in vertebrates. 
GLI factors are retained in the cytoplasm in association with the cytoskeleton (a), while in 
the presence of Sonic Hedgehog ligand (SHH) they traslocated to the nucleus when they 














1.8.1 Mouse models of Basal Cell Carcinoma 
GLI1 and GLI2 knockout mice display different phenotypes. In knockout mice, GLI2 
mutants which lacked most of the zinc-finger domains exhibited developmental 
defects in several organ systems including the skin (Mo et al., 1997; Ding et al., 
1998; Hardcastle et al., 1998; Motoyama et al., 1998). Conversely, mice homozygous 
for a mutation that removes most of the GLI1 zinc-finger domains develop normally 
(Matise et al., 1998; Park et al., 2000). However, overlapping function between GLI1 
and GLI2 in development also exist, as GLI2−/− developmental phenotype in mice 
can be substantially rescued by the expression of GLI1 from the GLI2 locus (Bai and 
Joyner, 2001). Both GLI1 and GLI2 result in epithelial tumours with characteristics 
of BCC when overexpressed in the basal epidermal layer of mice or frog skin 
(Dahmane et al., 1997; Grachtchouk et al., 2000; Nilsson et al., 2000; Sheng et al., 
2002). Targeted expression of human GLI2N in the basal layer of mouse skin 
results in basal cell carcinoma-like downgrowths indicating the ability to activate cell 
proliferation in a HH-independent manner similar to mouse GLI2N but not full-
length GLI2 (Grachtchouk et al., 2003; Mill et al., 2003; Hutchin et al., 2005). 
PTCH1 knockout mice (Ptch1 -/-) are not viable; mice who are heterozygous for 
PTCH1 (Ptch1 +/-) develop tumours similar to human trichoblastomas. Exposure to 
ultraviolet or ionizing radiation increases in the number of these tumours and cause 
their histology to be more similar to human BCCs (Aszterbaum et al., 1999; 
Mancuso et al., 2004). It is however still debated how closely these mice tumours 






1.8.2 In vitro models of Basal Cell Carcinoma and their use in elucidating 
GLI1 – GLI2 interactions  
Keratinocytes derived from BCC are been proven difficult to culture in vitro (Asada 
et al., 1992; Grando et al., 1996) and the reasons for this may include dependence of 
the tumours on the surrounding stroma. 
Expression of GLI factors in human keratinocyte cell lines helped dissected the 
potential molecular mechanisms by which GLI factors contribute to BCC 
tumorigenesis. GLI1 or GLI2N expression in human keratinocytes increases 
proliferation of cells in confluent cultures, possibly opposing cell cycle arrest of 
keratinocytes (Regl et al., 2004a). Using a gene expression profiling approach GLI2 
has been shown to induce genes involved in cell cycle progression and represses 
genes associated with epidermal differentiation (Regl et al., 2004a). GLI2 also 
contributes to tumorigenesis via the induction of Bcl-2 (Regl et al., 2004b), a key 
molecule involved in the prevention of the intrinsic apoptotic pathway, and by 
upregulating cFlip which antagonizes death ligand mediated apoptosis (Kump et al., 
2008). 
GLI1 expression in human keratinocytes has been shown to induce GLI2 mRNA; 
reciprocally, GLI2 specifically binds to the GLI1 promoter to induce its expression. 
Based on mRNA induction kinetics, activation of GLI2 by GLI1 is likely to be 
indirect (Regl et al., 2002) The in vivo relevance of the proposed GLI1-GLI2 
feedback for BCC development remains yet to be addressed. Ectopic GLI2 has also 
been shown to induce endogenous GLI1 protein expression in keratinocytes by 
Western Blotting; GLI2 protein induction by GLI1 was not analysed as no 
commercially available antibodies against GLI2 were available at the time (Ikram et 
al., 2004).   
In previous studies carried out in the Neill Group by Mr Sandeep Nadendla and Dr 
Graham Neill, an unexpected observation was made: GLI2 protein is downregulated 
upon ectopic expression of GLI1 in both primary prostate cells (PrEc) and 
immortalised keratinocytes (N/Tert-1). In Western Blotting analysis, ectopic GLI1 
suppresses a high molecular weight band corresponding to endogenous GLI2 in 
primary prostate epithelial cells (PrECs) (Fig. 1.7 a , lanes 1 and 2). Ectopic GLI2N 
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was expressed for comparison and two distinct bands were detected (Fig. 1.7 a, lane 
3): although the strength of the upper band may suggest it represents the ectopic 
protein, it is likely to be an endogenous isoform as its molecular weight is similar to 
the band detected in the pBabe lysate (Fig 1.7 a, lane 1); the lower band represents 
the ectopic mutant. A weak band representing endogenous GLI1 is detected in the 
PrEC-GLI2N lysates (Fig. 1.7 b, lane 3) which correlates with previously published 
work in human primary keratinocytes (Ikram et al., 2004). Subsequently, GLI2 
protein expression was analysed in N/Tert-1 keratinocytes overexpressing GLI1 
using the same vector system (pBabePuro) (work performed by Dr Graham Neill). 
As for PrECs, ectopic GLI1 suppressed the expression of a high molecular weight 
band corresponding to endogenous GLI2 (Fig. 1.8, cf. lanes 1 and 2). However, a 
slightly lower molecular weight band was also observed (Fig. 1.8, lane 2). To help 
identify this band, N/Tert-1 GLI2N lysates were included for comparison (Fig. 1.8, 
lane 3). Three bands were detected: the highest band represents endogenous GLI2; 
the middle band co-migrates with the lower band in N/Tert-1 GLI1 lysates; the 
lowest band represents ectopic GLI2N as it is unique to lane 3. By comparison with 
the upper and lowest band, the middle band in lane 3, which is also detected in 
N/Tert-1 GLI1 (lane 2), could represent a GLI2 degradation or cleaved product or, 
alternatively, a novel GLI2 isoform (i.e. because ectopic GLI2N induces 
endogenous GLI1 which may in turn induce this isoform) but this is unlikely because 
the expression of ectopic GLI2N is weak and because no induction of endogenous 
GLI1 was actually observed by Western blot (Fig. 1.8 b, lane 3). At this point these 
observations were not investigated further but it is important to note that the PrECs 
and N/Tert-1 cells in these experiments were cultured in specialist serum free media 
(SFM). As part of my PhD project, I tried to further extend these observations as 


























Figure 1.7: Western Blotting for GLI2 protein levels in primary epithelial 
prostate cells (PrEC) overexpressing either GLI1 or GLI2N 
Effect of GLI1 overexpression in primary epithelial prostate cells (PrEC) cells. Ectopic 
expression of GLI1 (Fig 1.7 b, lane 2) results in endogenous GLI2 protein downregulation 
(Fig 1.7 a, lane 2). Cells were grown in SFM (serum-free media). pBP, pBabePuro empty 
vector control. Total AKT was used as a loading control (Fig 1.7 c).  
Experiment was performed by Mr. Sandeep Nadendla, Centre for Cutaneous Research, 


















Figure 1.8: Western Blotting for GLI2 protein levels in N/Tert-1 keratinocytes 
overexpressing either GLI1 or GLI2N  
Effect of GLI1 overexpression in N/Tert-1 keratinocytes. Ectopic expression of GLI1 (Fig 
1.8 b, lane 2) results in GLI2 protein downregulation and appearance of a slightly lower 
molecular weight band (Fig 1.8 a, lane 2). Cells were grown in SFM (serum-free media). 
pBP, pBabePuro empty vector control. 







1.8.3 GLI factors expression in human Basal Cell Carcinoma 
The literature on GLI1 and GLI2 levels in BCC is not extensive and relies heavily on 
the measurement of mRNA levels, either by RT-PCR or in-situ hybridisation; only 
three publications analyse GLI expression in BCCs at a protein level. High level of 
GLI1 has been shown to be present in Basal Cell Carcinomas by reverse transcriptase 
polymerase chain reaction (RT-PCR) (Bonifas et al., 2001), and GLI1 has been 
proposed as a molecular marker to distinguish BCCs from other skin tumours (Hatta 
et al., 2005). Another study reported GLI1 transcript  was absent in normal skin, 
while 13 out of 14 BCCs analysed expressed GLI1; the presence of GLI1 in BCCs’s 
epithelial component was confirmed by in situ hybridization (Green et al., 1998). 
Dahmane et al. analysed 47 human BCC samples by in situ hybridization: all but one 
of the 47 BCCs examined showed expression of GLI1, although the level of 
expression varied. GLI1 gene expression was not detected in normal regions of skin 
distant from the tumour site, although GLI1 mRNA was present in normal basal 
keratinocytes immediately surrounding the tumour site. Single cells surrounding the 
main BCC tumour masses were rarely positive for GLI1; they were proposed to be 
either early invading tumour cells or other cell types that express GLI1 in response to 
a secreted tumour-derived factor (Dahmane et al., 1997). Two papers describe 
immunostaining of GLI1 in human BCC samples, Ghali et al. (Ghali et al., 1999), 
and Dahmane et al. (Dahmane et al., 1997). Ghali et al. reported GLI1 expression in 
BCCs by DAB immunohistochemistry on wax-sections using two different 
antibodies, one which recognises the carboxyl-terminal end of GLI1 and another 
which binds to the amino-terminus: staining was predominantly cytoplasmic. GLI1 
immunostaining was also detected in some regions of normal human skin, 
specifically in the outer root sheath keratinocytes of some hair follicles, in a 
subpopulation of mesenchymal cells in the vicinity of the bulge region of adult hair 
follicles and in the dermal sheath cells of developing hair follicles. Dahmane et al. 
used an in-house made antibody against the zinc finger domain of GLI1 and reported 
cytoplasmic expression of GLI1 by immunofluorescence in 6 out of 6 BCCs 
analysed. GLI2 expression at mRNA level in BCCs has been analysed in two 
publications. In Tojo et al. (Tojo et al., 2003), quantitative reverse transcriptase–
polymerase chain reaction performed on a series of 16 samples revealed GLI2 
mRNA upregulation in BCCs compared to normal skin and other skin tumours. GLI2 
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protein exists in four isoforms, GLI2 , , , and , resulting from combinations of 
two independent alternative splicing processes of the GLI2 gene (Tanimura et al., 
1998). The GLI2 isoform was shown to be the most expressed isoform in the 16 
BCCs analysed (Tojo et al., 2003). Using by in situ hybridization Ikram et al. (Ikram 
et al., 2004) reported GLI2 mRNA expression in 8 BCC samples, intefollicular skin 
and outer root sheath of hair follicles. Only one report describe GLI2 expression in 
the outer root sheath cells of hair follicles and BCCs by immunohistochemistry (Regl 
et al., 2004b) using an antibody against the amino-terminal of GLI2, though the 
number of BCC samples analysed is not specified. A comprehensive analysis of 
GLI1 and GLI2 at protein level to determine if they are co-expressed in BCC based 
on putative feedback loop described in Regl et al (Regl et al., 2002) has not been 
reported so far. The existence of a previously described positive GLI1-GLI2 
feedback loop in vitro would raise the question of why GLI1 has not been detected in 
normal human skin; this also suggests GLI1 – GLI2 interplay may be different in 
normal skin compared to BCCs, and it would be therefore important to understand 
these differences as they could be linked to the tumorigenic process. 
1.8.4 Non canonical induction of GLI factors 
GLI2 has been shown recently to be induced by transforming growth factor beta 
(TGF) (Dennler et al., 2007; Dennler et al., 2009), therefore non-canonical 
activation of GLI2 may also play a role in BCC tumorigenesis. TGF has been 
shown to induce GLI1 and GLI2 expression in keratinocytes even in the presence of 
cyclopamine, suggesting this activation may not be dependent on canonical 
Hedgehog signalling through PTCH1 and SMO (Dennler et al., 2007). During 
embryogenesis GLI2 is expressed in response to fibroblast growth factor (FGF) 
signalling (Brewster et al., 2000), and deletion of Notch in mice skin leads to 
development of BCCs associated with GLI2 upregulation (Nicolas et al., 2003). This 
suggests that in some instances GLI2 can function independently of canonical 
Hedgehog signalling. Moreover, GLI protein activity has also been shown to be 
modulated by interaction with other cellular pathways frequently activated in human 
malignancies such as RAS and EGFR (Riobo et al., 2006a; Lauth and Toftgard, 
2007; Schnidar et al., 2009). 
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1.9 The WNT signalling pathway 
The WNT signaling pathway is a highly conserved signal transduction cascade that 
has a central role in embryonic development, tissue regeneration, and, when 
deregulated, in tumorigenesis (Giles et al., 2003; Clevers, 2006).  Many of the genes 
in the WNT pathway, which were first discovered as genes affecting segmentation in 
Drosophila embryos, were later shown to act as oncogenes and tumour suppressors 
when deregulated in human cancer (Rijsewijk et al., 1987; Nusse et al., 1991). 
The WNT ligands are a family of 19 secreted glycoproteins (Miller, 2002) that, by 
interacting with different receptors present on the plasma membrane, regulate cell 
fate specification, proliferation, migration and adhesion (Wodarz and Nusse, 1998; 
Nusse, 2005). WNT signaling has been classified into two pathways: the canonical 
and non canonical pathways, or β-catenin-dependent and β-catenin-independent 
pathways (Chien et al., 2009) (Fig 1.9). Once secreted, WNT proteins act in a cell-
non autonomous fashion and bind to two distinct families of cell-surface receptors, 
the Frizzled (Fz) proteins and the low-density lipoprotein receptor-related proteins 5 
and 6 (LRP5/6). WNT ligand binding to Fzd and low-density lipoprotein receptor 
related protein 5/6 (LRP5/6) co-receptors leads to the activation of Dvl, although the 
mechanisms underlying this activation are still unclear. Canonical WNT signalling is 
characterized by signalling through -catenin. -catenin has two major functions: 
first, in simple epithelia, it is an integral part of adherens junctions, connecting E-
cadherin to the actin skeleton via -catenin (Peifer et al., 1992); second, dimers of -
catenin are one of the members of the TCF/LEF (T cell factor/lymphoid enhancer 
factor) family that function as a transcription factor when localized in the nucleus. In 
the absence of WNT ligand, the cytoplasmic pool of -catenin is depleted by the 
action of a destruction complex which targets -catenin for ubiquitin-dependent 
proteosomal degradation. The tumour suppressor protein Axin acts as the scaffold of 
this complex as it interacts with all other components: β-catenin, the tumour 
suppressor protein APC, and the two kinases CK1α and GSK3β. In the absence of 
the WNT ligand CK1 and GSK3β sequentially phosphorylate β-catenin in a series of 
Ser/Thr residues near its N- terminus; phosphorylated β-catenin is then recognized by 
the F box/WD repeat protein β-TrCP, a component of a dedicated E3 ubiquitin ligase 
complex. As a consequence, β-catenin is ubiquitinated and targeted for rapid 
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destruction by the proteasome (Aberle et al., 1997; Gao et al., 2002). Upon inhibition 
of GSK3 activity by WNT signaling dephosphorylated β-catenin translocates into the 
nucleus and activates expression of specific target genes by interacting with 
transcription factors of the T-cell factor (TCF) and lymphoid-enhancing factor (LEF) 
families (Behrens et al., 1996; vandeWetering et al., 1997).  
Numerous Tcf/Lef target genes have been identified, and many WNT target genes 
appear to be cell type specific. Some of them, such as cMyc and Cyclin D1, 
contribute to the oncogenic potential of disregulated WNT signaling (He et al., 1998; 
Tetsu and McCormick, 1999). Overexpression of different WNT ligands in epithelial 
cells led to the identification of a subset of WNT ligands capable of regulating 
morphological transformation of cells in the absence of β-catenin stabilization: this in 
turn led to the discovery of non-canonical WNT signalling (Shimizu et al., 1997; 
Veeman et al., 2003). 
Potential mechanisms of non-canonical WNT signal transduction are diverse, 
including signaling through calcium flux, JNK, and both small and heterotrimeric G 
proteins (Veeman et al., 2003). Examples of non-canonical WNT signalling are the 
planar cell polarity (PCP) pathway and the Ca2+ dependent WNT signalling 
pathway. Many functions of non-canonical WNT signalling have been described: for 
example, signalling by the PCP pathway in Drosophila and Xenopus embryos results 
in polarization of cells and directs cell motility (Seifert and Mlodzik, 2007). WNT 
signalling has been shown to be regulated by secreted proteins, including the 
Dickkopf (DKK) family and Frizzled-related proteins (sFRPs) (Kawano and Kypta, 
2003). The two major classes of WNT antagonists function in different ways: the 
sFRP class binds to WNT ligands, while the Dkk class binds to WNT coreceptors 
LRP5/6. The predicted theoretical outcome is that sFRPs inhibit canonical and non- 
canonical pathways whereas Dkks inhibit only the canonical pathway.  
Uncontrolled WNT–β-catenin signalling associated with elevated β-catenin levels, 
either by mutations in components of the destruction complex or by stabilizing 
mutation in β-catenin itself, has been linked to the development of different kind of 
cancers (Morin et al., 1997; Rubinfeld et al., 1997; Polakis, 2007). The non canonical 
ligand WNT5a has been proposed to suppress tumour formation by promoting GSK-
3 independent -catenin degradation in colon cancer cells (Topol et al., 2003). 
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WNT5a, however, does not seem to act as a tumour suppressor as WNT5a 
expression levels have been found to positively correlate with the severity of certain 
melanomas; modulation of WNT5a signaling can affect the motility and invasiveness 
of melanoma cells (Weeraratna et al., 2002). WNT5a expression also affect invasion 
of breast and gastric cancer cell lines (Kurayoshi et al., 2006; Pukrop et al., 2006). 
Another non canonical WNT, WNT11, has been shown to promotes migration of 
IEC6 intestinal epithelial cells (Ouko et al., 2004). Interestingly, the WNT proteins 
known to affect cell adhesion and movements in embryos can also affect cell 































Figure 1.9: The WNT signalling pathway 
Schematic representation of activated WNT pathway; binding of WNT proteins to membrane 
bound receptors initiate the signal transduction cascade, although the partial overlap between 
the canonical and non-canonical pathways has in some instances made it difficult to 













1.10 The TGF signalling pathway  
The transforming growth factor beta (TGF) superfamily is a composed by related 
cell regulatory proteins involved in vertebrate embryogenesis and in tissue 
homeostasis in adult organism; the main sub-groups of TGF-like genes include the 
TGFs I-V, the activins and inhibins and Bone Morphogenetic Proteins (BMPs) 
(Massague, 1998). TGF is a cytokine that controls proliferation, differentiation, 
migration, and apoptosis of different cell types (Massague et al., 2000). TGF was 
first described as a growth factor capable of inducing a transformed morphology in 
mouse cell lines (Moses et al., 1981), although it had been subsequently 
demonstrated that it can have both tumour suppressor and oncogenic activities. 
TGF is synthesized as part of a  precursor form that is cleaved before secretion from 
the cell (Derynck et al., 1985).  
The TGF propeptide, or latency associated peptide (LAP), remains noncovalently 
bound to TGF after secretion, retaining TGF in a latent form. In addition, latent 
TGF can contain a protein of variable size called the Latent TGF Binding Protein 
(LTBP); LTBP is implicated in TGF secretion, storage in the extracellular matrix, 
and activation  (Miyazono et al., 1993). Both the LAP and the LTBP must be 
removed before the mature protein can function; activation can occur by the action of 
proteases, integrins, the glycoprotein thrombospondin-1, reactive oxygen species 
(ROS) and changes in pH (Yu and Stamenkovic, 2000; Annes et al., 2003). TGF 
superfamily members require two different serine/threonine kinase receptors to 
signal, a type I (TR-I) and a type II (TR-II) (Wrana et al., 1992). The TGF ligand 
binds to a type II receptor dimer, which recruits a type I receptor dimer forming a 
hetero-tetrameric complex; type II receptor phosphorylate and activate type I 
receptor and this allows transduction of the signal to the nucleus (Wrana et al., 1994). 
The most studied signaling pathway downstream of TGF receptors is the Smad 
pathway (Liu et al., 1996), although other signaling pathways can also be activated in 
response to TGF, such as the mitogen-activated protein kinase (MAPK) pathway 
(Lee et al., 2007; Yamashita et al., 2008). The Smad family includes the receptor-
regulated Smads (R-Smads) Smad1, 2, 3, 5, 8, the co-Smad Smad4, and the 
inhibitory Smads Smad6 and 7 (Massague et al., 2005). Upon ligand binding the R-
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Smads are phosphorylated by the type I receptors, form homomeric and heteromeric 
complexes with Smad4 and subsequently accumulate in the nucleus where they 
regulate the transcription of target genes. TGF signalling is involved in different 
cellular processes and TGF responsive regions have been identified in the cyclin-
dependent kinase inhibitors p15Ink4b (Hannon and Beach, 1994) and p21Cip1 
(Datto et al., 1995), and in genes encoding extracellular matrix proteins such as 
collagen (Ritzenthaler et al., 1993) and elastin (Marigo et al., 1994). A TGF 
responsive element has also been recently identified in the promoter of GLI2 
(Dennler et al., 2009), a transcription factor part of the Hedgehog pathway. 
In normal skin TGF it is located in the keratinocytes in the epidermis and is present 
throughout the basal lamina in the extracellular matrix (Okane and Ferguson, 1997). 
TGF has been shown to promote wound healing by recruiting inflammatory cells 
and fibroblasts to the wound site and by inducing fibroblasts to produce increased 
amounts of collagen and fibronectin (Montesano and Orci, 1988).  
TGF plays a dual role in tumorigenesis, acting as a tumour suppressor at early 
stages and as a tumour promoter at later stages (Wakefield and Roberts, 2002). 
Cancer progression is often accompanied by a decreased responsiveness of the 
cancer cells to TGF mediated growth inhibition but display enhanced migration and 
invasive behavior in response to TGF stimulation (Cui et al., 1996; Oft et al., 1998).  
Notably, TGF pathway components have been shown to be present in the epithelial 
and stromal components of BCCs (Schmid et al., 1996; Furue et al., 1997; Verhaegh 
et al., 1997; Gambichler et al., 2007) and to promote invasion by acting on the 
stroma (Marsh et al., 2008), although their precise role in the development of this 







1.11 Aims of the project  
Molecular mechanisms involved in the aetiology of human Basal Cell Carcinoma are 
not yet fully understood, partly due to the difficulty in growing these tumours as 
explants. 
GLI transcription factors overexpression, though to be primarily mediated by the 
Sonic Hedgehog (SHH) signalling pathway activation, are associated with BCC 
development; to date, GLI1 and GLI2 expression has mainly been analysed at 
mRNA levels in in-vitro models and in a limited number of human BCC samples.  
Whether GLI1 or GLI2 is the primary effector with regard to BCC formation is 
currently debated, and their interplay has not yet been fully elucidated. BCC are 
rarely metastatic, although the morphoiec subtype has been shown to be more 
invasive than the others.   
The aims of this study are: 
(i) characterise GLI1 and GLI2 expression pattern at protein level in a panel of 
human BCC samples in order to better understand their clinical relevance for the 
aetiology of this kind of cancer; determine if there is a correlation with tumor 
aggressiveness 
(ii) clarify the interplay between GLI1 and GLI2, and their relation with other 
components of the HH pathway 
(iii) study the effects of the overexpression of an activated form of GLI2 on cell 












































2 Materials and Methods 
2.1 Cell Culture 
2.1.1 Cell Lines 
N/TERT-1 immortalised keratinocytes 
N/Tert-1 cells are human keratinocytes immortalized by ectopical expression of the 
telomerase catalytic subunit hTERT (Dickson et al., 2000). N/Tert-1 cells were a 
kind gift from professor J. Rheinwald and were grown in RM+ Medium (see 
Appendix I for details). 
N/TERT-1 GFP and N/TERT-1 GLI2N immortalised keratinocytes cell line 
The N/Tert-1 GLI2N immortalised keratinocytes cell line had been previously 
created and characterized in the lab (E. Pantazi et al, unpublished data). The 
construct CMV-EGFP-GLI2N was cloned into the pSIN plasmid, and the GFP-
GLI2N fusion protein is stably expressed under the control of the CMV promoter. 
GLI2N is a constitutively active form of GLI2 lacking the N-terminal repressor 
domain. N/Tert-1 GFP keratinocytes were transduced with the pSIN CMV-EGFP 
empty vector alone and used as the control cell line 
N/TERT-1 pBabe, N/TERT-1 pBGLI1 and N/TERT-1 pBGLI2N immortalised 
keratinocytes cell line 
N/Tert-1 pBGLI1 and N/Tert-1 pBGLI2N clonal cell lines, which stably express 
either GLI1 or GLI2N, along with its respective empty vector control N/Tert-1 
pBabe, were created and characterised in the lab by Dr Wesley Harrison.  
NEB-1 immortalised keratinocytes 
NEB-1 cells are human keratinocytes which have been immortalized by transduction 






NEB-1 pBabe, NEB-1 pBGLI1 and NEB-1 pBGLI2N immortalised 
keratinocytes cell line 
NEB-1 pBGLI1 and NEB-1 pBGLI2N clonal cell lines, which stably express either 
GLI1 or GLI2N, along with its respective empty vector control NEB-1 pBabe, were 
created and characterised in the lab by Dr Wesley Harrison. 
NEB-1 PTCH1 knockdown cells keratinocyte cell line 
NEB-1 PTCH1 knockdown keratinocyte clonal cell line (shPTCH1 189A) and its 
respective scramble control (shCON) were created and characterised in the lab by Mr 
Muhammad Rahman. NEB-1 cells were retrovirally transduced with either a shRNA 
construct that target exon 24 of human PTCH1 (shPTCH1 189A) or a non-targeting 
scramble control vector (shCON); the clone with the lowest PTCH1 levels was then 
selected, expanded and characterised (Rahman et al., unpublished results). 
N/TERT-1 EGFP and N/TERT-1 EGFP-GLI1 immortalised keratinocytes cell 
line 
Clonal N/Tert-1 keratinocytes stably expressing EGFP or an EGFP-GLI1 fusion 
protein were created in the lab by Dr Graham Neill (Neill et al., 2008 and Neill et al., 
unpublished results).  
Hacat immortalised keratinocytes 
Hacat are in vitro spontaneously transformed keratinocytes (Boukamp et al., 1988). 
Hacat cells were grown in KGM Medium (see Appendix I). 
Du145 prostate cancer epithelial cell line  
Du145 is a prostate carcinoma cell line derived from a brain metastasis (ATCC); 
Du145 cells were grown in RPMI 1640 media (see Appendix I).  
Human epidermal primary keratinocytes 
Human primary keratinocytes enzymatically isolated from redundant human skin 
obtained from facelift surgery were a kind gift from Mr. Sreekanth Vootukurireddy. 
Human primary keratinocytes were grown in RM+ Medium in the presence of 3T3 
mouse fibroblast feeder cells (Rheinwald and Green, 1975). 3T3 cells were 
previously lethally irradiated to prevent cell proliferation. 2 x 106 3T3 fibroblasts 
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were seeded into a 75 cm2 cell culture flask (T75) and incubated overnight; the next 
day 2 x 106 primary keratinocytes were seeded on top of the feeders cells.  
Human primary dermal fibroblasts 
Human dermal primary fibroblasts isolated from human redundant facelift skin 
removed during surgery were a kind gift from Jane Elliott. Human primary 
fibroblasts were grown in supplemented DMEM High Glucose (4.5 g / l) Medium 
(see Appendix I). 
Mouse 3T3 fibroblasts 
3T3 fibroblasts is a spontaneously immortalized cell line established from primary 
mouse embryonic fibroblast (Todaro and Green, 1963); they secrete growth factors 
that help the growth of primary keratinocytes and therefore routinely used for the 
cultivation of this type of cells. Irradiated 3T3 cells were a kind gift from Sreekanth 
Vootukurireddy and were grown in supplemented DMEM High Glucose (4.5 g / l) 
Medium (see Appendix I). 
2.1.2 Culture conditions and passaging of cells 
Adherent keratinocytes or fibroblasts were routinely grown on tissue culture treated 
flasks or dishes; all cells were incubated at 37oC in a humidified atmosphere of 90% 
air / 10% CO2.  Cells were passaged upon reaching approximately 70% confluence, 
counted and reseeded at the desired density. Cell media was replaced on alternate 
days or upon passaging. All tissue culture was carried out under aseptic conditions. 
2.1.2.1 Routine cell passaging 
 
Cell culture medium was aspirated from flasks and the cell monolayer was then 
washed with sterile phosphate buffered saline (PBS) to remove any trace of media. 
The PBS was then aspirated and trypsin – EDTA was added to disrupt cell adhesion; 
flasks were incubated for 5 min at 37°C 90% air / 10% CO2 and the progress of cell 
detachment from the flask surface monitored under a light microscope. Detached 
cells were removed from the flasks and transferred to a sterile falcon tube where the 
trypsinisation process was inhibited by the addition of an equal volume of media 
containing 10% (v/v) FCS. The process was repeated until all cells could be brought 
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into suspension. The cells were centrifuged at 1000 rpm for 5 min at RT (room 
temperature), the supernatant aspirated and the cell pellet resuspended in culture 
media for counting.  
The passaging of cells co-cultured with 3T3 feeders requires aspiration of culture 
media, washing with PBS and treatment with Versene (Invitrogen, U.K.) for 5 
minutes. Versene treatment results in detachment of feeders cells but not 
keratinocytes from the culture dish; 3T3 feeders could therefore be selectively 
removed and primary keratinocytes subsequently trypsinised.  
2.1.2.2 Cell counting 
 
The number of cells per unit volume of cell suspension is determined using a 
haematocytometer. The haematocytometer is a glass chamber engraved with 
perpendicular lines to form squares: since the area bounded by the lines and the 
depth of the chamber is known, it is possible to calculate the concentration of cells. 
10 l of cell suspension was pipetted into the haematocytometer and cells were 
counted using a light microscope; the number of cells per milliliter of media is 
calculated by multiplying the mean of the number of cells in each of the four squares 
by 104. It is then possible to calculate the number of cells present in the whole of the 
cell suspension and seed the required number of cells into new flasks. 
2.1.3 Cryopreservation 
Cells not needed for experiments or propagation were trypsinised, centrifuged at 
1000 rpm for 5 min at RT and resuspended in freezing solution (see Appendix I) at a 
concentration of 2x106 cells per milliliter. Aliquots of 1 ml of cell suspension were 
then transferred into individual cryovials (Corning Life Sciences, U.S.A.), put into a 
freezing container (Nalgene, U.K.) and stored at -80°C. The freezing container 
allows a steady cooling rate of about 1°C / hour to prevent damage to the cells. After 
1-2 days the vials were transferred into a liquid nitrogen tank for long term storage. 
When required, cells were thawed by defrosting vials in a 37°C waterbath, mixing of 
cell suspension with equal amount of cell media, centrifugation to remove freezing 
solution and resuspension of the cells pellet into the required amount of culture 
media. 
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2.2 De-epidermalized dermis (DED) based organotypic raft culture 
system 
In contrast to conventional submerged cultures, growth of keratinocytes on dermal 
substrates allows epithelial differentiation and recreates a situation closely related to 
the physiological setting; this system has been previously used to study different 
processes, including cell migration and invasion. The epidermis was removed from 
cadaveric skin using two different methods: in half of the skin removal was achieved 
by soaking in PBS plus antibiotics / antimycotics, while in the other half the 
epidermis was enzymatically removed using Dispase, a bacterial protease. Glycerol-
preserved skin (Euro Skin Bank, The Netherlands) was washed in PBS and incubated 
in PBS containing antibiotic mix (Antibiotic-Antimycotic Solution, PAA 
Laboratories GmbH, Austria) at 37°C 90% air / 10% CO2 for three weeks. Every 2 
days the antibiotic-antimycotic solution was replaced and the bottle gently shaken to 
facilitate epidermis detachment from the dermis. The remaining skin was treated 
with Dispase (Dispase, Roche, U.K.) at a 2 U/ml concentration overnight. The skin 
was then cut into 1.5 cm x 1.5 cm square pieces using a scalpel and the remaining 
epidermis scraped off with forceps.  
The squares of skin were placed on their reticular side in a 6-well plate, covered with 
a 1 cm diameter stainless steel ring and 1 x 106 human dermal fibroblasts seeded 
within the metal ring. 2-3 ml of fibroblast growth media was also pipetted into each 
well to prevent desiccation of the DED and the plate incubated overnight at 37°C 
90% air / 10% CO2. 1 x 106 human dermal fibroblasts were also seeded in a 24 well 
plate to allow verification of cell confluence, since the area delimited by the metal 
ring and that of a well of a 24 well plate are comparable. 
After 48 hours the rings were removed, the DED turned on their papillary surfaces 
and the rings subsequently put back into place. 1 x 106 human keratinocytes were 
seeded within each metal ring, 2-3 ml of media were added to each well to prevent 
desiccation and the plate incubate at 37°C 90% air / 10% CO2. 1 x 10
6 human 
keratinocytes were also seeded in a 24 well plate to allow verification of cell 
confluence. 
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After 48 hours a number of stainless steel grids equal to the number of the DEDs 
were placed in a new six-well plate. The DEDs were cut in half using a scalpel and 
carefully placed on top of the grids; 3-4 ml of keratinocyte media was added to each 
well so that the liquid meniscus would reach the bottom of the DED. This allows 
growth of keratinocytes on top of DEDs at the air-liquid interface, therefore 
mimicking the physiological setting in vivo.  
Keratinocyte media was replaced every 2-3 days and the DEDs harvested by either 
snap-freezing in liquid nitrogen or fixing in a 4% (v/v) paraformaldehyde (PAF) 
solution. Snap-frozen tissue was subsequently embedded in OCT and stored at –80°C 
while fixed tissue was incubated overnight at +4°C. The following day the PAF 
solution was removed by washing with PBS and the DEDs placed in 70% (v/v) 
ethanol ready for processing. The fixed tissue was dehydrated and impregnated with 
paraffin using a tissue processor (Tissue Tek VIP 3000, Sakura, Japan). The next day 
processed tissue was embedded into wax blocks using moulds. 
Frozen tissue samples were sliced using a cryostat (OTF5000, Bright Instrument, 
U.K.) and 7 m thick slices were mounted onto Superfrost Plus microscope slides 
(ThermoScientific, Germany). Sections were stored at –80°C until required.  
Paraffin embedded tissue samples were sliced using a microtome (RM 2235, Leica 
Microsystems, U.S.A.) and 7 m thick slices were mounted onto Polysine 
microscope slides (ThermoScientific, Germany). Sections were stored at RT.  
2.2.1.1 DED optimisation 
Two different methods of epidermis removal were tested: in half of the skin removal 
was achieved by soaking in PBS plus antibiotics / antimycotics, while in the other 
half the epidermis was enzymatically removed using Dispase, a bacterial protease. 
The effect of growth supplement media was also tested, as some of the DEDs were 
fed with RM+ media, namely DMEM: Ham’s F12 3:1 ratio with addition of RM+ 
supplement (see Appendix I), while the others were feed with the same media but 
lacking the RM+ supplement. 
A total of four DEDs were generated using primary keratinocytes, by combining 
epidermis removal with PBS or Dispase and feeding with or without RM+ 
supplement. 
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In all experiments 1 × 106 cells were used and both fibroblasts and keratinocytes 
were left to seed on the DEDs for 48 hours prior to the DEDs being raised to the 
grids. Dispase treatment did not seem to facilitate keratinocytes adhesion to the DED 
surface as primary keratinocytes were unable to adhere on Dispase-treated dermis 
(Fig. 2.1 a, b). When DEDs where fed with media lacking the RM+ supplement no 
keratinocytes attachment was observed, regardless of the method used for epidermis 
removal (PBS soaking or Dispase treatment) (Fig. 2.1 a, c).  
Primary keratinocytes grown on PBS-treated DED in the presence of RM+ 
supplement seem to adhere and differentiate properly, as judged by the appearance of 
the stratum corneum (Fig. 2.1 d): therefore these conditions were selected to perform 










Figure 2.1: Human primary keratinocytes organotypic raft cultures obtained 
using different methods of epidermis removal and differently supplemented 
growth media 
Haematoxylin and eosin stained transverse section of organotypic cultures of primary 
keratinocytes on De-Epidermalized Dermis (DED). Human primary keratinocytes were 
plated on top of DED and grown at the air-liquid interface for 13 days. (a) Primary 
keratinocytes organotypic raft, epidermis removed by Dispase treatment and grown in the 
absence of RM+ media supplement (b) Primary keratinocytes organotypic raft, epidermis 
removed by Dispase treatment and grown in the presence of RM+ media supplement (c) 
Primary keratinocytes organotypic raft, epidermis removed by PBS soaking and grown in the 
absence of RM+ media supplement (d) Primary keratinocytes organotypic raft, epidermis 
removed by PBS soaking and grown in the presence of RM+ media supplement. Scale bar 






2.3 Collagen-matrigel based organotypic raft culture system 
Type I collagen is the most abundant collagen found in the human body and it is 
commonly employed in the manufacture of artificial skin substitutes (Auger et al., 
1998). Matrigel is a basement membrane preparation containing extracellular matrix 
components such as laminin, collagen IV, heparan sulfate proteoglycans and 
different growth factors including transforming growth factor beta (TGF), 
epidermal growth factor (EGF), insulin-like growth factor (IGF), fibroblast growth 
factor (FGF) and tissue plasminogen activator (TPA). Extracellular matrix based 
substrata provide a physiological environment that supports cellular functions, and 
collagen-matrigel gels are widely used in the study of cell migration and invasion. 
Collagen-matrigel gels were prepared by mixing 3.5 volumes of type I collagen (Rat 
tail collagen type I, BD Biosciences, U.S.A.), 3.5 volumes of Matrigel (Matrigel 
Basement membrane matrix, BD Biosciences, U.S.A.), 1 volume of 10x DMEM, 1 
volume of fetal calf serum (Biosera, U.K.) and one volume of growth media 
containing 5 x 105 human dermal fibroblasts. Aliquots of this suspension were placed 
in a 24-well plate (1 ml per well) and incubated at 37°C 90% air / 10% CO2 for 1 
hour to allow the components to solidify. The gels were then detached from the sides 
of the wells by using a sterile pipette tip, covered with 1 ml growth media and 
incubated overnight at 37°C 90% air / 10% CO2.  
The next day the media was carefully aspirated from the wells, a plastic cloning ring 
was placed on each gel ring and a suspension of 5 x 105 human keratinocytes was 
seeded within the plastic ring. 5 x 105 keratinocytes were also seeded in a 48 well 
plate to allow verification of cell confluence and the plates incubated overnight at 
37°C 90% air / 10% CO2. The following day cell confluence of the keratinocytes 
plated in the 48 well was assessed and, if the confluence reached 100%, rings were 
removed from the gels. For each gel a sterile stainless steel grid was placed in a new 
6 well plate and gels were carefully lifted with a spatula and placed on the top of the 
grids; 3-4 ml of keratinocyte media was added to each well so that the liquid 
meniscus would reach the bottom of the grid. This setting allows growth of 
keratinocytes at the liquid-air interface, similar to the physiological situation.  
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Growth media was replaced every 2-3 days and gels were harvested after 14 days 
and preserved by freezing in dry ice. Gels were subsequently embedded in OCT 
media, sectioned using a cryostat (OTF5000, Bright Instrument, U.K.) and 7 m 
thick sections were mounted onto Superfrost Plus microscope slides 
(ThermoScientific, Germany). Sections were stored at –80°C until required. 
2.4 Hematoxylin and eosin staining of paraffin sections 
Hematoxylin and eosin (H&E) is a histological stain used to reveal the morphology 
and structure of a tissue. Hematoxylin has a deep blue-purple color and stains nuclei, 
while eosin is pink and stains proteins. Sections of tissue mounted on slides were 
placed into a rack and sequentially immersed in jars containing different chemicals 
as follows: tissue were deparaffinized by dipping into xylene I (5 minutes) and 
xylene II (3 minutes), then rehydrated by immersion in a scale of decreasing ethanol 
(EtOH) concentrations (EtOH I 100% (v/v) 3 minutes, EtOH II 100% (v/v) 3 
minutes, EtOH 90% (v/v) 3 minutes, EtOH 70% (v/v) 3 minutes). After a brief rinse 
in distilled water sections were immersed in hematoxylin for 3-5 minutes, washed in 
running tap water to remove excess stain and differentiated by dipping into acidic 
alcohol 2-6 times. The rack was placed in running tap water until the nuclei turned 
blue (approximately 5 minutes), then dipped into eosin for 2 minutes. The excess 
stain was removed by immersing in running tap water and the section were 
dehydrated using a scale of increasing ethanol concentrations (EtOH I 70% (v/v) 3 
minutes, EtOH II 90% (v/v) 3 minutes, EtOH 100% (v/v) 3 minutes, EtOH 100% 
(v/v) 3 minutes). Slides were then immersed in clean xylene (xylene I 2 minutes, 
xylene II 2 minutes) and coverslipped with glass slides (VWR International, U.K.) 
using DePeX Mounting Medium (BDH Laboratory Supplies, U.K.). Slides were 
observed using a light microscope. 
2.5 Hematoxylin and eosin staining of frozen sections 
Sections of frozen tissue mounted on slides were retrieved from the -80°C freezer, 
incubated at RT for 5 minutes to allow defrosting and then placed into a rack. Slides 
were immersed in a 95% (v/v) ethanol solution for 2 minutes and then washed briefly 
in distilled water. Slides were then immersed in a 1x solution of Scott’s tap water 
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(see Appendix I) for 2 minutes and then stained with hematoxylin. From this step 
onward the protocol used was identical to the one used to hematoxylin and eosin 
stain paraffin sections.  
2.6 RNA interference  
2.6.1 Principles of RNA interference 
Gene expression in eukaryotes can be modulated by double-stranded RNA (dsRNA) 
molecules that result in the degradation of a specific messenger RNA (mRNA) 
(Cerutti and Casas-Mollano, 2006). This mechanism, known as RNA interference, is 
evolutionarily conserved and provides a mean of modulating gene expression at a 
transcriptional level. The RNA interference process has been widely exploited in 
molecular biology to silence expression of a particular gene of interest. Short 
interfering RNAs (siRNAs) are synthetic duplexes of RNA about 21 bases in length 
with 3’ overhanging ends which are introduced into cells by electroporation or lipid 
mediated transfection.  
Once inside the cell one strand of the siRNA will be incorporated into the RNA 
induced silencing complex (RISC) where it will guide the cleavage of single-
stranded mRNAs that show complementarity with the siRNA sequence leading to its 





Figure 2.2: Cellular mechanism of RNA interference 
(Adapted from Bumcrot et al., 2006). 
2.6.2 siRNA reverse transfection  
Short interfering RNAs are introduced into the cells by opening transient pores in the 
cell membrane: this process is known as transfection and was achieved by taking 
advantage of the lipid-based reagent Hiperfect (Qiagen, U.K.). Sequences of siRNAs 
used can be found in Appendix II. siGLO Cyclophilin B siRNA (Dharmacon, 
U.S.A.) was used as a transfection control: siGlo is a fluorescently labelled siRNA 
against Cyclophilin B which localises to the endoplasmic reticulum and is used to 
assess transfection efficiency. A second non-fluorescent control was also used, 
Silencer Negative Control #1 siRNA (Ambion, U.K.). This scramble control (siAmb) 
is designed to have no significant sequence similarity to known human transcripts 
and was shown to have no impact on cell viability.  
Hiperfect was added to serum-free media (SFM) in polypropylene flow cytometry 
tubes and incubated for 5 minutes. The siRNA of interest (or siGLO) was pipetted 
into the well of a cell culture plate to obtain a 30nM final concentration, then the 
Hiperfect-SFM solution was added on top, mixed and incubated for 20 minutes. In 
the meantime, cells were trypsinised and counted; cells were then re-suspended in the 
appropriate volume of media before being added to the plates and incubated at 37°C, 
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10% CO2 overnight. siGLO fluorescence was observed under a fluorescence 
microscope after 24 hours to visually assess transfection efficiency. Media was 
changed after 48 hours and cells either harvested or fixed for analysis after 96 hours.  
2.7 Protein harvesting and quantification  
Whole cell protein lysates were obtained by adding 220 l of pre-heated  buffer A 
(50 mM Tris-HCl pH 8.0, 2% (w/v) SDS, 1 mM Na3OV4) for each 60 mm dish onto 
cells after media removal and PBS washing. Cells were scraped off the dishes, 
collected in eppendorf tubes and boiled at 95°C for 5 minutes, then incubated on ice. 
The lysate solutions were then mixed 3 times using a syringe with needle to help 
reduce viscosity and therefore enhance the release of proteins into solution. Protein 
concentration was determined using the DC Protein Assay (Bio-Rad Laboratories, 
U.S.A.): this assay is based on the Lowry assay method and relies on the shift in the 
absorbance of a chemical compound depending on the amount of proteins present in 
the solution. A stock colourimetric solution (Buffer AS) was made up according to 
the manufacturer’s instructions consisting of 2 l of Buffer S to 98 l of Buffer A 
per sample. 20 l of cell lysate was then added to 100 l of Buffer AS in a clean 
eppendorf tube, and 800 l of Reagent B were subsequently added. The reactions 
were incubated for 15 minutes at RT and then transferred into optical cuvettes for 
absorbance reading (Abs) at 655 nm using a spectrophotometer. The 
spectrophotometer was calibrated using a blank solution in which 20 l of lysis 
buffer were added to the previously described buffers instead of 20 l of cell lysate. 
Protein concentration is calculated using the equation ((Abs + 0.0009) / 0.213) = 
concentration (g/l) based on a standard curve generated using bovine serum 
albumin (Fig 2.3). A standard curve is made by measuring the absorbance of protein 
samples of known concentration, giving a range of absorbance values related to the 
varying concentrations of proteins. To determine the protein concentration of a 
sample from it absorbance, the standard curve is used to find the concentration of 
proteins that would have the same absorbance as the sample. 50 l of loading buffer 
was subsequently added and the lysated, followed by boiling at 95°C for 1 minute. 
Since the original sample in which the absorbance has been measured is diluted as a 
result of the addition of the loading buffer, a correction factor (0.8 = 200 l / 250 l) 
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is added to the equation to give (((Abs + 0.0009) / 0.213)*0.8) = concentration 
(g/l). The protein samples were then either used for Western Blotting analysis 








Figure 2.3: BSA standard curve for protein assay. 
2.8 Western Blotting 
2.8.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a technique used to separate proteins taking advantage of their 
different electrophoretic mobility. SDS binds to proteins and confers them a negative 
charge proportional to the length of the polypeptide: when the proteins are loaded 
onto a polyacrylamide gel in the presence of an electric field they migrate toward the 
positive electrode (anode) and are separated on the basis of their molecular masses. 
Gels were assembled using a specific apparatus (Mini-PROTEAN 3 Cell, BioRad, 
U.S.A.) and consist of two parts, stacking and resolving (see Appendix I): the 
stacking gel function is to concentrate (or ‘stack,) the protein samples loaded into 
wells into tight bands, while the resolving gels separate the proteins depending on 
their molecular weight. Proteins of known molecular weight (Prestained Protein 
Marker, New England Biolabs, U.K.) were used as reference. Samples were loaded 
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in the wells of 5% stacking - 10% resolving gels, the tank was filled with running 
buffer (see Appendix I) and proteins separated at by applying a 120V difference in 
potential until the dye front reached the base of the gel.  
2.8.2 Electrotransfer 
This technique allows the transfer of proteins from an electrophoretic gel to a solid 
support, usually a nitrocellulose membrane. Transfer was achieved by using a 
specific apparatus after the gel had been placed onto a nitrocellulose membrane 
(Amersham Hybond ECL, GE Healthcare, U.K.) and sealed in place with blotting 
paper and sponges. The tank was then filled with transfer buffer (see Appendix I) and 
a 100V difference in potential was applied for one hour. 
2.8.3 Immunoblotting  
Immunoblotting is a  technique that allows the detection of a particular protein by 
using a specific antibody. Non-specific binding sites on the nitrocellulose membrane 
containing the proteins were saturated by placing the membrane in a small plastic 
bag, covering with a solution of 10% (w/v) milk TBS-T and leaving on a gently 
shaking rotor for 1 hour. The first antibody to be applied (primary, see Table 2.1) is 
specific for protein of interest and, after being diluted in 5% (w/v) milk TBS-T, was 
incubated with the membrane on a gently shaking rotor at +4°C overnight. The next 
day, the membrane was put in a small plastic box and washed 3 times for 5 minutes 
with TBS-T to remove the unbound primary antibody. The secondary antibody (see 
Table 2.1), which binds to the primary, was then diluted 1:2000 in 5% (w/v) milk 
TBS-T and incubated with the membrane in a small plastic box for 45 min-1 hour. 
The unbound secondary antibody was then removed by 3 washing with TBS-T, 5 
minutes each. The secondary antibody is linked to an enzyme that allows visual 
identification of proteins (see section 2.8.4). 
2.8.4 Enhanced chemiluminescence detection and development 
Chemiluminescent detection methods rely on a secondary antibody linked to a 
reporter enzyme (horseradish peroxidase) which can convert an appropriate substrate 
into a luminescent product. The light emitted is then detected by using a 
photographic film: bands corresponding to the detected protein of interest will appear 
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as dark regions on the developed film. ECL plus reagent A and B (ECL Plus Western 
Blotting Detection Reagents, GE Healthcare, U.K.) were mixed in a ratio of 40:1 and 
put onto the membrane for 3-5 minutes to allow the reaction to develop. The signal 
was then detected by exposing the membrane to a photographic film (Hyperfilm, GE 
Healthcare, U.K.) for 1-5 minutes followed by development using an automatic film 
processor. 
 














2.9.1 Basal Cell Carcinoma tissue samples 
Normal human hair bearing skin and Basal Cell Carcinoma tumour samples were 
obtained from the tissue banks of the Royal London Hospital, London, U.K., with the 
approval of local ethical committees. Samples had been previously snap frozen in 
liquid nitrogen, transferred into cryovials and stored at –80°C.  
2.9.2 Samples preparation 
Tissues were included in OCT embedding medium (Cryo-M-bed, Bright Instrument, 
U.K.), placed onto a cork disc and put onto dry ice to allow the OCT to solidify. 
Samples were sectioned using a cryostat (OTF5000, Bright Instrument, U.K.) and 
7 m thick sections were mounted onto Superfrost Plus microscope slides 
(ThermoScientific, Germany). Sections were stored at –80°C until required. 
2.9.3 Immunofluorescent histochemistry on BCC frozen sections 
Immunohistochemistry is a technique used to reveal the presence of a specific 
protein in a tissue of interest by using a primary antibody that binds to the protein 
and a secondary antibody labeled with either a fluorescent dye or an enzyme  that 
allows for detection. Immunofluorescent histochemistry was used to determine the 
protein expression pattern of GLI factors in normal human hair bearing skin and in 
Basal Cell Carcinomas (BCC) samples (see Table 2.2 for list of antibodies used).  
Tissue sections were allowed to defrost for 10 minutes at RT and then fixed in ice-
cold acetone for 15 minutes at –20°C. Samples were then washed in PBS for 15 
minutes before being transferred into 1% (w/v) milk-PBS blocking solution for 
another 15 minutes. Slides were washed in 0.05% (v/v) Tween 20-PBS for 5 minutes 
prior to being covered with a drop of 0.05% (v/v) Tween 20, 5% (v/v) serum PBS in 
which the primary antibody had been diluted. Slides were put into a humidified 
chamber and incubated with the primary antibody overnight at +4°C .The next day 
the slides were washed three times for 5 minutes in 0.05% (v/v) Tween 20-PBS and 
then covered with a drop of 0.05% (v/v) Tween 20, 5% (v/v) serum PBS containing 
the diluted secondary antibody. Sections were incubated for 30 minutes in the dark at 
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RT, and then washed 3 times for 5 minutes. Slides were then incubated in PBS 
containing 4’,6-diamidion-2-phenylindole dihydrochloride (DAPI) (1:10000, 
Invitrogen, U.K.) for 10 minutes to allow visualization of the cells’ nuclei. Slides 
were then washed 2 times in PBS (2 minutes each). Sections were subsequently 
coverslipped with glass slides (VWR International, U.K.) using Vectashield 
mounting medium (Vector Laboratories, U.S.A.). Slides were observed using a 
confocal microscope.  
 
Table 2.2: List of antibodies used for fluorescent immunohistochemical analysis 







2.9.4 Immunofluorescent histochemistry on De-epidermalised dermis (DED) 
wax-embedded sections 
Tissue were deparaffinized and rehydrated by transferring slides into xylene I (5 
minutes) and xylene II (5 minutes), ethanol (EtOH 100% (v/v) 5 minutes, EtOH 90% 
(v/v) 5 minutes, EtOH 70% (v/v) 5 minutes, EtOH 50% (v/v) 5 minutes), then 
distilled water (5 minutes) and PBS (5 minutes). Antigen retrieval was performed by 
incubating the slides in a 0.01 M Sodium Citrate solution and microwaving at 800 
Watt for three cycles of 5 minutes each; slides were then left to cool down to room 
temperature. Blocking of aspecific binding sites was achieved by incubation in a 5% 
(v/v) serum PBS solution for 1 hour. Slides were then covered with a drop of 5% 
(v/v) serum PBS solution in which the primary antibody had been diluted. Slides 
were put into a humidified chamber and incubated with the primary antibody 
overnight at +4°C. The next day the slides were washed three times for 5 minutes in 
0.05% (v/v) Tween 20-PBS and then covered with a drop of 5% (v/v) serum PBS 
solution containing the diluted secondary antibody. Sections were incubated for 1 
hour in the dark at RT, and then washed 3 times for 5 minutes. Slides were then 
incubated in PBS containing 4’,6-diamidion-2-phenylindole dihydrochloride (DAPI) 
(1:10000, Invitrogen, U.K.) for 10 minutes to allow visualization of the cells’ nuclei. 
Slides were then washed 2 times in PBS (2 minutes each). Sections were 
subsequently coverslipped with glass slides (VWR International, U.K.) using 
Vectashield mounting medium (Vector Laboratories, U.S.A.). Slides were observed 









Table 2.3: List of antibodies used for fluorescent immunohistochemical analysis 



















2.10 Image acquisition, image processing and data analysis of Basal 
Cell Carcinomas immunofluorescent staining 
Fluorescence quantification is a sequential process involving image acquisition, 
image preprocessing, and data analysis steps. Confocal imaging was performed using 
a Zeiss LSM 510 META microscope (Carl Zeiss, Germany) and associated software 
(Zeiss LSM Image Browser v. 4.2.0.121). Fluorochrome excitation of secondary 
antibodies was achieved by 488-nm or 543-nm filtered emission from a laser source. 
All images have been acquired using a pre-determined Multi Track Configuration 
(either DAPI – 488nm or DAPI – 488nm – 543nm); using this option, sequential 
scanning are performed. Optimal power values for each laser were already set by Dr 
Ann Wheeler (BICMS Imaging Facility manager) for each configuration and have 
not been altered. A frame size (number of pixels) of 1024 was selected for every 
image, with a dynamic range of 12 Bit per pixel (4096 gray levels). For each channel 
pinhole size was set to 1 Airy unit. Line averaging (to improve the image by 
increasing the signal to noise ratio) was set as 4. Images were acquired using as 
follows: an objective was selected (either Plan-Neurofluar 10x / 0.3 Ph1or Plan-
Neurofluar 20x / 0.5 Ph2) and continuous fast scanning was used to put the image 
into focus. By using the ‘Palette’ and ‘Range Indicator’ options the image was 
converted into grayscales in which areas which exceed the maximum limit of 
detection (saturation) were shown as red whereas areas which are below detection 
were shown as blue. Red saturation over the maximum was minimized by decreasing 
the Detector Gain, while undetected blue areas were reduced by increasing the 
Amplifier Offset. Amplifier Gain was kept as 1. These steps were repeated for each 
individual channel, ensuring images were within the linear range of the 
photomultiplier tube detectors. For quantification purposes, each flourescence 
measurement was normalised against the value of the black background of the same 
slide. Image noise was further reduced using Image J software (v.1.41, NIH, U.S.A.) 
during the image preprocessing step. The ‘Threshold’ tool in Image J allows the user 
to set lower and upper threshold values on the fluorescence intensity distribution 
histogram, segmenting the image into features of interest. Pixels with brightness 
values included in a specified range can be highlighted and their average 
fluorescence intensity calculated. Taking advantage of this feature the fluorescence 
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intensity of the signal in the epithelial and in the mesenchymal components of each 
tumour was measured. Conventional statistical analysis on the intensity of the 
fluorescence signals of different samples was performed to obtain graphical 
representations of the results (Student’s T-Test, two-sample assuming unequal 
variance). 
2.11 Immunoperoxidase - DAB immunohistochemistry  
Normal human skin and Basal Cell Carcinoma tumour samples were obtained from 
the tissue banks of the Royal London Hospital, London, U.K., with the approval of 
local ethical committees. Samples had been previously fixed, dehydrated and 
paraffin wax embedded. Wax embedded tissue samples were sliced using a 
microtome (Leica RM2235, Leica, Germany) and 7 m thick slices were placed onto 
Poly-L-Lysine Coated Microscope Slides  (ThermoScientific, Germany).  
Sections were stained using the streptavidin/biotin-based staining technique. The 
streptavidin/biotin is an indirect immunohistochemical staining method based on the 
high affinity that streptavidin has for biotin. Streptavidin has four binding sites for 
biotin and this allow macromolecular complexes (ABCs) to be formed between 
streptavidin and biotinylated molecules, including enzymes and antibodies. In this 
technique the primary antibody is applied to the tissue, followed sequentially by the 
biotinylated secondary antibody and by a preformed  streptavidin-biotin -peroxidase 
complex (ABC technique) (Hsu et al., 1981). The horseradish peroxidase (HRP) 
linked to streptavidin catalyzes hydrogen peroxide oxidation of the 3,3'-
Diaminobenzidine tetrahydrochloride (DAB) substrate to yield a brown staining 
product wherever primary and secondary antibodies are attached to the tissue (DAB 
staining), providing a high and specific signal at the antigen binding site location. 
Tissue were deparaffinized and rehydrated by transferring slides into xylene I (2 
minutes) and xylene II (2 minutes), ethanol (EtOH 100% (v/v) 2 minutes, EtOH 70% 
(v/v) 2 minutes) and then running water (5 minutes).  
Since wax-embedded tissues are fixed with formaldehyde prior to embedding, an 
antigen retrieval step is required to remove the methylene bridges formed due to the 
formaldehyde treatment as they could mask the antigen.  
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Antigen retrieval step was performed using different conditions depending on the 
primary antibody used (conditions are listed in Table 2.4). Briefly, slides were placed 
in a rack and immersed in the appropriate antigen unmasking solution, then either 
microwaved in a plastic container or put into a coplin jar into the waterbath. 
Endogenous peroxidase activity was then inhibited by immersing the slides in a 
solution of 3% (v/v) hydrogen peroxide for 15 minutes, followed by washing in 
running water for 5 minutes. Slides were then placed in a staining chamber and 
covered with a drop of wash buffer (Dako, Denmark).   
All subsequent steps were performed using the Vectastain® Universal Elite® ABC 
kit (Vector Laboratories, California) according to the manufacturer’s instructions; 
incubations were carried out at room temperature in a humidified chamber. The wash 
buffer was removed and the sections covered with a drop of horse serum for 20 
minutes to block non-specific binding sites. Serum was then removed and primary 
antibody (see Table 2.4) was diluted in Antibody Diluent solution (Dako, Denmark) 
and applied to the tissue for 40 minutes. Slides were washed twice with wash buffer 
(2 minutes each) and the tissues covered with either biotinylated anti rabbit and 
mouse solution  (from Vectastain® Universal Elite® ABC kit) or biotynilated anti-
rat secondary antibody (Anti-Rat Immunoglobulins/HRP, Dako, Denmark, 1:300 
dilution) for 30 minutes. After washing the Vectastain ABC reagent was applied for 
30 minutes. Slides were washed twice with wash buffer (2 minutes each) and DAB 
solution was prepared in the meantime by adding one drop of DAB chromogen to 1 
ml of DAB substrate buffer (Vector Laboratories, California). Tissues were 
incubated with DAB solution for 5 minutes followed by washing in running water for 
5 minutes. Sections were counterstained in Gill’s haematoxylin and subsequently 
dehydrated and mounted using DePex mounting media (Sigma, Poole, U.K.) under 
22 x 64 mm coverslips (VWR, U.K.) using an automated coverslipping machine 
(ThermoScientific, Germany). Negative controls were performed in which the 
diluted primary antibody was omitted from the staining procedure. 
2.11.1 Antigen retrieval optimization procedure  
In order to find the optimal antigen retrieval condition for each antibody, an 
optimization procedure that tests twelve different conditions was employed. This 
procedure gives a quick indication of the most suitable method, which can then be 
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fine tuned if required. The twelve conditions differ in pH of the antigen retrieval 
solution, heating method (microwave or waterbath) and time of incubation; 
conditions are listed in Table 2.4. 
 
 










solution and pH 
Microwave Microwave Waterbath Waterbath 
Vector Antigen 
unmasking solution  
pH 6.0  
(VectorLab, USA) 
10 min  
(condition 1) 
35 min  
(condition 2) 
10 min  
(condition 3) 
35 min  
(condition 4) 
Tris EDTA Citrate 
unmasking solution  
pH 8.1 
10 min  
(condition 5) 
35 min  
(condition 6) 
10 min  
(condition 7) 
35 min  
(condition 8) 
Tris EDTA Citrate 
unmasking solution 











Table 2.5: List of antibody used for DAB immunohistochemical analysis of GLI 


















2.12 Immunofluorescent cytochemistry and quantification 
Cells were seeded onto sterile 19 mm cover slips within 6- well tissue culture plates 
(2x104 cells each) and cultured to subconfluence. Culture media was removed and 
cells washed twice in PBS and fixed in 4% (w/v) paraformaldehyde overnight. The 
next day paraformaldehyde was removed and cells washed in PBS (three times, 5 
minutes each). Keratinocytes were permeabilised in 0.1% (v/v) Triton X-100 -PBS 
and aspecific binding sites were subsequently blocked with 3% (w/v) BSA-PBS 
(Sigma-Aldrich, U.K.). The blocking solution was removed and primary antibody 
(see Table 2.5) diluted in 3% (w/v) BSA-PBS was added to the wells for 1 hour 30 
minutes. Cells were washed in PBS (three times, 5 minutes each) to remove the 
unbound primary antibody and subsequently incubated with the appropriate 
secondary antibody (Alexa Fluor, Invitrogen, U.K.) for 1 hour 30 minutes in the 
dark. After washing with PBS (three times, 5 minutes each), cells were incubated in a 
4’,6-diamidion-2-phenylindole dihydrochloride (DAPI) solution (1:5000 in PBS, 
Invitrogen, U.K.) for 5 minutes. Unbound DAPI was removed by washing with PBS 
(5 minutes) and coverslips inverted and mounted onto slides with fluorescent 
mounting media (Vector Laboratories, U.S.A.). Slides were observed using a Zeiss 
LSM 510 META microscope (Carl Zeiss, Germany). Image quantification was 
performed with Image J software (v.1.41, NIH, U.S.A.). Briefly, using the ‘freehand 
selection tool’ the contour of a cell is selected and its area and fluorescence intensity 
values are measured; by multiplying the area by the fluorescence intensity an 
integrated fluorescence density value is obtained. The integrated fluorescence density 
of ten randomly selected cells is measured for each picture. Relative fluorescence 
density values are obtained by dividing integrated fluorescence density values of a 
sample by the integrated fluorescence density values of an appropriate control (e.g. 
untreated cells). Results are expressed as a relative fluorescence increase or decrease 












2.13 Total RNA extraction from cultured cells 
All work surface and pipettes were cleaned with RNase Zap (Ambion, U.K.) to 
remove RNAses. Total RNA extraction was achieved using RNeasy Mini Kit 
(Qiagen, U.K.) following the manufacturer’s instructions. Briefly, 10 l of -
mercaptoethanol were added to each 1 ml of kit component Buffer RLT and this 
solution used to scrape cells off the culture dishes after the media had been removed. 
Buffer RLT disrupts the cell membrane allowing release of RNA into the solution; it 
also contains a denaturing agent that inactivates RNase enzymes, thus preserving 
RNA integrity.  
All centrifugation steps were performed at 13,000 rpm for 15 sec at room 
temperature and all flow-throughs were discarded unless stated otherwise. Cell 
lysates were homogenized using a QIAshredder Mini Spin column (Qiagen, U.K.) by 
centrifugation at 13,000 rpm for 2 min. One volume of 70% (v/v) ethanol was added 
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to the flow through solution, the sample was transferred into an RNeasy Mini Spin 
column and centrifuged. Genomic DNA was digested by adding 10 l DNase I stock 
solution to 70 l Buffer RDD (RNase Free DNase Set, Qiagen, U.K.) and placing the 
80 l solution on top of the column for 15 min at room temperature. 700 l of RW1 
buffer was then added to the column and the samples centrifuged, followed by two 
washing with 700 l and 500 l of RPE buffer (last centrifugation step was 
performed at 13,000 rpm for 2 min). Finally, the column was transferred to a fresh 
RNase-free microfuge tube and the RNA was eluted by addition of 40 l RNase free 
water to the column followed by centrifugation at 10,000 rpm for 1 min. The last step 
was repeated using the resulting eluate to yield higher RNA concentrations. The 
RNA was quantified (see section 2.15) and stored at -80C until required. 
2.14 Total RNA extraction from tissue 
2.14.1 Whole frozen tissue 
Frozen normal human skin or BCC samples were placed in a sterile eppendorf tube, 
covered with lysis buffer (approx 300 l, depending on sample size) from the 
RNeasy Fibrous Tissue Mini Kit (Qiagen, U.K.) and homogenized using a Tissue 
Rupture (Qiagen, U.K.) according to manufacture’s instructions. Extraction of total 
RNA was subsequently achieved using the RNeasy Fibrous Tissue Mini Kit (Qiagen, 
U.K.). The RNA extraction procedure is similar to that employed for RNA extraction 
from cultured cells (see sections 2.13) except for additional digestion with 10 μl of 
proteinase K solution at 55°C for 10 min followed by centrifugation before the 
ethanol precipitation step. 
2.14.2 Sectioned frozen tissue 
Frozen normal human skin samples were sectioned using a cryostat (OTF5000, 
Bright Instrument, U.K.) and sections of 7 m thickness were placed into a sterile 
eppendorf tube containing 100 l lysis buffer. Extraction of total RNA was 
subsequently achieved using the RNeasy Micro Kit (Qiagen, U.K.). The RNA 
extraction procedure is similar to that employed for RNA extraction from cultured 
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cells (see sections 2.13) except for one extra washing with buffer RW1 and scaling 
down of volumes according to sample size.  
2.14.3 Sectioned wax-embedded tissue 
Wax-embedded normal human skin tissue samples were sectioned using a microtome 
(RM 2235, Leica Microsystems, U.S.A.) and 7 m thick sections were placed into a 
sterile eppendorf tube containing 100 l lysis buffer. Extraction of total RNA was 
subsequently achieved using the RNeasy FFPE Kit (Qiagen, U.K.). The RNA 
extraction procedure is similar to that employed for RNA extraction from cultured 
cells (see sections 2.13) except for previous removal of paraffin by sequential 
addition of 1 ml xylene and 1 ml 100% ethanol to the samples, followed by 
centrifugation. Also, an additional digestion with 10 μl of proteinase K solution at 
55°C for 10 min followed by centrifugation was performed before the ethanol 
precipitation step. 
2.15 RNA quantification 
Isolated RNA was quantified using a NanoDrop ND-1000 Spectrophotometer 
(Labtech, U.K.). The sample RNA concentration and purity was estimated from a 1 
l aliquot loaded on the spectrophotometer. The 260/280 nm ratio of absorbance was 
used to assess RNA purity; for RNA a ratio significatively lower than 2.0 indicates 
the presence of protein or phenol contaminants. A 260/230 nm ratio was also 
measured as values appreciably lower than 2 denote contamination from carryover of 
reagents used in the extraction process. 
2.16 Reverse transcriptase complementary DNA synthesis 
Reverse transcriptase is used to copy the RNA into its complementary DNA 
sequence (cDNA). The synthesis of cDNA from total RNA template was achieved 
using SuperScript III First-Strand Synthesis SuperMix (Invitrogen, U.K.). In RNA-
free microcentrifuge tubes the components listed in Table 2.6 were added and the 
mixture incubated for 10 min at 65oC to denature secondary structures and allow 
primers (random hexamers) binding.  
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After chilling on ice for 1 minute 10 l of the cDNA synthesis mix (see Table 2.7) 
was added to each tube, the solution mixed gently and incubated for 10 minutes at 
RT and then for 50 minutes at 50°C. The reverse transcriptase was omitted in the 
negative control (-RT). 
 









The reaction was terminated by heating at 85°C for 5 minutes. After chilling on ice 1 
l of RNase H was added to each tube to remove any RNA/DNA duplex and the 
reaction incubated at 37°C for 20 minutes. cDNA was stored at -20C until needed.  
2.17 Real-time polymerase chain reaction (qPCR) 
Real-time polymerase chain reaction or quantitative PCR (qPCR), is a technique 
based on the polymerase chain reaction (PCR), which is used to amplify and 
simultaneously quantify a targeted DNA or c-DNA molecule in a given sample. 
Selective amplification is obtained by using primers specific for the gene of interest: 
primers are short oligonucleotides that serve as a starting point for the DNA 
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synthesis catalysed by the polymerase. Quantification is achieved using fluorescent 
molecules that correlate qPCR product concentration to fluorescence intensity. 
Fluorescence is monitored during each cycle of amplification allowing the detection 
of the reaction in real time. The three major steps in a qPCR reaction, which are 
repeated for a definite number of cycles, are: denaturation, annealing and extension. 
The reaction mixture is heated causing the double strand of DNA to melt open 
(denaturation); primers anneal to the complementary regions in the DNA (annealing) 
giving rise to short region of double strand DNA that are extended by the polymerase 
(extension). Primers are designed to amplify a product of a specified size range, for 
qPCR they should be between 70-150 bp in length. Taq polymerase is used in qPCR 
reactions as it is a very processive enzyme and it also can withstand the high 
temperatures needed for DNA strand separation. During each cycle the Taq 
polymerase synthesises new DNA, creating more template DNA for the next cycle. 
The reaction proceeds in an exponential manner, doubling the amount of target 
during each cycle until one of the reagents becomes limiting and the reaction reaches 
a plateau. In qPCR a specific (TaqMan probes) or non-specific (SYBR Green) 
detection chemistry allows the quantification of the amplified product. The amount 
of cDNA detected at a certain point of the run is directly related to the initial amount 
of target in the sample. SYBR Green, the most used non-specific dye, it is an 
intercalating molecule that fluoresces once bound to double strand DNA; the amount 
of fluorescence emitted is related to the amount of target amplified. Since SYBR 
Green will bind to any double strand DNA, primer dimers or unspecific products can 
interfere with the quantification. To check for the specificity of the product 
amplified, it is common practice to run a melting curve at the end of the qPCR run; 
since every product will have a different dissociation temperature depending on their 
size and base contents, it is possible to check the number of products amplified. A 
valid primer pair should produce a single peak on the melting curve. At the 
beginning of the qPCR reaction there is a linear ground phase (usually the first 10 
cycles) where fluorescence emission has not yet risen above background which is 
used to calculate baseline fluorescence. During the exponential amplification phase 
the software generates a curve plotting the fluorescence values of each sample in 
relation to the cycle number. A fluorescence threshold value is selected (manually or 
automatically) where all the samples are undergoing exponential amplification. The 
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Ct value is defined as the cycle number at which a specific sample reaches the 
threshold value. The Ct value is dependent on the amount of the target initially 
present in the sample: the more abundant the template sample, the quicker this point 
is reached, giving lower Ct values. There are two different methods to measure the 
levels of expressed genes by qPCR based on Ct values, absolute and relative 
quantification. Absolute quantification relates the fluorescent signal to initial target 
amount using a standard curve, while relative quantification measures the relative 
change in mRNA expression level (comparative Ct method). In these experiments 
absolute quantification was used: a standard curve was generated for every primer 
pairs with serially diluted standards of known concentrations (100 ng, 50 ng, 10 ng, 
1ng, 0.1 ng) using cDNA from cells that express the genes of interest. The level of 
expression of the gene of interest was subsequently normalised to a housekeeping 
gene (a gene that is expressed at a constant level), namely Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Normalised values are then expressed as fold 
change expression relative to an appropriate control e.g. normal tissue, empty vector 
etc. taken as 1. Each qPCR reaction contained the components listed in Table 2.8 in a 
final volume of 20 l. 
 








Every reaction was performed in duplicate and a negative control by omission of 
cDNA (no template control) was added to each experiment. Plates were run on an 
Applied Biosystem 7500 qPCR machine (Applied Biosystem, U.K.). 
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The qPCR program was set for an initial holding step of 10 minutes at 95°c followed 
by the cycling stage. The denaturation stage was set at 95°c for 15 seconds, followed 
by the annealing and extension stage which lasted for 1 minute at 60°c; the qPCR 
machine recorded SYBR green fluorescence values during the extension step. The 
cycling stage (denaturation / annealing / extension) was repeated 40 times before the 
final dissociation stage which generated a melting curve.   
2.18 Primer design and selection 
Genomic DNA sequences for human GLI1 were obtained using Entrez, an online 
DNA sequence search engine (www.ncbi.nlm.nih.gov/entrez/query.fcgi) using the 
GenBank accession number GLI1 NM_005269. 
Primers were then designed using Primer3, an online PCR primer design program 
(www.genome.wi/mit.edu/cgi-bin/primer/primer3www.cgi), and compared against 
human sequences using an online sequence comparison program, BLAST 
(www.ncbi.nlm.nih.gov/BLAST) to ensure specific binding. Primers were designed 
to be around 20 nucleotides in length, with a 40%-60% GC content and minimal 
inter- and intra-complementary sequences to prevent hairpin and primers dimer 
formation. Sequences of both newly designed primers and primers derived from 

























2.19 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to check the integrity of the extracted RNA. 
Agarose powder was poured in TAE buffer (tris-acetate ethylediaminetetra-acetic 
acid, see Appendix I) to obtain a 1% (w/v) agarose - TAE solution. The solution was 
heated up in the microwave to dissolve the agarose and then poured in a tank; a small 
comb was placed into the solution to create wells to load the samples. When the 
agarose was set, samples were loaded onto the gel placed into a tank filled with TAE 
running buffer. To allow visualization of RNA 1 g/ml SYBR Green II RNA Gel 
Stain (Invitrogen, U.K.) was added to the gel before solidification. RNA bands were 
visualized using an U.V. translilluminator (Alpha Innotech Corporation, USA). 
2.20 Transwell migration assay 
The movement of cells from one area to another in response to a chemical signal is a 
central function in wound repair, development and the tumour metastasis. The 
transwell migration assay is a widely used test to study the migratory response of 
cells to chemotattic stimuli. The transwell is placed into a 12 well plate to form a 
system comprised of a lower and an upper chamber containing the cell suspension. 
During the assay cells are placed on the upper chamber on top of a coated cell 
permeable membrane; following an incubation period the cells that have migrated 
through the membrane are stained and counted. Cell migration assay was performed 
in Transwell chambers (tissue culture treated, 10 mm diameter, 8 m pores, Nunc, 
USA). Cells were serum starved in RM+ media containing 0.5% (v/v) FBS overnight 
and transwells were coated with either 100 g / ml collagen or 10 g / ml 
fibronectin. The following day 30000 cells per well were resuspended, added to the 
top of each chamber and allowed to migrate. After 4 hours cells that had not 
migrated were removed by using a cotton swab whereas migrated cells were fixed 





2.21 Adhesion assay 
Adhesion assays are widely used to assess the adhesive properties of cells. Cells 
were serum starved in RM+ media containing 0.5% (v/v) FBS overnight and 96 well 
plates were coated with either 100 g / ml collagen or 10 g / ml fibronectin. The 
following day cells were resuspended, placed in a 50 ml falcon tube and left in 
agitation on a rotating wheel for 1 hour. 10000 cells were placed in each 96 well and 
left to adhere for different amounts of time (45, 30, 15 or 1 minutes) before fixation 
with 4% (v/v) paraformaldehyde. Each timepoint was repeated in triplicate. Cells 
were stained with 1% crystal violet for 10 minutes, washed with PBS and 20% (w/v) 
SDS was then added to solubilise the crystal violet. The plated was put on a 
laboratory shaker for 10 minutes at 130 rpm and absorbance values at 550 nm were 









































3  Analysis of the putative feedback loop between GLI1 
and GLI2 in human epithelial cells  
 
3.1 Introduction  
Basal Cell Carcinoma development is associated with loss of the PTCH1 tumour 
suppressor gene resulting in increased expression of the GLI (GLI1 and GLI2) 
transcription factors which are thought to be vital for tumour formation. 
Overexpression of either GLI1 or GLI2 in the basal layer of mice or frog skin results 
in BCC-like tumours (Dahmane et al., 1997; Grachtchouk et al., 2000; Nilsson et al., 
2000; Sheng et al., 2002). Both GLI1 and GLI2 possess tumorigenic properties, 
though their sequence of activation is still debated; moreover it is not clear whether 
one has a predominant role in the genesis of the tumours or if they have a synergistic 
effect. This would be ideally investigated using in vitro models of BCC, though at 
the moment a very limited number exist (see section 1.8.2). From mammalian 
developmental studies, the activation of GLI1 is thought to depend upon GLI2 (Bai 
and Joyner, 2001). Indeed, using a cell-based inducible system, Regl et al. (2002) 
(Regl et al., 2002) showed that a constitutively active mutant of GLI2 (GLI2N) 
induces endogenous GLI1 mRNA expression in HaCat cells and this was later 
confirmed at the protein level in primary human keratinocytes (Bonifas et al., 2001; 
Ikram et al., 2004). Regl et al (2002) also showed that ectopic GLI1 induces 
endogenous GLI2 mRNA expression and thus proposed the presence of a positive 
GLI1-GLI2 feedback loop that may perpetuate the oncogenic effects of both 
transcription factors in BCC. Based upon the kinetics of transcripts expression, GLI1 
is thought to be a direct transcriptional target of GLI2N; moreover, GLI2N binds 
to the human GLI1 promoter (Bonifas et al., 2001; Ikram et al., 2004). On the other 
hand, based upon the kinetics of transcript expression and by comparison with the 
induction of PTCH1 mRNA,  GLI2 appears to be an indirect target of GLI1 (Regl et 
al., 2002). 
In contrast to these studies based on mRNA levels, previous work in the lab had 
found evidence that endogenous GLI2 protein is suppressed in prostate cells by 
ectopic GLI1 (see section 1.8.2). We proposed to analyse the GLI1-GLI2 feedback 
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loop at protein level in N/Tert-1 keratinocytes. Clarifying this interplay in skin cells 
and understanding its relevance for BCC development may be useful for choosing 


























3.2.1 GLI2 protein appears to be downregulated upon ectopic expression of 
GLI1 in immortalised keratinocytes (N/Tert-1) 
Continuing work previously carried out in the Neill group (described in section 
1.8.2), I analysed GLI2 protein levels in GLI1-expressing N/Tert-1 keratinocytes. At 
the time I started this project, the Neill group employed N/Tert-1 keratinocytes 
cultured in KGM which contains 10% FCS. This was done because maintaining 
expression of ectopic proteins (GLI1 and GLI2N) during serial passage was not 
possible in cells cultured in SFM. Using the same antibody employed in the past 
(GLI2 H-300, Santa Cruz) but different aliquots, expression of GLI2 in clonal 
N/Tert-1 cells stably expressing EGFP or an EGFP-GLI1 fusion protein was 
analysed. The pattern of GLI2 expression was different to that observed in N/Tert-1 
cells cultured in SFM with the most notable difference being the presence of a very 
strong band migrating between the 47 and 62 kDa marker proteins (cf. Fig. 1.8, lane 
1 and Fig. 3.1, lane 1). The identity of this band has not been established but it has 
also been observed in LNCaP and DU145 prostate cancer cells cultured in RPMI 
1640 medium containing 10% FCS (Mr Sandeep Nadendla, data not shown). 
However, it likely represents GLI2 as, along with several other distinct bands, its 
expression appears to be suppressed in the N/Tert-1 EGFP-GLI1 lysate (Fig. 3.1 a, 
lane 2).  
This Western Blotting experiment was repeated using the same lysates but probing 
the membrane with a different aliquot of the GLI2 H-300 antibody. The expression 
of several bands was suppressed in EGFP-GLI1 cells suggesting that ectopic GLI1 
may suppress GLI2 protein expression in human keratinocytes (Fig. 3.2). 
GLI2 protein expression was also analysed in N/Tert-1 keratinocytes overexpressing 
GLI1 using the pBabePuro vector system and cultured in KGM media (10% FCS). 
N/Tert-1 pBabe, N/Tert-1 pBGLI1 and N/Tert-1 pBGLI2N cell lines were 
previously generated in the lab by Dr Wesley Harrison by transduction followed by 
drug selection; these keratinocytes stably express either GLI1 or GLI2N. In 
pBGLI1 keratinocytes, a reduction in the level of endogenous GLI2 is observed (Fig 
3.3 a, lane 2) by Western Blotting. GLI2 is downregulated upon GLI1 expression, 
 105 
although not as strongly as in the EGFP – EGLI1 system (Fig 3.1). A slight reduction 
in the intensity of the lower molecular band at around 60 KDa is also observed; 
because of the strength of the band, this is more evident with a lower time exposure 
(Fig 3.3 a, lower panel). A third aliquot of the GLI2 H-300 antibody, different from 
the ones used previously, was employed. GLI1 was detected taking advantage of a 
newly commercialized antibody, GLI1 965 RD (GLI1 Part 965884, ExactaChIP Kit, 
R&D Systems), whose epitope sequence or localization could not be disclosed by 
R&D Systems technical service. Two bands are detected and, since they are only 
present in the pBGLI1 lane (Fig 3.3 b, lane 2), they likely represent ectopic 
expressed GLI1 and either a degradation product or an induced isoform. Different 
GLI1 variants have been described in the literature (Shimokawa et al., 2008; Lo et 
al., 2009; Altaba, 1999; Stecca and Ruiz i Altaba, 2009).  
NEB1 pBabe, NEB1 pBGLI1 and NEB1 pBGLI2N cell lines, also created by Dr 
Wesley Harrison, were also tested. No ectopic GLI1 (Fig 3.9 b, lane 2) nor GLI2 
expression (Fig 3.9 a) could be detected; concerning the latter, no unique band is 
present in the pBGLI2N lane compared to pBabe and pBGLI1, suggesting ectopic 
GLI2 is not detected. Two bands are observed in all lanes (pBabe, pBGLI1 and 
pBGLI2N), whose intensity is overall similar, with a slight decrease in the 
pBGLI2N lane. They likely represent endogenous GLI2, although it is unusual for 
GLI2 to be weaker in pBGLI2N cells as it is usually the same strength or even 
stronger in the pBGLI2N lane compared to pBabe (cf. Fig 1.7 a, Fig 1.8 a and Fig 
3.3 a). The intensity of the lower molecular band at around 60 KDa is comparable in 
all lanes. Analysis of levels of endogenous GLI2 protein expression pattern in NEB1 
keratinocytes will need to be addressed in further studies, as it may differ from those 
of other cell lines previously analysed; moreover, the identity of the lower molecular 
band should be confirmed, as argued in the Discussion section.  
The extent of GLI2 downregulation in N/Tert-1 keratinocytes (grown in serum-
containing media KGM) was not as strong using the pBabe expression system 
compared to the EGFP system (based on pSIN vectors, see Materials and Methods), 
as observed comparing Fig. 3.1 and Fig. 3.3. To help understand this discrepancy, 
qPCR experiments were performed.  
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In N/Tert-1 pBGLI1 keratinocytes there is a roughly 6 fold increase (logarithmic 
scale) in the mRNA levels of GLI1 compared to pBabe control, as expected (Fig. 
3.4); GLI2 mRNA levels are increased less than 2-fold. Conversely, N/Tert-1 
pBGLI2N keratinocytes show a 5 fold increase for both GLI2 and GLI1 mRNA 
levels. These observations are consistent with previous publications, as GLI1 is 
thought to be a direct transcriptional target of GLI2N, while activation of GLI2 by 
GLI1 is likely to be indirect (Bonifas et al., 2001; Ikram et al., 2004; Regl et al., 
2002). Levels of GLI target gene PTCH1 were also measured, using two different 
pairs of primers: a similar increase in PTCH1 mRNA (between 2.5 – 3 fold) is 
observed in both pBGLI1 and pBGLI2N cells, regardless of the pair of primers 
used (Fig 3.4).  
Levels of PTCH1 mRNA were also analysed in NEB1 keratinocytes: PTCH1 is 
induced only about 1 fold in pBGLI1 keratinocytes compared to control, whereas 
virtually no PTCH1 induction is detected in pBGLI2N keratinocytes (Fig 3.10). 
These data, combined with the fact no ectopic GLI1 or GLI2 is detected by Western 
Blotting in NEB1 keratinocytes (Fig 3.9), suggest the proteins are either not strongly 
expressed or not very active; therefore, experiments with NEB1 cells were no longer 
pursued. 
To further analyse GLI1-induced downregulation of GLI2 at protein level, 
immunofluorescence cytochemistry experiments were performed on N/Tert-1 pBabe, 
N/Tert-1 pBGLI1 and N/Tert-1 pBGLI2N keratinocytes. Staining with GLI1 965 
RD is stronger in pBGLI1 cells, as it would be expected, as both endogenous and 
ectopic GLI1 are detected; of note, GLI1 staining is heterogeneous in both intensity 
and localisation, e.g. some cells stain stronger than others, and GLI1 can be nuclear 
and cytoplasmic or predominantly nuclear (Fig 3.5 c). Although not statistically 
significative, quantification of GLI1 965 RD staining reveals an increase in GLI1 
staining in pBGLI1 keratinocytes compared to N/Tert-1 and N/Tert-1 pBabe cells, 
and also a slight increase of GLI1 in pBGLI2N cells (Fig 3.6).Similarly to what has 
been observed for GLI1, GLI2 H-300 staining is more intense in pBGLI2N 
keratinocytes; again, staining heterogeneity is striking feature, as different staining 
intensities are present even in the same colony of cells (Fig. 3.7 d). Staining 
quantification highlights the increase in GLI2 in pBGLI2N cells and shows a 
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negligible increase in pBGLI1 cells compared to N/Tert-1 and pBabe cells, which is 
not statistically significative (Fig 3.8).  
To address the physiological relevance of these preliminary findings, and to 
determine the extent of GLI1 – GLI2 co-expression in vivo (which has never been 
previously investigated) immunohistochemical analysis for GLI1 and GLI2 in human 
BCCs samples has been performed (see Chapter 4). 
 
Please note: GLI1 965 RD (GLI1 Part 965884, ExactaChIP Kit, R&D Systems) was 
only made commercially available after this thesis was originally submitted; 
experiments performed with this antibody were added subsequently to that date as 
part of the thesis corrections. This is the reason why GLI1 965 RD has not been used 
in immunofluorescence experiments on Basal Cell Carcinoma sections (which could 
be part of future work concerning this project) and is not further discussed in the 

















































Figure 3.1: Western Blotting for GLI2 protein levels in N/Tert-1 keratinocytes 
overexpressing GLI1 (GLI2 H-300 antibody - batch 1) 
Effect of GLI1 overexpression in N/Tert-1 keratinocytes. In EGFP empty vector control cells 
endogenous GLI2 as well as lower molecular bands are present, the strongest at about 50 
KDa (Fig 3.1 a, lane 1). Ectopic expression of GLI1 (Fig 3.1 b, lane 2) seems to induce full 
length GLI2 protein downregulation and disappearance of the lower molecular weight 
product (Fig 3.1 a, lane 2). Total ERK was used as a loading control (Fig 3.1 c). Cells were 





























Figure 3.2: Western Blotting for GLI2 protein levels in N/Tert-1 keratinocytes 
overexpressing GLI1 (GLI2 H-300 antibody - batch 2) 
Effect of GLI1 overexpression in N/Tert-1 keratinocytes. Lysates from Figure 3.1 were run 
on a new gel and the membrane probed with a different batch of GLI2 H-300 antibody 
compared to the one used in Figure 3.1 (Fig 3.2 a, batch 2, Figure 3.1 a, batch 1). In EGFP 
empty vector control cells endogenous GLI2 as well as lower molecular bands are present, 
the strongest at about 50 KDa (Fig 3.2 a, lane 1). Ectopic expression of GLI1 (Fig 3.2 b, lane 
2) seems to induce full length GLI2 protein downregulation (Fig 3.2 a, lane 2) and 
disappearance of the lower molecular weight product (Fig 3.2 a, lane 2). Cells were grown in 






























Figure 3.3: Western Blotting for GLI2 protein levels in N/Tert-1 keratinocytes 
overexpressing either GLI1 or GLI2N  
Effect of GLI1 overexpression in N/Tert-1 keratinocytes. Ectopic expression of GLI1 (Fig 
3.3 b, lane 2) slightly reduces GLI2 protein levels (Fig 3.3 a, lane 2). Total ERK was used as 
loading control (Fig 3.3 c).Cells were grown in KGM (10% serum media). pBP, pBabePuro 








Figure 3.4: qPCR analysis of N/Tert-1 keratinocytes overexpressing either GLI1 
or GLI2N  
qPCR measurements of mRNA levels of GLI1, GLI2 and PTCH (two different sets of 
primers) in N/Tert-1 keratinocytes stably expressing GLI1 or GLI2N. All values refer to 
mRNA levels normalised to GAPDH and are expressed as logarithmic fold changes relative 

































Figure 3.5: Immunofluorescent analysis of N/Tert-1 keratinocytes 
overexpressing either GLI1 or GLI2N using GLI1 965 RD antibody  
N/Tert-1 (a), N/Tert-1 pBP(b), N/Tert-1 pBP GLI1 (c) and N/Tert-1 pBP GLI2N (d) 







Figure 3.6: Quantification of immunofluorescent analysis of N/Tert-1 
keratinocytes overexpressing either GLI1 or GLI2N using GLI1 965 RD 
antibody 
Quantification of GLI1 965 RD antibody fluorescence intensity in N/Tert-1, N/Tert-1 pBP, 
N/Tert-1 pBP GLI1 and N/Tert-1 pBP GLI2N keratinocytes. Images displayed in Fig. 3.5 
were quantified using the image processing software Image J. Data are expressed as mean ± 

































Figure 3.7: Immunofluorescent analysis of N/Tert-1 keratinocytes 
overexpressing either GLI1 or GLI2N using GLI2 H-300 antibody  
N/Tert-1 (a), N/Tert-1 pBP(b), N/Tert-1 pBP GLI1 (c) and N/Tert-1 pBP GLI2N (d) 






Figure 3.8: Quantification of immunofluorescent analysis of N/Tert-1 
keratinocytes overexpressing either GLI1 or GLI2N using GLI2 H-300 
antibody 
Quantification of GLI2 H-300 antibody fluorescence intensity in N/Tert-1, N/Tert-1 pBP, 
N/Tert-1 pBP GLI1 and N/Tert-1 pBP GLI2N keratinocytes. Images displayed in Fig. 3.7 
were quantified using the image processing software Image J. Data are expressed as mean ± 




































Figure 3.9: Western Blotting for GLI2 protein levels in NEB1 keratinocytes 
overexpressing either GLI1 or GLI2N  
Effect of GLI1 overexpression in NEB1 keratinocytes. No ectopic GLI1 (Fig 3.4 a, lane 2) 
nor GLI2 expression (Fig 3.4 b) could be detected. Total ERK was used as a loading control 











Figure 3.10: qPCR analysis of NEB1 keratinocytes overexpressing either GLI1 
or GLI2N  
qPCR measurements of mRNA levels of PTCH (two different sets of primers) in N/Tert-1 
keratinocytes stably expressing GLI1 or GLI2N. All values refer to mRNA levels 
normalised to GAPDH and are expressed as logarithmic fold changes relative to 











3.3 Discussion  
GLI2 Western Blot analysis of epithelial cells upon GLI1 overexpression revealed an 
unexpected downregulation of GLI2 as well as differences in GLI2 expression 
pattern between different cell types (see Fig. 1.7, 1.8, 3.1 and 3.3). To interpret these 
results, it is useful to consider a number of complexities which are intrinsic to 
Hedgehog /GLI signalling. 
Full length GLI proteins have been speculated to have activator as well as repressor 
functions, the latter as a result of carboxyl-terminal cleavage by the proteasome 
(Ruiz i Altaba et al., 2002). Two GLI1 splice variants (Shimokawa et al., 2008; Lo et 
al., 2009) and four different isoforms of GLI2 have so far been described (Tanimura 
et al., 1998); moreover, GLI2 transcript has been shown to be subject to alternative 
splicing in different cell lines (Speek et al., 2006). The complete full length GLI2 
sequence had only been discovered in 2005 (Roessler et al., 2005); before this date a 
truncated form of GLI2, subsequently named GLI2N, was thought to represent the 
whole protein.  
In some contexts GLI proteins have been shown to be activated independently of HH 
signalling in response to fibroblast growth factor (FGF) signalling (Brewster et al., 
2000), loss of the tumour suppressor Notch (Nicolas et al., 2003) or exposure to 
TGF ligand (Dennler et al., 2007; Dennler et al., 2009). GLI protein activity has 
also been shown to be modulated by interaction with other cellular pathways 
frequently activated in human malignancies such as RAS and EGFR (Lauth and 
Toftgard, 2007; Schnidar et al., 2009).  
Normal, immortalised and malignant epithelial cell lines have different genetic 
arrangements, and specific signalling pathways may be active in each cell: this could 
explain the different GLI2 expression pattern observed in primary prostate epithelial 
cells (PrEc) compared to the immortalised keratinocytes cell line N/Tert-1 (both 
grown in serum-free media). In N/Tert-1 keratinocytes the amount of full-length 
GLI2 is reduced upon GLI1 overexpression, together with the appearance of a 
slightly lower molecular band that could be either a degradation product or a yet 
unidentified GLI2 isoform (Fig 1.8). In PrEc cells this lower band is not noticeable 
while full-length GLI2 is almost absent when GLI1 is overexpressed (Fig 1.7). A 
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lower band at about 50 kDa is observed but because of its weakness it is difficult to 
interpret.  
GLI2 pattern of expression seem also to be influenced by the culture media used, as 
it presents some differences in N/Tert-1 grown in serum free media (Fig 1.8) 
compared to KGM (10% serum, Fig 3.1 and 3.2). While in SFM a single full-length 
GLI2 band is present in control cells, multiple bands are observed in serum-
containing media; of particular interest is a strong band of about 50 kDa molecular 
weight that is present in control cells but is downregulated upon GLI1 
overexpression. This low molecular band has also been detected in prostate cancer 
cell lines (Mr. Sandeep Nadendla and Dr. Graham Neill, unpublished data) grown in 
serum-containing media (RPMI 1640), raising the hypothesis that expression of this 
putative degradation product or novel isoform could be the result of cellular 
pathway(s) that are only activated in the presence of serum. 
GLI2 possesses an amino-terminal repressor domain, a central zinc-finger DNA-
binding domain and a carboxyl-terminal activator domain; it can act as activator or a 
repressor of transcription. In the absence of HH signalling, GLI2 is converted from a 
transcriptional activator to a transcriptional repressor: protein kinase A (PKA) 
phosphorylation leads to a proteasome-mediated processing which yields a carboxyl-
terminus truncated repressor (Ruiz i Altaba et al., 2002; Sasaki et al., 1999; Pan et 
al., 2009). As a result of HH binding processing of GLI2 is inhibited, leading to the 
accumulation of its full-length form and the activation of specific target genes 
(Stecca and Ruiz i Altaba, 2010). Full length GLI2 is a weak transcriptional 
activator; in response to HH signalling, proteolytic removal of the amino terminal 
repressor domain appears to be required to convert GLI2 into a strong activator 
(Sasaki et al., 1999; Sheng et al., 2002; Roessler et al., 2005). A study in mice 
revealed full length GLI2 is highly unstable in the absence of HH signalling; GLI2 
degradation is dependent on consecutive phosphorylations by PKA, CK1 and GSK3, 
which result in interaction with the β-TrCP ubiquitin ligase and proteasome-mediated 
degradation (Pan et al., 2006b). The hyperphosphorylation of GLI2 creates binding 
sites for the β-TrCP ubiquitin ligase; the mutation of serine 662 to alanine in the 
binding motif of GLI2 significantly impairs its ability to interact with β-TrCP (Bhatia 
et al., 2006). Mice GLI2 has been reported to be inefficiently proteolytically 
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processed to form a transcriptional repressor in vivo (Pan et al., 2006b). Both 
processing and degradation of GLI2 are inhibited by activated HH signalling. In 
biochemical studies based on exogenous GLI2 overexpression several protein 
fragments smaller than full-length GLI2 have been detected, which provide further 
evidence of GLI2 proteolytic processing (Altaba, 1999; Aza-Blanc et al., 2000). 
GLI2 proteolytic processing adds a layer of complexity to the regulation of HH 
signalling and its relevance for BCC development has not been fully elucidated yet. 
Four different GLI2 isoforms have been reported, alpha (), beta (), gamma () and 
delta (), whose transcripts are generated by combinations of two independent 
alternative splicing sites (Tanimura et al., 1998). Alternative splicings result in a 51-
base deletion of the coding frame in the beta () and delta () isoforms, and a 1,231-
base deletion in the gamma () and delta () isoforms. The longest clone, alpha (), 
was thought to consists of 4,961 bp and to encode a 1,258 amino acids protein.  
A previously unidentified 328 amino acids long N-terminal domain of the human 
GLI2 protein has later been described (Roessler et al., 2005), and now the full-length 
protein is thought to be composed  of 1586 amino acids. Four different protein 
variants are encoded by the four transcripts, with the region between amino acids 
positions 394 and 410 missing in the beta () and delta () isoforms and the region 
between amminoacids positions 1158 and 1586 is missing in the gamma () and delta 
() isoforms (according to UniProtKB/Swiss-Prot database, GLI2_HUMAN, 
accession number P10070, see also Appendix III). Predicted molecular weights for 
alpha (), beta (), gamma () and delta () protein isoforms are, respectively, 133-, 
131-, 88-, and 86-kDa (Tanimura et al., 1998). Differences in size between alpha () 
(133 kDa) and beta () (131 kDa) and between gamma () (88 kDa) and delta () (86 
kDa) are too small to be detected by Western Blot (only a few kDa difference); 
however, alpha () plus beta () isoforms can be distinguish from gamma () plus 
delta () as the difference in molecular weight is around 50 kDa (133 and 131 kDa 
alpha () plus beta () versus 88 and 86 kDa gamma () plus delta ()).  
Using an in-house antibody against a region present in all the isoforms and located at 
the N-terminus of human GLI2, these alpha / beta (/) and gamma / delta (/) 
isoforms have been detected by Western Blot (Tanimura et al., 1998) in Hut 102 
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cells (Fig 3.7). This antibody was raised against amino acids 1 to 506 of human 
GLI2; bearing in mind that the full-length GLI2 was only discovered afterward, that 
would mean the region recognised would correspond to amino acids 328 to 834 (328 
+ 506 = 834): nonetheless, all the isoforms would be recognised. This observation 
could offer a possible explanation of the discrepancy between the predicted 
molecular weights of alpha () plus beta (), around 133 kDa, and the migration 
observed upon Western Blot analysis, around 155 kDa (Fig 3.11) (Tanimura et al., 
1998). GLI2 N-terminal domain, discovered in 2005, is composed of 328 amino 
acids (Roessler et al., 2005); considering the average molecular weight of one amino 
acid to be around 135 daltons (da), 328 amino acids would amount to approximately 
44 kDa. These additional 44 kDa would make GLI2 molecular weight about 170 
kDa; a similar case could be made for gamma () plus delta () isoforms, which 
would go from 88 to 120 kDa. This observation highlights how molecular weights 
should be interpreted with caution.  
GLI2 protein isoforms were described by Tanimura et al. using Hut102, a T-cell 
lymphoma cell line grown in media containing 10% serum. Of note, a lower 
molecular band is detected by Western blot, which is hyphothesised to be a degraded 
fragment of GLI2 but whose identity is not further investigated in the paper. It is 
tempting to speculate this band could be related to the one observed in N/Tert-1 
keratinocytes grown in serum-containing media (Fig 3.1 and 3.2). 
The antibody used for Western Blotting, GLI2 H-300 (Santa Cruz), is a rabbit 
polyclonal raised against amino acids 841-1140 mapping near the C-terminus of 
human GLI2; all known GLI2 isoforms mRNA encode this region and therefore this 
antibody could recognise all protein variants. Other commercially available 
antibodies against human GLI2, though raised against different sequences, also 
recognise all isoforms. If a similar pattern of band would be observed by Western 
Blot analysis using a different GLI2 antibody this would confirm the specificity of 













Figure 3.11: Identification of protein isoforms of human Gli2 in Hut102 cells by 
Western blot analysis (Adapted from Tanimura et al., 1998). 
 
 
Discriminating between alpha () (133 kDa) and beta () (131 kDa) and between 
gamma () (88 kDa) and delta () (86 kDa) by Western Blotting is not a feasible 
approach as the difference in molecular weight is tiny; even if a specific antibody 
against those 17 amino acids could be generated, differences in migration would not 
be appreciable on a Western Blot. However, an antibody whose epitope would fall in 
the region between positions 1158 and 1586, which are missing in the gamma () and 
delta () isoforms, would only recognise the alpha () and beta () isoforms and 
could be used by immunoprecipitation to specifically separate these isoforms. 
The identity of the novel GLI2 bands observed in N/Tert-1keratinocytes (Fig 1.8, 
3.1) remains to be addressed, as discussed below. Nonetheless, would they be proven 
to be novel GLI2 isoforms, targeted antibodies could be generated that would 
recognise only one or a specific subset of isoforms based on the differences in their 
sequence. It is likely that those antibodies will need to be custom-made, as 
commercially available antibodies are generally raised against conserved sequences.  
Upon GLI1 overexpression, disappearance of the main GLI2 band is accompanied by 
appearance of lower molecular weight bands that could be either degradation 
productions or differentially induced novel isoforms. To distinguish between these 
two possibilities proteasome inhibitors like MG-132 could be used; if the low 
molecular weight bands would not disappear after MG-132 treatment they are likely 
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to be novel GLI2 isoforms. Another possible approach would be using 
immunoprecipitation (IP) followed by mass spectroscopy (MS) to see if the bands 
are yet unidentified variant of the GLI2 protein. Specificity of the bands observed 
could be further investigated by performing short interfering RNA (siRNA) 
experiments. For siRNA experiments, different harpins against different regions of 
GLI2 mRNA could be needed: if a harpin targets a region which is not present in the 
putative short new isoform, the correspondent mRNA would not be targeted for 
degradation. Consistent with the hypothesis of the existence of yet unidentified GLI2 
isoforms, novel alternatively spliced forms of GLI2 generated by skipping exon 3, or 
exons 4 and 5 were recently reported (Speek et al., 2006). These variants were shown 
to be differentially expressed in normal human tissues and in a panel of cell lines; the 
presence of these transcripts could be investigated in PrEc and N/Tert-1 cells by RT-
PCR. Serial analysis of gene expression (SAGE) analysis could also be perform in 
order to identify novel GLI2 isoforms; this technique relies on bioinformatics to 
predict novel splicing variants that can be subsequently validated by RT-PCR using 
specifically designed primers. 
Previous work in the lab revealed GLI1 expression from a pBabe plasmid is able to 
downregulate GLI2 protein levels in both primary prostate cells (work performed by 
Mr Sandeep Nadendla, Fig. 1.7) and N/Tert-1 immortalised keratinocytes (work 
performed by Dr. Graham Neill, Fig. 1.8). Of note, in both experiments cells were 
grown in serum-free media (SFM). When I started this project, N/Tert-1 
keratinocytes were routinely cultured in serum-containing media (KGM, 10% FCS). 
This choice was made as maintaining expression of ectopic proteins (GLI1 and 
GLI2N) during serial passage was not possible in cells cultured in SFM (Neill et 
al., unpublished results). In the experiments I performed, GLI2 downregulation upon 
GLI1 overexpression in N/Tert-1 keratinocytes grown in serum-containing media 
(KGM) appears to be strong when cells are transduced with the EGFP – EGLI1 
system (which is based on pSIN vectors, Fig. 3.1); this phenomena, although less 
evident, is still observed when cells are transduced using the pBabe system (Fig. 3.3). 
Moreover, GLI2 expression pattern as well as the extent of GLI2 downregulation in 
N/Tert-1 keratinocytes differs from cells grown in serum-free media. A strong band 
of around 50 kDa (thought to be a GLI2 novel isoform or degradation product) is 
specifically observed in 10% serum and downregulated upon GLI1 expression in 
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EGFP-GLI1 cells but not affected in pBGLI1 keratinocytes (cf. Fig. 3.1 and Fig. 
3.3). A different putative GLI2 novel isoform / degradation product, whose 
molecular weight is intermediate between endogenous and ectopic GLI2, is 
specifically observed in pBGLI1 keratinocytes only when grown in serum-free media 
(cf. Fig. 1.8 and Fig. 3.3). Since, as mentioned before, two different expression 
system were used (pBabe or pSIN – based vectors) those differences cannot be solely 
attributed to the presence or absence of serum, although it definitely has an 
influence: it has been shown serum plays a role in regulating GLI protein levels (as 
suggested by the fact that ectopic GLI expression is lost upon passaging in SFM); 
moreover, serum-modulated cellular pathways such as RAS and EGFR are known to 
influence GLI protein activity (Riobo et al., 2006a; Lauth and Toftgard, 2007; 
Schnidar et al., 2009). The expression system used also plays a role in the 
intracellular levels of ectopic GLI1, and therefore on its ability to downregulate 
GLI2. The EGFP – EGLI1 system is based on the pSIN vector (Neill et al., 2008) 
and ectopic gene expression is driven by the cytomegalovirus (CMV) promoter, 
whereas in the pBabe system the viral Long Terminal Repeats (LTR) act as the 
promoter; LTR are prone to be methylated, which results in loss of gene expression. 
GLI1 expression levels using pBabe may be lower compared to EGFP – EGLI1: if 
we assume the negative feedback loop only operates at high GLI1 levels (e.g. over a 
certain threshold), it could explain why GLI2 downregulation is not as effective. In 
addiction to the intracellular amount of GLI1, the level of its transcriptional activity 
could influence its ability to downregulate GLI2; as mentioned before, there are 
evidences GLI protein activity is dependent on the culture media used. In the latest 
experiments (Fig. 3.4 and Fig 3.10), GLI1 mRNA levels were measured by qPCR: 
although in N/Tert-1 pBGLI1 keratinocytes there is an increase of about 6 folds 
(logarithmic scale) compared to pBabe control (Fig. 3.4), higher levels of GLI1 may 
be required for effective GLI2 downregulation (moreover, measured mRNA levels 
may be different from protein levels due to post-transcriptional regulation 
mechanisms). qPCR for the GLI target gene PTCH1 was also performed in order to 
evaluate how active GLI1 was in these cells: an increase in PTCH1 mRNA of about 
3 fold (logarithmic scale) was observed in N/Tert-1 pBGLI1 keratinocytes compared 
to pBabe control (Fig 3.4). This increment, although informative about the fact GLI1 
is indeed active in these cells, may not be sufficient to strongly inhibit GLI2 
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expression and therefore explain why only a partial reduction in GLI2 protein levels 
is observed in N/Tert-1 pBGLI1 keratinocytes (Fig. 3.3). 
Virtually no PTCH1 induction was observed in NEB1 pBGLI1 and NEB1 
pBGLI2N cells, suggesting GLI proteins are not very active (Fig 3.10); therefore, 
NEB1 keratinocytes were not analysed further. 
Immunofluorescence cytochemistry experiments performed on N/Tert-1 pBabe, 
N/Tert-1 pBGLI1 and N/Tert-1 pBGLI2N keratinocytes confirmed GLI1 or GLI2 
overexpression (respectively) as well as highlighting heterogeneity in GLI protein 
levels and localisation (Fig 3.5 – 3.8). No clear GLI2 staining intensity decrease was 
observed in pBGLI1 cells compared to N/Tert-1 and pBabe cells (Fig 3.7 b, 3.8). 
Although this result slightly differs from what has been observed by Western 
Blotting, it is most likely due to the heterogeneity in GLI2 staining intensities (Fig 
3.7 c). While immunofluorescence is an informative technique regarding GLI protein 
staining heterogeneity and localisation, it is focused by its nature on detecting 
phenomena at cellular level; in Western Blotting, on the other hand, a substantial 
number of cells is analysed and may therefore be more informative on what happens 
in the whole cell population. 
In conclusion, despite the differences in the magnitude of GLI2 downregulation upon 
GLI1 expression (due to the different expression systems and growth conditions are 
used), this phenomena was observed in both prostate cells (Fig. 1.7, Mr Sandeep 
Nadendla work) and N/Tert-1 keratinocytes (Fig 1.8 and this Chapter). This 
unexpected result questions the existence of a positive feedback loop between GLI1 
and GLI2 in human Basal Cell Carcinoma, which had been proposed based on 
mRNA levels. Consistent with this hypothesis, another project in the group (M. 
Rahman et al., unpublished results) has shown that PTCH1 suppression in NEB1 
human keratinocytes leads to an increase of GLI1 but not GLI2 mRNA. In order to 
address the biological relevance of these preliminary data, the GLI1-GLI2 interplay 
was analysed ex-vivo by immunostaining of normal human skin and Basal Cell 
Carcinoma samples; to our knowledge, this is the first study to address GLI proteins 


























4 Immunohistochemical staining for GLI proteins in 
Normal Human Hair Bearing Skin and in Basal Cell 
Carcinomas 
 
4.1 Introduction  
The Hedgehog pathway (HH) and GLI transcription factors have been shown to be 
involved in hair follicle development (St-Jacques et al., 1998; Chiang et al., 1999), 
hair regeneration (Sato et al., 1999; Wang et al., 2000b) and Basal Cell Carcinoma 
(BCC) etiology (Daya-Grosjean and Couve-Privat, 2005).  
Overexpression of either GLI1 or GLI2 in mouse or frog skin lead to the 
development of BCC-like tumors. (Dahmane et al., 1997; Grachtchouk et al., 2000; 
Nilsson et al., 2000; Sheng et al., 2002; Hutchin et al., 2005). At a molecular level, 
GLI factors are though to contribute to BCC tumorigenesis by opposing cell cycle 
arrest of keratinocytes (Regl et al., 2004a); moreover, GLI2 has been shown to 
induce anti-apoptotic genes and to repress genes associated with epidermal 
differentiation (Regl et al., 2004a; Regl et al., 2004b; (Kump et al., 2008). Whether 
GLI1 or GLI2 has a predominant role in the genesis of the tumours is still debated; 
moreover, there are only a few publications which have analysed GLI protein  
expression in human BCCs. GLI1 has been shown to be expressed in human BCCs 
by RT-PCR and in situ hybridization (Dahmane et al., 1997; Green et al., 1998). In a 
subsequent study, GLI1 protein was confirmed to be present in BCCs and was also 
observed in normal human skin, specifically in the outer root sheath of hair follicles 
and in a subset of surrounding mesenchymal cells. Of note, GLI1 was found to be 
expressed at higher levels in the ORS compared to tumour islands (Ghali et al., 
1999). GLI2 was shown to be expressed in normal skin (interfollicular epidermis and 
outer root sheath of hair follicles) and also in BCCs by in situ hybridisation (Bonifas 
et al., 2001; Ikram et al., 2004). GLI2 mRNA was also detected in skin and BCCs 
using q-PCR (Regl et al., 2002) and GLI2 protein observed by 
immunohistochemistry in outer root sheath cells of hair follicles and one BCC (Regl 
et al., 2004b). 
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Most of these studies analysed GLI factors mRNA levels; GLI protein expression by 
immunohistochemistry has been performed on a limited number of samples. Studies 
were also hindered by the lack of commercially available antibodies against GLI 
proteins. Recently, different antibodies against GLI transcription factors have been 
made commercially available: some of these were tested and optimised for detection 
of GLI proteins by immunohistochemistry in normal human hairy skin and in BCCs. 
The aim of this chapter is to characterise GLI1 and GLI2 expression pattern at the 
protein level in a panel of human BCC samples in order to better understand their 
relevance to tumor development and to determine if there is any correlation with 
tumor aggressiveness. Details on antigens used to generate the different antibodies 

































4.2 Results  
4.2.1 Lists of Human Hair Bearing Skin (NHS) and Basal Cell Carcinomas 
samples stained with antibodies against Hedgehog pathway components  
 
A panel of Hair Bearing Skin (NHS) and Basal Cell Carcinomas samples were 
stained with antibodies against Hedgehog pathway components, as summarised in 









Table 4.1: List of Hedgehog pathway antibodies optimised using Human Hair 





Table 4.2: List of all Basal Cell Carcinomas samples stained with different antibodies against Hedgehog pathway components  
4.2.2 Immunofluorescent staining of Normal Human Hair Bearing Skin with 
GLI1 (H-300) antibody 
Frozen sections of normal human hairy skin obtained from an abdominoplasty (Fig 
4.1 a, b) or a facelift surgery (Fig 4.2 a, b) were stained with the rabbit polyclonal 
antibody GLI1 H-300 (GLI1 H-300 sc-20687, Santa Cruz Biotechnology). This 
antibody has been raised against amino acids 781-1080 of GLI1 of human origin (C-
terminus); these amino acids positions span a rather large region situated from the 
centre of the GLI1 protein to its carboxyl-terminal end (see Appendix III).  
Consistent with previously published data (Ghali et al., 1999), GLI1 was found to be 
present in the outer root sheath of hair follicles and shows a predominantly 
cytoplasmic localization (Fig 4.1) with some perinuclear and nuclear staining 
observed in a few regions. In addition to the hair follicle, some positive staining was 
seen in the surrounding areas, which could be attributed to adjacent mesenchymal 
cells. This pattern of staining appears to be similar in both skin samples. The 
different intensity in the staining could be due to hair follicles being in different 
growing stages (Ghali et al., 1999). Of note, GLI1 staining is also present in the 
interfollicular epidermis, appearing to be stronger in the upper layers of the skin 






Figure 4.1: GLI1 expression in Normal Hair Bearing Human Skin derived from 
an abdominoplasty using GLI1 (H-300) antibody 
Normal human hairy skin cryosections derived from an abdominoplasty (a, b) were stained 
with an antibody against a C-terminal epitope of GLI1; positive fluorescent signal is present 
in the epidermis and in outer root sheath of the hair follicle. GLI1 is predominantly 
cytoplasmic, with a few regions displaying nuclear localization. Some staining is also 
observed in the area surrounding the hair follicle, possibly due to the adjacent mesenchymal 







Figure 4.2: GLI1 expression in Normal Hair Bearing Human Skin derived from 
a facelift using GLI1 (H-300) antibody 
Normal human hairy skin cryosections derived from a facelift surgery (a, b) were stained 
with an antibody against a C-terminal epitope of GLI1; positive staining is present in the 
epidermis and in outer root sheath of the hair follicle. GLI1 localization is predominantly 
cytoplasmic, with a few regions displaying nuclear localization. The staining pattern appears 
similar to the results observed in skin cryosections derived from an abdominoplasty (see Fig 




4.2.3 Immunofluorescent staining of Basal Cell Carcinomas with GLI1 (H-
300) antibody 
A panel of 31 BCCs belonging to different subtypes (nodular (n=20), micronodular 
(n=1), morphoeic and infiltrative (n=5), superficial (n=3), nodular / micronodular 
(n=1), nodular / morphoeic (n=1)) was stained using the GLI1 H300 (Santa Cruz) 
antibody. Staining appears to be predominantly cytoplasmic with perinuclear or 
nuclear staining observed in some areas. Out of 31 BCCs analysed, 23 (belonging to 
different subtypes) showed GLI1 staining in the tumour and also in the adjacent 
stroma, with staining appearing to be higher in intensity in the stroma (Fig 4.3, 4.4, 
4.5). In 8 BCCs GLI1 staining was mostly restricted to the epithelial component of 
the tumour, with GLI1 staining in the stroma absent or almost absent (Fig 4.6). There 
does not appear to be any correlation between the presence of GLI1 staining in the 
stroma and the BCC subtype, although since the vast majority of the samples belong 
to the nodular and micronodular subtypes (23 out of 31), no definitive conclusion 
could be reached (BCCs positive for stromal staining: nodular and micronodular  
n=15, nodular / morphoeic n=1, morphoeic n=2, infiltrative n=2, superficial n=3; 
BCCs negative for stromal staining, nodular and micronodular  n=7, infiltrative n=1).  
Positive staining cells surrounding the neoplastic lesion are likely to be of 
mesenchymal origin as they stain with an antibody against vimentin (Fig 4.7). 
Vimentin is an intermediate filament protein generally found in cells of 
mesenchymal origin and was therefore used as a bona-fide marker to distinguish the 
epithelial and mesenchymal components of basal cell carcinomas. Figure 4.7 shows 
vimentin staining of a morpheaform BCC (JG 138); another section of the same 
tumour had previously been stained with GLI1 H300 (see Fig 4.5). Vimentin staining 
is located outside the dense tumour masses and appears to be superimposable to the 
GLI1 bright stained cells observed outside the BCC tightly packed tumour structures 
(Fig 4.5).  
Out of 31 BCCs stained with GLI1 H-300 antibody, 8 (25%) showed weaker GLI1 
staining in palisading cells compared to cells located at the centre of the tumour 
masses. Basal cell carcinoma samples in which the overlying epidermis was present 
were 13, and in 9 out of 13 (69%) GLI1 H-300 staining appeared to be weaker in the 
tumour compared to the epidermis 
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Figure 4.3: GLI1 H-300 antibody staining in a nodular Basal Cell Carcinoma 
and its surrounding stroma 
Sections of BCCs belonging to different subtypes showing immunostaining for GLI1 in the 
epithelial and mesenchymal component of the tumour (Fig. 4.3, 4.4, 4.5, 4.6). Representative 
images are shown, with respective hematoxylin and eosin (H&E) staining of each tumour 
shown above the images. FP 200 – nodular BCC GLI1 staining (Fig 4.3 a, b) and H&E (Fig 
4.3 c, d). Out of 31 BCCs analysed belonging to different subtypes, 23 (74%) showed 
positive GLI1 staining in the tumour and also in the stroma (representative images in Fig. 
4.3, 4.4, 4.5). In 8 BCCs GLI1 staining appears to be restricted to the epithelial component 
(representative images in Fig. 4.6). Scale bar represents 50 µm in (a) and (b) and 200 µm in 




Please see figure legend on the next page 
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Figure 4.4: GLI1 H-300 antibody staining in a nodular/morpheaform Basal Cell 
Carcinoma and its surrounding stroma 
Sections of a nodular/morpheaform BCC (JS 668) displaying immunostaining for GLI1 in 
the epithelial and mesenchymal component of the tumour. GLI1 staining (Fig. 4.4 a, b) and 
































Please see figure legend on the next page 
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Figure 4.5: GLI1 H-300 antibody staining in a morphoeic Basal Cell Carcinoma 
and its surrounding stroma 
Sections of a morphoeic BCC (JG 138) displaying immunostaining for GLI1 in the epithelial 
and mesenchymal component of the tumour. staining GLI1 staining (Fig. 4.5 a, b) and H&E 
































Please see figure legend on the next page 
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Figure 4.6: GLI1 (H-300) antibody staining in the epithelial component of a 
nodular Basal Cell Carcinoma 
Sections of a nodular BCC (TT 686) displaying immunostaining for GLI1 restricted to the 
epithelial component of the tumour. GLI1 staining (Fig. 4.6 a, b) and H&E staining (Fig. 4.6 




































Figure 4.7: Vimentin staining in a morphoeic Basal Cell Carcinomas  
Staining of a morphoeic BCC (JG 138) with an antibody against vimentin. Cells surrounding 
the tumour mass that show positive GLI1 immunostaining (see Fig. 4.5) were postulated to 






4.2.4 Quantification of GLI1 (H-300) antibody staining in Basal Cell 
Carcinomas 
Because of the brightness of GLI1 H-300 staining in the stroma of 23 out of 31 
BCCs, we sought to quantify the intensity of the staining in the stroma compared to 
the tumour in these 23 samples.  
Out of 23 samples, 17 were suitable for quantification purposes: the remaining 6 
samples showed either similar staining intensity in the stroma and in the epithelia (n 
= 4) or the stromal component was difficult to highlight (n = 2) using the procedure 
described below. 
The image processing software ImageJ allows quantification based on fluorescence 
intensity distribution: by setting threshold values, this method permits selection of 
the epithelial or the mesenchymal component of the tumour and determination of 
their specific intensities (Fig 4.8). To allow comparison between slides, each 
flourescence measurement was normalised against the black background. Analysis of 
the quantifiable 17 BCCs in which GLI1 is present in the mesenchyme as well as in 
the epithelia reveals a statistically significative difference (P < 0.05) between the two 
tumour components, with GLI1 fluorescence intensity in the stroma notably higher 
than in the tumour (Fig. 4.9) in the samples analysed. Student’s t-Test (two-sample 
assuming unequal variance) was used for statistical analysis; the variance is assumed 
to be unequal as the tumours are derived from different individuals. 
A possible explanation for this observation is the existence of a paracrine mechanism 
of HH signalling in BCCs. Paracrine activation of HH signalling in some types of 
cancer has recently been reported (Yauch et al., 2008; Nolan-Stevaux et al., 2009; 
Tian et al., 2009) and has been shown to influence tumour growth. Alternatively, 
non-canonical activation of GLI transcription factors by transforming growth factor 
beta (TGF) has recently been described in human keratinocytes and fibroblasts 
(Dennler et al., 2007; Dennler et al., 2009); it could be responsible for the result 
observed and play a role in BCC tumorigenesis. To help distinguish between these 
two possibilities, BCCs samples were stained with an antibody against SHH (see 
section 4.2.11) to verify if SHH ligand was present in the tumour area and therefore 













Figure 4.8: Measurement of GLI1 expression levels using the Image J software 
Representative screenshots of the image processing software ImageJ highlighting either the 
epithelial (Fig. 4.8 b) or the mesenchymal (Fig. 4.8 c) component of the morphoeic BCC JG 





























Figure 4.9: Quantification of GLI1 expression levels in a subset of 17 Basal Cell 
Carcinomas that showed positive staining in both stromal and epithelial 
components 
Analysis of GLI1 fluorescence intensity in 17 BCC samples using the image processing 
software Image J reveals a statistically significative difference (P < 0.05) with staining 
intensity in the stroma notably higher compared to the tumour in the subset of samples 
analysed. Student’s t-Test (two-sample assuming unequal variance) was used, data are 










4.2.5 Immunofluorescent staining of Normal Human Hair Bearing Skin with 
GLI1 (C-18) antibody 
 
Frozen sections of normal hair bearing skin obtained from an abdominoplasty were 
stained with a different antibody against GLI1, GLI1 C-18 (GLI1 (C-18) sc-6152, 
Santa Cruz Biotechnology). GLI1 C-18 is a goat polyclonal antibody that maps 
within the range of  amino acids 1056-1106 of GLI1 of human origin (C-terminus).  
The epitope recognised is located within the last 50 amino acids of the human GLI1 
protein. These 50 residues partly overlap with the longer amino acids sequence 
recognised by GLI1 H-300  (positions 781-1080, approximately 300 amino acids, for 
further details see Appendix III). Similarly to what has been observed with GLI1 H-
300  antibody, positive staining is present in the different layers of the epidermis 
(Fig. 4.10 a) and also in the outer root sheath of the hair follicle (Fig. 4.10 b and also 
(Ghali et al., 1999). However, staining of adjacent mesenchymal cells which was 
prominent with GLI1 H-300 appears to be almost non-existent with GLI1 C-18.  
Further attempts to repeat staining with GLI1 C-18 gave inconclusive results, with 
widespread non-specific staining observed. Normal skin stained with a second batch 
of antibody showed positive green signal diffused throughout the epidermis and also 
into the dermis (Fig. 4.11 a, b). Figure 4.11 (a) and Figure 4.11 (b) show 
representative images of staining experiments performed on different days. A third 
batch of GLI1 C-18 was also tested and failed to give specific staining: green signal 
is faint and scattered through the dermis, with no staining present in the hair follicles 
(Figure 4.11 c). This inconsistency in staining results could be attributed to the high 









Figure 4.10: GLI1 expression in Normal Hair Bearing Human Skin using GLI1 
(C-18) antibody (batch 1) 
Normal human hairy skin cryosections were stained with GLI1 (C-18), an antibody that 
recognise the carboxyl-terminal end of the GLI1 protein; positive staining is present 
thorough the epidermis (a) and in the outer root sheath of the hair follicle (b). GLI1 
localisation appears to be predominantly cytoplasmic. Skin was derived from an 







Please see figure legend on the next page 
 150 
Figure 4.11: GLI1 expression in Normal Hair Bearing Human Skin using GLI1 
(C-18) antibody (batch 2 and batch3) 
Normal human hairy skin cryosections were stained with GLI1 (C-18), an antibody that 
recognise the carboxyl-terminal end of the GLI1 protein; two different batches of antibody 
were used, distinct from the one used for staining showed in Figure 4.10. No specific 
staining could be detected, with either batch 2 (Fig. 4.11 a, b) or batch 3 (Fig. 4.11 c). Figure 
(a) and (b) represent two different experiments using batch 2 and in both cases signal is 
diffused throughout the epidermis the dermis. Using batch 3 (Fig. 4.11 c), green signal is 
faint and no staining is present in the hair follicles. Skin was derived from a facelift surgery. 


























4.2.6 Immunofluorescent staining of Normal Human Hair Bearing Skin with 
GLI1 (RD) antibody 
Frozen sections of normal hair bearing skin obtained from an abdominoplasty were 
stained with a third antibody against GLI1. GLI1 RD (GLI1 MAB3324, R&D 
Systems)  is a rat monoclonal antibody raised against amino acids 1-234 of GLI1 of 
human origin (N-terminus); contrary to the antibodies previously used (GLI1 H-300 
and GLI1 C-18), GLI1 RD recognises the amino-terminal portion of human GLI1. 
GLI1 staining is present thorough the epidermis, although its intensity varies (Fig. 
4.12 a); positive staining is also observed in the outer root sheath of the hair follicle 
(Fig. 4.12 b), similarly to the results obtained with GLI1 H-300 and GLI1 C-18. 
Staining appears to be predominantly cytoplasmic. GLI1 RD seemed not to be 
affected by problems of variability with different batches of antibodies and was 
therefore selected to perform double immunostaining experiments (see sections 



















Figure 4.12: GLI1 expression in Normal Hair Bearing Human Skin using GLI1 
(RD) antibody 
Normal human hairy skin cryosections stained with GLI1 (RD), a monoclonal antibody 
raised against the amino-terminal end of GLI1. GLI1 staining is present in the different 
layers of the epidermis and diffuse throughout the root sheath of the hair follicles. GLI1 is 
mainly localised in the cytoplasm. Skin was derived from an abdominoplasty surgery. Scale 




4.2.7 Immunofluorescent staining of Basal Cell Carcinomas with GLI1 (RD) 
antibody 
Six Basal Cell Carcinoma samples, all belonging to the nodular subtype, were 
initially stained using the GLI1 RD antibody. Staining throughout the tumours 
appears to be predominantly cytoplasmic.  
The GLI1 RD antibody was subsequently used to perform double immunostaining 
experiments with either Sonic Hedgehog (SHH) (see sections 4.2.10 and 4.2.11) or 
GLI2 (sections 4.2.15 and 4.2.16): taking into account those experiments a total of 20 
BCCs were stained with GLI1 RD antibody. Of these 20 samples 4 (20%) showed 
weaker GLI1 staining in palisading cells (Fig. 4.13 b). The epidermis was present in 
18 BCCs sections and in 9 of them (50%) GLI1 staining intensity appeared to be 
weaker in the tumour compared to the epidermis.  
BCC samples that gave a stromal GLI1 immunofluorescence pattern with the GLI1 
H-300 antibody were also analysed with GLI1 RD; contrary to what had been 
observed with GLI1 H-300, none of the 6 BCCs stained with GLI1 RD showed 




















Figure 4.13: GLI1 (RD) antibody staining in Basal Cell Carcinomas  
Sections of two BCCs stained with GLI1 RD antibody. Representative images are shown, (a) 
AK 674 and (b) DS 327, both nodular BCCs. GLI1 staining appears to be restricted to the 







4.2.8 DAB staining optimization of GLI1 and GLI2 antibodies on Normal 
wax-embedded Human Skin  
Some of the GLI1 and GLI2 antibodies used for immunofluorescent staining were 
also tested and optimised to be used for DAB (3,3'-Diaminobenzidine 
tetrahydrochloride) staining on wax-embedded sections; this was done in order to 
take advantage of the large number of wax embedded BCCs conserved in the 
Pathology archive as well as eliminating logistic problems associated with working 
with frozen samples. DAB staining optimisation was carried out on wax-embedded 
normal skin sections.  
In immunofluorescent immunohistochemistry the secondary antibody is linked with a 
fluorophore that allows the visualization of the antigenic sites in tissue sections, 
while in immunoperoxidase-based immunohistochemistry the secondary antibody is 
linked with the enzyme horseradish peroxidase (HRP). This enzyme catalyses 
hydrogen peroxide oxidation of the 3,3' Diaminobenzidine (DAB) substrate to yield a 
colored product which stains antigen-antibody sites brown (see also the Materials 
and Methods section).  
Prior to wax-embedding, tissues are fixed in 4% (v/v) paraformaldehyde which 
results in cross-linking of the amino groups of proteins through the formation of 
methylene bridges. These methylene linkages need to be removed before staining as 
they could mask antigenic sites and therefore interfere with primary antibody 
binding. Antigen retrieval can be heat-mediated (using a waterbath or a microwave) 
or enzymatic. The composition and the pH of retrieval buffers in which the tissues 
are heated up could also be modified to obtain the best antigen retrieval conditions. 
Details of the antigen retrieval procedure are outlined in Table 2.4. Twelve different 
conditions were tested for each antibody, each consisting of a different combination 
of heating methods, time of incubation and pH variations in the retrieval buffer. 
Pictures of the conditions that gave the best results for each of the different 
antibodies are shown in Figures 4.14 - 4.17.  
GLI1 H300, a polyclonal antibody that recognises the carboxyl-terminal end of 
human GLI1, gives a faint diffuse staining (both cytoplasmic and nuclear) thorough 
the epidermis which is best highlighted using condition 6 (Fig. 4.14 c); this condition 
was subsequently used to stain Basal Cell Carcinoma samples (see section 4.2.8). 
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GLI1 RD, a monoclonal antibody that recognises the amino terminal of human GLI1, 
also seems to work better using staining condition 6 (Fig. 4.15 b). This antibody 
gives a clearer staining which appears to be mainly nuclear and slightly stronger in 
the basal layer of the epidermis. GLI1 H300 and GLI1 RD antibodies were also used 
to stain wax-embedded Basal Cell Carcinoma samples using both fluorescence and 
DAB-based immunohistochemistry techniques (see section 4.2.8). 
Two antibodies against GLI2 were also tested, GLI2 H-300 and GLI2 Abcam; GLI2 
H300 recognise an epitope at the carboxyl-terminal end of human GLI2, while GLI2 
Abcam epitope is located in the central region of the protein. For further details 
please see section Appendix III. 
GLI2 H-300 staining is quite faint and mainly localised in the basal cell layer of the 
epidermis; this antibody seems to give similar results regardless of the condition 
used, though condition 4 seems to give a slightly clearer signal (Fig. 4.16 b).  
GLI2 Abcam staining is stronger and more diffuse thorough the epidermis, with both 
nuclear and cytoplasmic localisation; condition 6 seems to combine good signal 
specificity and limited background stain (Fig. 4.17 c). GLI2 Abcam was also used in 
immunofluorescent staining experiments on frozen skin and Basal Cell Carcinomas 


















Figure 4.14: GLI1 (H-300) antibody DAB staining optimization on wax-
embedded normal skin sections 
DAB staining of normal wax-embedded skin sections with GLI1 (H-300) antibody. 
Representative images of 4 of the 12 conditions tested: (a) condition 2, (b) condition 4, (c) 
condition 6, (d) condition 10. Condition 6 (c) seems to combine good signal specificity with 
reduced level of background and was therefore subsequently used to stain Basal Cell 










Figure 4.15: GLI1 (RD) antibody DAB staining optimisation on wax-embedded 
normal skin sections 
DAB staining of normal wax-embedded skin sections with GLI1 (RD) antibody. 
Representative images of 4 of the 12 conditions tested: (a) condition 2, (b) condition 6, (c) 
condition 8, (d) condition 11. Condition 6 (b) seems to combine good signal specificity with 
reduced level of background and was therefore subsequently used to stain Basal Cell 






Figure 4.16: GLI2 (H-300) antibody DAB staining optimization on wax-
embedded normal skin sections 
DAB staining of normal wax-embedded skin sections with GLI2 (H300) antibody. 
Representative images of 4 of the 12 conditions tested: (a) condition 2, (b) condition 4, (c) 
condition 6, (d) condition 10. This antibody appears to work similarly in different conditions, 
though condition 4 (b) seems to give a slightly clearer signal. For details of staining 







Figure 4.17: GLI2 (Abcam) antibody DAB staining optimisation on wax-
embedded normal skin sections 
DAB staining of normal wax-embedded skin sections with GLI2 Abcam antibody. 
Representative images of 4 of the 12 conditions tested: (a) condition 2, (b) condition 1, (c) 
condition 6, (d) condition 10 Condition 6 (c) seems to combine good signal specificity and a 
limited background stain. For details of staining conditions see Table 2.4. Scale bar 












4.2.9 Comparison between immunofluorescent and DAB staining with GLI1 
(H-300) and GLI1 (RD) antibodies using Basal Cell Carcinomas wax-
embedded sections  
Wax-embedded sections from two Basal Cell Carcinomas, one belonging to the 
nodular (8396A2) and one to the infiltrative (1759) subtype, were stained with either 
GLI1 H-300 (Fig. 4.18 and 4.19) or GLI1 RD antibody (Fig. 4.20, 4.21). For each 
antibody, both immunofluorescence and DAB-based immunohistochemistry were 
used. Two different batches of GLI1 RD antibody were tested to asses the impact of 
batch to batch variability, as this issue had arisen when other antibodies against GLI 
proteins were used. Pictures of immunofluorescence and DAB staining were taken of 
representative areas of both BCCs and overlying epidermis. Staining pattern appears 
to be overall similar with both techniques, though sometimes slightly fainter when 
DAB chemistry is used. No significative difference was observed using two different 
batches of GLI1 RD antibody. GLI1 H-300 is an antibody that recognises the 
carboxyl-terminal end of human GLI1, previously used for immunofluorescence on 
frozen sections and also optimised for use on wax-embedded section: condition 6 
(see Table 2.4) was used to perform this staining experiment. With GLI1 H-300 
antibody GLI1 staining is present in BCCs and also in all layers of epidermis, and its 
localisation appears diffuse in both the nucleus and the cytoplasm. GLI1 H-300 
seems to work better in frozen sections, with staining on wax-embedded slides being 
overall fainter (Fig. 4.18 and 4.19 compared to Fig. 4.3 to 4.6). GLI1 RD, a 
monoclonal antibody that recognise the amino-terminal end of human GLI1, also 
used in immunofluorescence experiments, seems to work better on wax-embedded 
section using staining condition 6. GLI1 RD staining results are comparable using 
two different batches of antibody and overall similar to the staining pattern observed 
with GLI1 H-300, the only noticeable difference being the increased nuclear 
localisation with GLI1 RD (Fig. 4.20, 4.21). GLI1 staining is present in all layers of 
the epidermis and also in underlying BCCs tumour masses. GLI1 RD staining seems 
to be also present in the stroma when DAB chemistry is used, while this feature is 











































Figure 4.18: Staining of a nodular wax-embedded BCC using GLI1 (H-300) 
antibody 
A nodular wax-embedded Basal Cell Carcinomas (8396A2) was stained using 
immunofluorescence (Fig. 4.18 a, c, e) or DAB-based immunohistochemistry (Fig. 4.18 b, d, 
f). Representative images of three different areas of the BCC are shown, with 
immunofluorescence staining juxtaposed to DAB staining (lower right panel). Staining 
pattern appears to be similar with both techniques, although slightly fainter when DAB 
chemistry is used. GLI1 staining is present in all layers of the epidermis and also in BCCs 
tumour masses, and its localisation seems to be diffused in both the nucleus and the 










































Figure 4.19: Staining of an infiltrative wax-embedded BCC using GLI1 (H-300) 
antibody 
An infiltrative wax-embedded Basal Cell Carcinomas (1759) was stained using 
immunofluorescence (Fig. 4.19 a, c, e) or DAB-based immunohistochemistry (Fig. 4.19 b, d, 
f). Representative images of three different areas of the BCC are shown, with 
immunofluorescence staining juxtaposed to DAB staining (lower right panel). Staining 
pattern appears to be similar with both techniques, and GLI1 localisation is similar to what is 
observed in a nodular BCC (8396A2, Fig. 4.18 a-f). GLI1 staining is present in all layers of 
the epidermis and also in BCCs tumour mass and is diffused in both the nucleus and the 






































































































Figure 4.20: Staining of a nodular wax-embedded BCC using two different 
batches of GLI1 (RD) antibody 
Two distinct batches of GLI1 RD antibody were tested to asses the impact of batch to batch 
variability (batch 1 Fig. 4.20 a-f, batch 2 Fig. 4.20 g-l). A nodular wax-embedded Basal Cell 
Carcinoma (8396A2) was stained using either immunofluorescence (Fig. 4.20 a, c, e and g, i, 
l) or DAB-based immunohistochemistry (Fig. 4.20 b, d, f and h, j, l). Staining pattern 
appears to be similar with both techniques, and no significative difference is present when 
the two batches of antibody are compared. GLI1 staining is present in the epidermis and also 
in underlying BCCs tumour masses. GLI1 localisation seems to be more nuclear with GLI1 
RD if compared with staining results using the GLI1 H300 antibody (Fig. 4.19), but areas of 
































































































Figure 4.21: Staining of an infiltrative wax-embedded BCC using two different 
batches of GLI1 (RD) antibody 
Two distinct batches of GLI1 RD antibody were tested to asses the impact of batch to batch 
variability (batch 1 Fig. 4.21 a-f, batch 2 Fig. 4.21 g-l). An infiltrative wax-embedded Basal 
Cell Carcinoma (1759) was stained using either immunofluorescence (Fig. 4.21 a, c, e and g, 
i, l) or DAB-based immunohistochemistry (Fig. 4.21 b, d, f and h, j, l). Staining results are 
similar with both techniques, and no significative difference is present when the two batches 
of antibody are compared. GLI1 staining is present in both the epidermis and in underlying 
BCCs tumour masses. GLI1 localisation seems to be more nuclear if compared with staining 




4.2.10 Immunofluorescent staining of rat adrenal cortex with Sonic Hedgehog 
(AbCam) antibody 
The Sonic Hedgehog ligand (SHH) is expressed in the outer murine adrenal cortex 
and is implicated in the adrenal gland development (King et al., 2009). In order to 
test the specificity of a Sonic Hedgehog ligand antibody (SHH, ab19897, Abcam), 
frozen sections of rat adrenal cortex were stained. Positive staining is present in the 
outer region of the adrenal cortex (zona glomerulosa) (Fig. 4.22 a, b), in accordance 
to what has been previously published (King et al., 2009). 
This SHH antibody has subsequently been used to stain BCC samples to investigate 
the hypothesis of a paracrine mode of Hedgehog signalling activation in the stroma 
























Figure 4.22: Sonic Hedgehog ligand (SHH) expression in rat  adrenal cortex 
using SHH (Abcam) antibody 
Rat adrenal cortex cryosections were stained with SHH (ab19897, Abcam), an antibody that 
recognise the amino terminal end of the Sonic Hedgehog peptide. Positive staining is present 






4.2.11 Double immunofluorescent staining of Normal Human Hair Bearing 
Skin with GLI1 (RD) and Sonic Hedgehog (AbCam) antibodies 
 
A double immunofluorescence experiment was performed on a frozen section of 
normal hair bearing skin obtained from an abdominoplasty using GLI1 (RD), a rat 
monoclonal antibody against GLI1, and SHH (AbCam), a rabbit polyclonal antibody 
against Sonic Hedgehog. GLI1 is localised through the epidermis and in the outer 
root sheath of the hair follicle, while Sonic Hedgehog is present in the upper layers 
of the epidermis and in the inner root sheath of the hair follicle (Fig. 4.23 a, b), 
consistent with data that has been previously published (Oro and Higgins, 2003). 
Of note, SHH staining was also observed in cutaneous nerve fibers, as recently 
reported by Brownell et al.; SHH action on bulge stem cells is necessary to maintain 
their ability to become epidermal stem cells and participate in epidermis regeneration 












































Figure 4.23: GLI1 and Sonic Hedgehog ligand expression in Normal Hair 
Bearing Human Skin using GLI1 (RD) and Sonic Hedgehog (AbCam) 
antibodies 
A normal human hairy skin cryosection was double stained using GLI1 (RD) (green) and 
Sonic Hedgehog (AbCam) (red) antibodies. GLI1 positive staining is present thorough the 
epidermis and in the outer root sheath of the hair follicle. GLI1 localisation appears to be 
predominantly cytoplasmic. SHH staining is localised in the upper layers of the epidermis 
and in the inner root sheath of the hair follicle. SHH staining is also observed in cutaneous 
nerve fibers. Skin was derived from an abdominoplasty surgery. Scale bar represents 50 µm. 
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4.2.12 Double immunofluorescent staining of Basal Cell Carcinomas with GLI1 
(RD) and Sonic Hedgehog (AbCam) antibodies 
Double immunofluorescence experiments using GLI1 (RD) and SHH (AbCam) were 
also performed on frozen sections of Basal Cell Carcinomas. Because of the intensity 
of GLI1 staining in the stroma using GLI1 H-300 antibody (see section 4.2.2), SHH 
ligand expression levels in BCCs were analysed in order to test the hypothesis of a 
paracrine mode of Hedgehog signalling activation in the stromal compartment. 
Although GLI1 stromal staining has been observed with GLI1 H300 and therefore it 
would have been ideal to double stain samples with GLI1 H300 and SHH, this could 
not be done as both are rabbit polyclonal antibodies. To perform double 
immunostaining experiments the two antibodies must have been raised in different 
species. GLI1 RD is a rat monoclonal antibody and was therefore chosen to double 
stain with SHH. 
A panel of 13 BCCs belonging to different subtypes: nodular (n=10), superficial 
(n=1), nodular / micronodular (n=1), nodular / morphoeic (n=1) were stained (Fig. 
4.24). 
Out of 13 BCCs analysed, only 4 showed positive staining for Sonic Hedgehog: of 
note, in 2 of these 4 samples staining intensity was very weak (Table 4.4). This 
seems to argue against paracrine signalling in BCC.  
Notably, GLI transcription factors have been recently reported to be activated by 
TGF (Dennler et al., 2007; Nolan-Stevaux et al., 2009), therefore TGF mediated 
non-canonical activation of GLI1 in the stroma may offer another possible 












Table 4.3: List of all Basal Cell Carcinomas samples stained with GLI1 (RD) 




















































































Figure 4.24: GLI1 and Sonic Hedgehog ligand expression in Basal Cell 
Carcinomas samples using GLI1 (RD) and SHH (Abcam) antibodies 
Sections of BCCs showing double immunostaining for GLI1 (GLI1 RD, green) and Sonic 
Hedgehog (red). Representative images are shown. (a) AV 501– nodular BCC (b) BD 641- 
nodular BCC (c) WC 51b – nodular BCC (d) WJ 140- nodular / micronodular BCC.  
Out of 13 BCCs analysed, belonging to different subtypes, only 4 (30%) showed positive 
SHH staining (Fig. 4.24 c); in 2 of these 4 samples SHH staining was very weak (Fig. 4.24 




4.2.13 Immunofluorescent staining of Normal Human Hair Bearing Skin with 
GLI2 (H-300) antibody 
GLI2 H-300 (GLI2 (H-300) sc-28674, Santa Cruz), a rabbit polyclonal antibody 
raised against amino acids 841-1140 mapping near the carboxyl-terminal of GLI2 of 
human origin, was used to stain frozen sections of normal human hairy skin obtained 
from an abdominoplasty. Positive staining is observed in all layers of epidermis and 
also in the outer root sheath of the hair follicles (Fig. 4.25 a, b). GLI2 localisation is 
diffuse, though slightly more cytoplasmic in the hair follicles.  
When further staining was carried out with this GLI2 antibody widespread non-
specificity was observed, possibly due to variability between batches of antibodies 



















Figure 4.25: GLI2 expression in Normal Hair Bearing Human Skin using GLI2 
(H-300) antibody 
Normal human hairy skin cryosections were stained with GLI2 H-300, a polyclonal antibody 
raised against the carboxyl-terminal end of GLI2. Positive GLI2 staining is present in the 
different layers of the epidermis (a) and in the outer root sheath of the hair follicles (b). GLI2 
localisation is both nuclear and cytoplasmic. Skin was derived from an abdominoplasty 






4.2.14 Immunofluorescent staining of Basal Cell Carcinomas with GLI2 (H-
300) antibody 
 
Two nodular Basal Cell Carcinomas AV 501 (Fig. 4.26 a) and TT686 (Fig. 4.26 b) 
were stained with GLI2 H300 antibody: this antibody recognises an epitope situated 
at the carboxyl-terminal of GLI2 of human origin. Staining is diffuse thorough the 
tumour, both in the nucleus and in the cytoplasm. Further staining with this antibody 






























Figure 4.26: GLI2 expression in Basal Cell Carcinomas using GLI2 (H-300) 
antibody 
Sections of BCCs stained with GLI2 (H-300) antibody, AV 501 (a)  and TT686 (b), both 
nodular BCCs. GLI2 is present in the epithelial component of the tumour, showing both 






4.2.15 Immunofluorescent staining of Normal Human Hair Bearing Skin with 
GLI2 (AbCam) antibody 
Frozen sections of normal human hairy skin obtained from either from an 
abdominoplasty were stained with a rabbit polyclonal antibody against GLI2 (GLI2 
ab26056, Abcam). This antibody has been raised against amino acids 600 – 649 of 
GLI2 of human origin, located in the central region of the protein. GLI2 staining is 
present in all layers of epidermis (Fig. 4.27 a), appearing slightly stronger in the 
basal layer. GLI2 is also present in the outer root sheath of hair follicles (Fig. 4.27 b) 
and shows a predominantly cytoplasmic localization, with nuclear staining observed 




















Figure 4.27: GLI2 expression in Normal Hair Bearing Human Skin using GLI2 
(Abcam) antibody 
Normal human hairy skin cryosections were stained with an antibody against an epitope 
located in the central region of the GLI2 protein; positive staining is present in all layers of 
the epidermis (a) and in the inner and outer root sheath of the hair follicle (b). GLI2 is 
mainly cytoplasmic, with nuclear localization present in some regions. Skin is derived from 





4.2.16 Double immunofluorescent staining of Normal Human Hair Bearing 
Skin with GLI1 (RD) and GLI2 (AbCam) antibodies 
A double immunofluorescence experiment was performed on frozen sections of 
normal hair bearing skin obtained from an abdominoplasty using GLI1 (RD), a rat 
monoclonal antibody against GLI1, and GLI2 (AbCam), a rabbit polyclonal antibody 
against GLI2. GLI1 RD is a rat monoclonal antibody raised against amino acids 1-
234 of GLI1 of human origin (N-terminus) while GLI2 Abcam is a rabbit polyclonal 
antibody against an epitope in the central region of the GLI2 protein corresponding 
to amino acids 600 - 649. Both GLI1 and GLI2 staining is localised through the 
epidermis (Fig. 4.28 a) and in the outer root sheath of the hair follicle (Fig. 4.28 b). 
GLI2 staining seems to be slightly stronger in the basal cell layer of the epidermis 




































































Figure 4.28: GLI1 and GLI2 expression in Normal Hair Bearing Human Skin 
using GLI1 (RD) and GLI2 (AbCam) antibodies 
Normal human hairy skin cryosections were double stained using GLI1 (RD) (green) and 
GLI2 AbCam (red) antibodies. GLI1 positive staining (green) is present thorough the 
epidermis, GLI2 staining (red) is also scattered through the epidermis but appears slightly 
stronger in the basal layer (a). Both GLI1 and GLI2 staining are present in the outer root 
sheath of the hair follicle (b). Localisation of both proteins is mainly cytoplasmic. Skin was 




4.2.17 Double Immunofluorescent staining of Basal Cell Carcinomas with GLI1 
(RD) and GLI2 (AbCam) antibodies 
Double immunofluorescence experiments using GLI1 (RD) and GLI2 (AbCam) were 
also performed on frozen sections of Basal Cell Carcinomas. A panel of 18 BCCs 
belonging to different subtypes: nodular (n=13), micronodular (n=1), superficial 
(n=3), nodular/micronodular (n=1) were stained. In most samples GLI1 and GLI2 
show extensive areas of co-expression, as well of areas where one protein appears to 
be more abundant than the other (Fig. 4.29).  
GLI1 staining appears to be diffused but sometime weaker at the invading front of 
the tumour (e.g. in the palisading cells) compared to the centre of the tumour masses 
(in about a fifth of the samples stained). It is sometimes difficult to distinguish 
between staining in the basal layer and staining in the BCC as some tumours appears 
as outgrowth from the epidermis into the dermis; it is hard to discriminate between 
normal and hyperplastic tissue. GLI2 on the other hand is sometime stronger and 
more defined in the basal layer. Some samples show areas in which GLI1 is clearly 
nuclear or perinuclear, especially in the epidermis, while a comparable pattern is 

















































































Figure 4.29: GLI1 and GLI2 expression in Basal Cell Carcinoma samples using 
GLI1 (RD) and GLI2 (AbCam) antibodies 
Eighteen frozen sections of Basal Cell Carcinomas belonging to different subtypes were 
double stained using GLI1 (RD) (green) and GLI2 (AbCam) (red) antibodies. Representative 
BCCs are shown: WC51b – nodular (a), DS327 – nodular (b), AK674 nodular (c), WJ140 – 
nodular / micronodular (d). GLI1 and GLI2 staining is present thorough the epidermis and in 
the BCC tumour masses, showing areas of overlapping expression as well as areas where one 
protein appears to be more abundant than the other. Localisation of both proteins is overall 
mainly cytoplasmic. Scale bar represents 50 µm. 
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4.2.18 Analysis of antibodies specificity in cultured cell lines 
4.2.18.1 Immunofluorescent analysis using SMO inhibitors  
 
Antibodies against GLI1 and GLI2 have been made commercially available recently 
and therefore not thoroughly been tested for specificity; however, most of the 
antibodies I used for staining of tissue sections had been used in recent publications 
(see Appendix IV). Positive results indicating good antibody specificity for GLI1 H-
300 and GLI1 C-18 have been obtained by other members of the group, as described 
in the following sections. Moreover, GLI2 H-300 has been validated in a recent 
publication (Bishop et al., 2010).   
Antibodies specificity was analysed by immunofluorescence using NEB1 
keratinocytes exposed to SMO inhibitors KAAD-cyclopamine (KAAD-cyc) and 
SANT-1. NEB1 wild-type keratinocytes had been shown to express GLI1 (M. 
Rahman et al, unpublished results); NEB1 PTCH1 knockdown keratinocytes 
(shPTCH1 189A), in which GLI1 has been shown to be upregulated (M. Rahman et 
al, unpublished results), have also been tested. KAAD-cyclopamine is a cyclopamine 
derivative that has been shown to inhibit Hedgehog signaling in a mouse cultured 
cell assay (Taipale et al., 2000), while SANT-1 is a chemically synthesized 
Hedgehog pathway inhibitor identified in a high-throughput screening (Chen et al., 
2002); both molecules act as SMO antagonists.  
Other work in the group has shown that exposure of NEB1 keratinocytes to either 
KAAD-cyc or SANT-1 100 nM for 24 hours suppresses GLI1 expression as shown 
by qPCR and immunofluorescence with the GLI1 H-300 and GLI1 C-18 antibodies 
(M. Rahman et al, unpublished data). Reciprocally, targeted suppression of PTCH1 
with shRNA leads to an increase of GLI1 as shown by qPCR and 
immunofluorescence with GLI1 H-300 and GLI1 C-18 antibodies thus helping 
confirm their specificity. In NEB1 PTCH1 knockdown keratinocytes (shPTCH1 
189A) GLI1 H-300 gives a nuclear pattern in whereas GLI1 C-18 gives a more 
diffuse cytoplasmic/nuclear pattern (M. Rahman et al, unpublished data). Using the 
conditions optimised by Mr Muhammad Rahman, I performed a preliminary 
experiment to validate GLI1 RD antibody specificity using GLI1 H-300 as a positive 
control. NEB1 keratinocytes were exposed to either KAAD-cyclopamine (100 nM), 
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SANT-1 (100 nM) or DMSO (negative control) for 24 hours, then fixed and stained 
with either GLI1 RD or GLI1 H300 antibody (Fig. 4.30); staining intensity was 
subsequently measured using the ImageJ software (Fig. 4.31). 
No significative decrease in immunofluorescence was observed with either antibody 
in cells treated with SMO antagonists (as measured with the Image J software (Fig. 
4.31)), but exposure to KAAD-cyc resulted in a partial loss of the nuclear 
immunofluorescent signal with the GLI1 H-300 (Fig. 4.30, panel e); this suggest 
GLI1 is inhibited from entering the nucleus which correlates with what is know 
about the mechanism of canonical HH signalling. The different results obtained in 
the experiment I did are possibly due to the fact a different batch of inhibitor was 
used, and this may not have been as effective (other people in the group have also 
noted batch to batch variation with SMO antagonists). I subsequently employed 
NEB1 shPTCH1 keratinocytes to determine if an increase in GLI1 fluorescence 
could be detected with the GLI1 RD antibody, similarly to what has been observed 
by Mr Muhammad Rahman with the GLI1 H-300 antibody; I included GLI1 H-300 
antibody in this experiment a positive control. 
NEB1 scramble control (shCON) or NEB1 PTCH1 knockdown keratinocytes 
(shPTCH1 189A) were fixed and then stained with either GLI1 RD or GLI1 H300 
antibody (Fig. 4.32); staining intensity was measured using the ImageJ software (Fig. 
4.33).  
With GLI1 RD antibody there seems to be slightly an increase in GLI1 fluorescence 
in PTCH1 knockdown cells (shPTCH1 189A) compared to scramble control 
(shCON) (as measured with the Image J software (Fig. 4.33)), although this is not 
statistically significative. Surprisingly this is not observed with GLI1 H-300. GLI1 
H-300 staining appears more nuclear in PTCH1 knockdown cells (shPTCH1 189A) 
(Fig 4.32), consistent with GLI1 nuclear translocation as a result of PTCH1 
inactivation; this is not as clearly observed using the GLI1 RD antibody. 
Since a decrease in GLI1 RD immunofluorescence was not observed using SMO 
antagonists, nor a clear GLI1 RD fluorescence increase in PTCH1 knockdown cells, 

























Figure 4.30: Immunofluorescent analysis of NEB1 keratinocytes treated with 
SMO inhibitors using GLI1 (RD) and GLI1 (H-300) antibodies 
NEB 1 keratinocytes were treated with SMO inhibitors KAAD-cyclopamine or SANT-1   
(both 100 nM) for 24 hours, fixed and stained with either GLI1 RD (panel a, b, c) or GLI1 
H300 antibody (panel d, e, f). Control cells were treated with DMSO only (a, d). 
Quantification of staining intensity from these images is shown in Figure 4.31. Scale bar 



























Figure 4.31: Quantification of immunofluorescent analysis of NEB1 
keratinocytes treated with SMO inhibitors using GLI1 (RD) and GLI1 (H-300) 
antibodies 
Quantification of GLI1 antibodies fluorescence intensity in NEB1 keratinocytes exposed to 
SMO inhibitors. Images displayed in Figure 4.30 were quantified using the image processing 
software Image J. (a) GLI1 RD antibody (b) GLI1 H300 antibody. Data are expressed as 


























Figure 4.32: Immunofluorescent analysis of NEB1 PTCH1 knockdown 
keratinocytes using GLI1 (RD) and GLI1 (H-300) antibodies 
NEB 1 scramble control (shCON) (a, c) or PTCH1 knockndown (sh PTCH1 189A) (b, d) 
keratinocytes were then fixed and stained with either GLI1 RD (a, b) or GLI1 H300 (c, d) 
antibody. Quantification of staining intensity from these images is shown in Figure 4.33. 





























Figure 4.33: Quantification of NEB1 PTCH1 knockdown keratinocytes using 
GLI1 (RD) and GLI1 (H-300) antibodies 
Quantification of GLI1 fluorescence intensity in NEB1 scramble control (shCON) or PTCH1 
knockdown keratinocytes (189A) using GLI1 RD or GLI1 H300 antibody. Images displayed 
in Figure 4.32 were quantified using the image processing software ImageJ. Data are 













4.2.18.2 GLI1 siRNA optimisation in NEB 1 keratinocytes  
 
Short interfering RNA (siRNA) is a technique used to modulate the expression of a 
particular gene by interfering with the stability of its messenger RNA (mRNA). Short 
double stranded RNA molecules against a specific mRNA target are introduced into 
cells by transfection; once in the cytoplasm the RNA is unwound and processed, so 
that it can bind to complementary sequence found on the mRNA leading to its 
degradation.  Conditions for GLI1 siRNA were optimised by Mr Sandeep Nadendla, 
who observed ectopic GLI1 was maximally suppressed in LNCaP-GLI1 prostate 
cancer cells 96 hours post-transfection by Western Blotting and qPCR (Nadendla et 
al., 2011). He employed a commercially available siRNA against GLI1 (si5816, 
Ambion) at 30 nM concentration. Moreover, at 96 hours post-transfection levels of 
endogenous GLI1 mRNA were reduced in DU145 and PC-3 prostate cancer cells 
(Nadendla et al., 2011)). Another positive results indicating good antibody 
specificity for GLI1 H-300 came from data obtained by Miss Jane Elliott. GLI1-
expressing BCC-derived fibroblasts were transfected with siRNA si5816 using 
Lipofectamine: after 96 hours of transfection GLI1 H-300 fluorescence was almost 
completely abolished compared to the Lipofectamine only mock transfection (J. 
Elliott et al., unpublished results). 
siGlo is a fluorescently labelled siRNA against Cyclophilin B which localises to the 
endoplasmic reticulum and is used to assess transfection efficiency. I therefore tested 
two different commercially available siRNAs (si5815 and si5816, Ambion, see 
Appendix II for details) against GLI1 in NEB 1 keratinocytes using the optimal 96 
hours timepoint and 30 nM final concentration. siGLO Cyclophilin B siRNA was 
used as a control: siGLO Cyclophilin B are fluorescent double stranded siRNA 
against Cyclophilin B, a protein widely expressed in human cells whose silencing 
does not impact on cell viability. Cells were reverse-transfected with siRNAs, grown 
for 96 hours, then fixed and stained with GLI1 RD antibody (Fig. 4.34). If the siRNA 
had successfully downregulated GLI1 mRNA levels there should be a reduction in 
the amount of GLI1 protein present inside the cell and therefore a reduction in 
staining intensity. A lower level of fluorescence in cells silenced for GLI1 would 
suggest good antibody specificity. Similar validation could be carried out for GLI2 
antibodies. There seem to be no significative reduction in staining intensity in GLI1 
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silenced cells compared to siGLO controls using GLI1 RD antibody (staining 
intensity was quantified using the ImageJ software) (Fig. 4.35). Lack of reduction in 
fluorescence levels in GLI1 siRNA cells could be due to inefficient silencing, 
therefore in the following experiment GLI1 mRNA levels were analysed before 
staining for GLI1. Since NEB1 keratinocytes have been shown to be quite difficult to 
transfect (M. Rahman et al., unpublished data), Hacat keratinocytes and more easily 

























































Figure 4.34: Immunofluorescent analysis of NEB1 GLI1 siRNA keratinocytes 
using GLI1 (RD) antibody  
NEB 1 keratinocytes were treated with two different short interfering RNA (siGLI1 5815, 
panel b and siGLI1 5816, panel c) for 96 hours, then fixed and stained with GLI1 RD 
antibody. siGlo control (panel a). siGlo fluorescence in NEB1 keratinocytes: brightfield (d), 
























Figure 4.35: Quantification of immunofluorescent analysis of NEB1 GLI1 
siRNA keratinocytes using GLI1 (RD) antibody 
Quantification of GLI1 RD antibody fluorescence intensity in NEB1 keratinocytes treated 
with two different short interfering RNA (si5815, si5816); control cells were treated with 
siGlo. Images displayed in Figure 4.35 were quantified using the image processing software 





















4.2.18.3 GLI1 siRNA optimisation in Hacat keratinocytes  
 
Levels of messenger RNA (mRNA) for Cyclophilin B and for GLI1 were measured 
in Hacat cells transfected with two different commercially available siRNAs against 
GLI1 (si5815 and si5816, Ambion). Two control siRNAs were used: siGlo against 
Cyclophilin B (see section 4.2.17.2) and siAmb, a scramble non-fluorescent control 
from Ambion (Silencer Negative Control #1, Ambion, U.K.). Cyclophilin B is a 
protein expressed in most human cells and measuring the level of its mRNA in the 
siGLO Cyclophilin B siRNA transfected cells gives an indication of the efficiency of 
the transfection and a hint that successful silencing could be achieved with the 
conditions used (though siRNA against GLI1 could have a different efficiency as this 
is dependent on other factors, including the sequence used). Hacat keratinocytes were 
transfected with siRNAs and grown for 96 hours, then RNA was extracted using a 
commercially available kit (RNeasy Mini Kit, Qiagen, U.K.) and qPCR analysis was 
performed. Primers used for detection of GLI1 (Yauch et al., 2008) are designed 
against a region located in the middle of the human GLI1 mRNA transcript. 
Cyclophilin B mRNA levels appear to be reduced in Hacat siGLO cells, indicating 
successful transfection (Fig. 4.36, a). There seem to be a reduction in GLI1 mRNA 
levels with siRNA 5815 but levels are increased with siRNA 5816 (Fig. 4.36, b).  
The results of these preliminary experiments are unexpected and further investigation 












































Figure 4.36: qPCR analysis for Cyclophilin B and for GLI1 of Hacat 
keratinocytes transfected with two different GLI1 siRNAs 
qPCR measurements of mRNA levels of Cyclophilin B and of GLI1 in Hacat keratinocytes 
transfected with two different GLI1 siRNA (si5815 and si5816). All values are expressed 







4.2.18.4 GLI2 siRNA optimisation in Du145 cells and Hacat keratinocytes 
(experiment 1) 
 
In order to validate the GLI2 Abcam antibody, siRNA experiments were carried out 
similar to what has been done for GLI1. Conditions for GLI2 siRNA were optimised 
by Mr Sandeep Nadendla, who observed a reduction in the levels of endogenous 
GLI2 mRNA at 96 hours post-transfection in DU145 and PC-3 prostate cancer cells 
(Nadendla et al., 2011); he used a commercially available siRNA against GLI2  
(si5817, Ambion) at 30 nM concentration. GLI2 H-300 has been validated for 
immunofluorescence in a recent publication (Bishop et al., 2010) and was used as a 
positive control. I therefore tested GLI2 si5817 siRNA (using the optimal 96 hours 
timepoint and 30 nM final concentration) in Hacat (spontaneously transformed 
keratinocytes) and Du145 (prostate cancer cell line) cells as they are reported to be 
relatively easy to transfect; Du145 cells have also been shown to express high levels 
of GLI2 (Nadendla et al., 2011). Cells were stained with either GLI2 H300 or GLI2 
Abcam antibody (Fig. 4.37 - 4.38 and Fig. 4.40 - 4.41); staining intensity was 
subsequently measured using the ImageJ software (Fig. 4.39 and Fig 4.42). No 
significative differences in staining intensity were observed in knockdown cells 
compared to control with either antibody; this is true for both Du145 and Hacat cells. 
qPCR analysis reveals levels of Cyclophilin B are reduced approximately by half in 
both cell types tested (Du145, Fig. 4.43a and Hacat, Fig. 4.44a). In Du145 cells 
siRNA si17 seems to reduce GLI2 level by half, though only by about 15% in Hacat 
cells (Fig. 4.43b and 4.44b). As no difference was observed by immunofluorescence 
and because of the discrepancy with the qPCR data, Western Blotting analysis was 
also performed. GLI2 levels appear reduced with si17 by Western Blot using the 
GLI2 H300 antibody; however, GLI2 levels in the controls raise some concerns as 
they seem to vary in Du145 cells while in Hacat keratinocytes siGlo and siAmb 
GLI2 levels are very similar to si17 (Fig. 4.45). To try and understand the reason for 



































Figure 4.37: Immunofluorescent analysis of Du145 GLI2 siRNA cells using 
GLI2 (H-300) antibody  
Du145 cells were treated with a short interfering RNA (siGLI2 5817) for 96 hours, then 
fixed and stained with GLI2 H300 antibody (c). Untreated cells (a), cells treated with siAmb 









































Figure 4.38: Immunofluorescent analysis of Du145 GLI2 siRNA cells using 
GLI2 (Abcam) antibody  
Du145 cells were treated with a short interfering RNA (siGLI2 5817) for 96 hours, then 
fixed and stained with GLI2 Abcam antibody (c). Untreated cells (a), cells treated with 




















































Figure 4.39: Quantification of immunofluorescent analysis of Du145 GLI2 
siRNA cells using GLI2 (H-300) and GLI2 (Abcam) antibodies. 
Quantification of GLI2 H-300 (a) and GLI2 Abcam (b) antibody fluorescence intensity in 
Du145 cells treated with short interfering RNA si5817. Images displayed in Fig. 4.38 - 4.39 
were quantified using the image processing software Image J. Data are expressed as mean ± 
































Figure 4.40: Immunofluorescent analysis of Hacat GLI2 siRNA keratinocytes 
using GLI2 (H-300) antibody  
Hacat keratinocytes were treated with a short interfering RNA (siGLI2 5817) for 96 hours, 
then fixed and stained with GLI2 H300 antibody (c). Untreated cells (a), cells treated with 








































Figure 4.41: Immunofluorescent analysis of Hacat GLI2 siRNA keratinocytes 
using GLI2 (Abcam) antibody  
Hacat keratinocytes were treated with a short interfering RNA (siGLI2 5817) for 96 hours, 
then fixed and stained with GLI2 Abcam antibody (c). Untreated cells (a), cells treated with 


















































Figure 4.42: Quantification of immunofluorescent analysis of Hacat GLI2 
siRNA keratinocytes using GLI2 (H-300) and GLI2 (Abcam) antibodies. 
Quantification of GLI2 H-300 (a) and GLI2 Abcam (b) antibody fluorescence intensity in 
Hacat keratinocytes treated with short interfering RNA si5817. Images displayed in Fig. 4.41 
- 4.42 were quantified using the image processing software Image J. Data are expressed as 






































Figure 4.43: qPCR analysis for Cyclophilin B and for GLI2 of Du145 cells 
transfected with GLI2 siRNA 
qPCR measurements of mRNA levels of Cyclophilin B and of GLI2 in Du145 cells 
transfected GLI2 siRNA (si5817). All values are expressed relative to Du145 siAmb 





































Figure 4.44: qPCR analysis for Cyclophilin B and for GLI2 of Hacat 
keratinocytes transfected with GLI2 siRNA 
qPCR measurements of mRNA levels of Cyclophilin B and of GLI2 in Hacat keratinocytes 
transfected GLI2 siRNA (si5817). All values are expressed relative to Hacat siAmb scramble 

























Figure 4.45: Western Blotting for GLI2 protein levels in Du145 cells and Hacat 
keratinocytes transfected with GLI12 siRNA (GLI2 H300 antibody) 
Western Blot analysis of Du145 or Hacat cells with GLI2 H300 antibody. Cells, untreated 
cells; siAmb, scramble siRNA control; siGlo, Cyclophilin B siRNA fluorescent control, si17, 
























4.2.18.5 GLI2 siRNA optimisation in Du145 cells and Hacat keratinocytes 
(experiment 2) 
A second GLI2 siRNA experiment was performed using two different GLI2 siRNAs, 
si17 (see section 4.2.17.4) and si44 (see Appendix II for details). 
The transfection seem to have worked in all cell types judging by Cyclophilin B 
levels analysed by qPCR (Fig. 4.46a and Fig. 4.47a) but GLI2 interference looks 
effective  
only in Du145, with si17 giving the best result. In Hacat keratinocytes GLI2 siRNA 
appears ineffective at reducing GLI2 levels (si44) or, paradoxically, seems to 
increase its levels (si17) (Fig. 4.46 b and Fig. 4.47 b). In Western Blotting analysis 
using the GLI2 H300 antibody no significative difference in GLI2 band intensity was 
observed between siRNA cells and controls in both Du145 and Hacat cells (Fig. 
4.48). LnCap and PC3 (prostate cancer cell lines) cells were included for 
comparison. GLI2 expressed by these cells migrates at a slightly lower molecular 
weight, in line with the hypothesis that different isoforms or differently cleaved 
products of GLI2 are expressed by different cell types. In Western Blot analysis of 
Du145 cells using GLI2 Abcam antibody (Fig. 4.49) GLI2 was only picked up in 
LnCap cells included in the blot as a reference. Immunofluorescent analysis revealed 
an extremely faint staining with both GLI2 H-300 and GLI2 Abcam and no 
difference in intensity could be detected in GLI2 silenced cells (data not shown). 
Because of the anomalies observed in the analysis of GLI2 siRNA cells, the 
specificity of the GLI2 Abcam antibody cannot be confirmed with the data gathered 
so far and further experiments would be needed.  
To help confirm the validity of the immunohistochemistry work previously described 
Laser Capture Microdissection could be used; preliminary experiments to optimise 










































Figure 4.46: qPCR analysis for Cyclophilin B and for GLI2 of Du145 cells 
transfected with two different GLI2 siRNAs 
qPCR measurements of mRNA levels of Cyclophilin B and of GLI2 in Du145 cells 
transfected with two different Gli2 siRNA (si17 and si44). All values are expressed relative 








































Figure 4.47: qPCR analysis for Cyclophilin B and for GLI2 of Hacat 
keratinocytes transfected with two different GLI2 siRNAs 
qPCR measurements of mRNA levels of Cyclophilin B and of GLI2 in Hacat keratinocytes 
transfected with two different Gli2 siRNA (si17 and si44). All values are expressed relative 











































Figure 4.48: Western Blotting for GLI2 protein levels in Du145 cells and Hacat 
keratinocytes transfected with two different GLI2 siRNAs (GLI2 H300 
antibody)  
Western Blot analysis of Du145 or Hacat siGLI2 cells with GLI2 H300 antibody. Cells, 
untreated cells; siAmb, scramble siRNA control; siGlo, Cyclophilin B siRNA fluorescent 

















Figure 4.49: Western Blotting for GLI2 protein levels in Du145 cells transfected 
two different GLI12 siRNAs (GLI2 Abcam antibody)  
Western Blot analysis of Du145 siGLI2 cells with GLI2 Abcam antibody. Cells, untreated 
cells; siAmb, scramble siRNA control; siGlo, Cyclophilin B siRNA fluorescent control, si17, 














4.2.19 Optimisation of total RNA extraction from small tissue samples 
To confirm GLI1 expression in the stroma of Basal Cell Carcinomas samples which 
has been detected using immunohistochemistry (see section 4.2.2), as wells as 
analyzing GLI1 - GLI2 relative abundance and the potentially complex network of 
interactions that governs GLI expression (both canonical and non-canonical), we 
planned to use Laser Capture Microdissection (LCM) followed by RNA extraction 
and qPCR. Preliminary experiments were carried out to optimize RNA extraction 
from small samples, which is a known problem when performing LCM experiments.  
LCM is a microscope-based dissection system that allows separation of specific cell 
populations from histological tissue sections. RNA can be subsequently extracted 
from these cells to analyse gene expression in the selected population by qPCR. A 
major drawback of this technique is the small starting amount of biological material, 
in which an extremely low amount of RNA is present (usually a few nanograms per 
section). Another problem is RNA stability: recovery from tissue that is frozen or 
wax-embedded is problematic as sample processing could lead to RNA degradation, 
therefore further reducing the amount of RNA available for analysis.    
The feasibility of this approach was tested by extracting RNA from whole BCC 
samples in the first place, and then see if the process could be scaled down to tissue 
sections and to specific areas microdissected from a single section. So far successful 
RNA extraction was achieved from whole frozen tissue and from pooled frozen or 
wax-embedded sections. 
RNA extracted from whole frozen BCC samples could also be used to quantify the 
amount of GLI1 and GLI2 by qPCR and therefore analyse the interplay of these two 
transcription factors ex vivo. 
4.2.20 RNA extraction from whole frozen tissue 
To avoid loss of precious samples, RNA extraction from whole frozen tissue was 
optimised using incompletely or badly labelled specimens. Samples were 
homogenized using a Tissue Rupture (Qiagen, U.K.) according to manufacture’s 
instructions. Extraction of total RNA was subsequently achieved using the RNeasy 
Fibrous Tissue Mini Kit (Qiagen, U.K.); this kit is designed for purification of up to 
100 µg total RNA from fiber-rich tissues, including skin. RNA purification from skin 
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is hindered by the presence of connective tissue and contractile proteins such as 
collagen: during the extraction process the sample is treated with proteinase K, so 
these proteins are degraded and can then removed by centrifugation. 
RNA was extracted from three frozen tissue samples, one micronodular BCC 
(Sample 1) and two incompletely labelled samples, thought to be also BCCs but 
whose identity cannot be confirmed due to lack of information in the records. Total 
RNA yields varied from about 30 g to 2 g of RNA (Table 4.4). The ratio of 
absorbance at 260 nm and 280 nm is used to assess RNA purity; a ratio lower than 
2.0 indicates the presence of protein or phenol contaminants; all ratio were above 2 
and therefore acceptable. A 260/230 ratio was also measured as values appreciably 
lower than 2 denote contamination from carryover of reagents used in the extraction 
process: sample 1 could potentially be affected by reagents contamination. 
 
Table 4.4: RNA yields from whole frozen tissues samples  
 
4.2.21 Preliminary qPCR experiments on RNA extracted from frozen tissue 
1 g of RNA from each of the frozen tissue samples was retrotranscribed into cDNA 
using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen, U.K.) 
according to manufacturer’s instructions. This kit is optimised for cDNA synthesis 
from a range of starting materials that goes from 0.1 pg to 5 g of total RNA. qPCR 
experiments were performed using primers against PTCH1 as well as with two 
different primers against GLI1, one against a region in the mRNA that corresponds 
to the N-terminus of the protein (GLI1 RD) and another against a region located at 
the C-terminus of the protein (GLI1 H300)(Fig. 4.50). Sample 3 was arbitrarily 
chosen as a reference sample. In Sample 1 there is a clear upregulation of PTCH1, 
consistent with the fact this is the only sample who is a BCC, while this is not 
observed in Sample 2. The amount of GLI1 present in Sample1 seems to differ 
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slightly when two different primers are used, as it appears the amount of GLI1 
mRNA in which the region corresponding to the C-terminus region is present is a bit 
higher compared to the amount detected used the primers against the N-terminus. 
This preliminary data need to be confirmed before it can be speculated if this 























Figure 4.50: qPCR analysis for GLI1 and PTCH1 on whole frozen tissues 
 
Two different pairs of primers were used for GLI1: GLI1 RD, targeting a region at the 5’ end 
of the mRNA (corresponding to the N-terminus of the protein) and GLI1 H300, which 
targets a region at the 3’ end of the mRNA (corresponding to the C-terminus of the protein). 

















4.2.22 RNA extraction from sectioned frozen or wax-embedded tissue 
RNA extraction optimisation was carried out on frozen or wax-embedded normal 
skin sections as these samples are more easily available and less precious than 
tumour tissue. Tissue was sectioned using a cryostat (frozen samples) or a microtome 
(wax-embedded samples).  
Frozen normal human skin samples were sectioned using a cryostat and sections 
were placed into an eppendorf tube containing 100 l lysis buffer from the RNeasy 
Micro Kit. Extraction of total RNA was subsequently achieved using the RNeasy 
Micro Kit (Qiagen, U.K.), following manufacture’s instructions.  
Wax-embedded normal human skin was sectioned using a microtome and sections 
were placed in an eppendorf tube containing 100 l lysis buffer from the RNeasy 
FFPE Kit. Extraction of total RNA was subsequently achieved using the RNeasy 
FFPE Kit (Qiagen, U.K.). The RNA extraction procedure is similar to that employed 
for RNA extraction from cultured cells except for previous removal of paraffin by 
sequential addition of xylene and 100% ethanol, followed by centrifugation. Also, an 
additional digestion with proteinase K was performed before the ethanol 
precipitation step. Table 4.5 illustrates RNA yield from different amount of starting 
material (number of sections) for both frozen and wax samples; from this preliminary 
experiment it seems RNA yield increases using more sections in wax samples while 
it decrease in frozen samples. The issue of mRNA integrity needs also to be 
considered, as sample processing could lead to degradation and fragmentation of 
RNA. mRNA quality is usually assessed by electrophoresis of total RNA and 
visualization of the 28S and 18S ribosomal RNA (rRNA) bands. Ribosomal RNA 
makes up the majority (around 80%) of the total RNA samples, and is assumed 
rRNA quality reflects the underlying mRNA population (which cannot be detected 
even with the most sensitive of methods). RNA samples listed in Table 4.5 were run 
on agarose gel and visualized using SYBR Green II RNA Gel Stain (Invitrogen). 
SYBR Green II Stain was used as it is significantly more sensitive than Ethidium 
Bromide and can detect as little as 100 pg RNA. The 18S and 28S ribosomal RNA 
bands are visible, although faint, in frozen samples (Fig. 4.51b) and therefore good 
quality mRNA can be inferred while in wax samples RNA appears as a smear and is 
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therefore degraded (Fig. 4.51a). For this reason, frozen samples appear to be more 
suitable for LCM analysis.  
It should be noted so far RNA has been extracted from the whole tissue present on 
the slides, while for LCM only a fraction of the tissue on the slide will be used. Since 
the average RNA yield per section in frozen slides is about 40 ng (Table 4.5) and 
assuming a tenth of the section will be used for LCM, the amount of RNA would be 
400 pg in the best case scenario (40 ng / 10 = 0.4 ng = 400 pg). In order to extract 
RNA from such a tiny sample, different RNA extraction kits could be used in 
addition to the RNeasy Micro Kit (Qiagen), such as The PicoPure RNA Isolation Kit 
(Arcturus), which is optimized for use with cells acquired using Laser Capture 
Microdissection. Due to the low quantities of RNA extracted, a further RNA 
amplification step may be needed prior to the retrotranscription step; among all the 
commercial kits available the RNA-Amp kit (Epistem) has been reported to give the 
best result on LCM samples. Sections will need to be stained to reveal morphology in 
order to be cut using the Laser Capture Microdissection machine; as staining has 
been shown to affect RNA integrity (Wang et al., 2006), different histological stains 
would need to be tested; a good starting point could be the HistoGene Stain 
(Arcturus).   
These preliminary RNA extractions experiments highlight the feasibility of the Laser 
Capture Microdissection approach to address the heterogeneity of GLI protein 
expression in Basal Cell Carcinomas; however, further optimisation on all critical 










Table 4.5: RNA yields from varying numbers of either wax or frozen sliced 














































Figure 4.51: Integrity analysis of RNA samples  
RNA samples listed on Table 3.5 were run on a 2% agarose gel containing SYBR Green II 
Stain (Invitrogen). RNA extracted from frozen tissues (b) seem to be of good quality while 























Different commercially available antibodies against GLI1 and GLI2 have been tested 
on human skin and Basal Cell Carcinoma samples. A widespread heterogeneity was 
observed in terms of staining patterns using different antibodies and staining 
techniques, which highlights the known complexity of the Hedgehog pathway and 
warrants further investigation. Some antibodies like GLI1 C-18 and GLI2 H-300 
presented consistency issues, as subsequent staining performed with different 
aliquots showed widespread aspecificity, with a diffuse signal which sometimes 
extended into the underlying dermis. They were therefore abandoned and staining on 
BCC samples was performed with the other antibodies. A strategy for double 
immunofluorescent staining was also developed in order to analyse the presence of 
either GLI1 and Sonic Hedgehog ligand (SHH) or GLI1 and GLI2 in the same 
sample. The vast majority of the staining was performed on frozen samples as this 
allows for double staining using secondary antibodies coupled with different 
fluorochromes. However, some antibodies were also tested on wax-embedded BCCs 
to see if these samples could be used (they are easier to obtain as most Pathology 
departments routinely wax-embed specimen for diagnostic purposes).   
I will first summarise the main results of my staining experiments and compare them 
with the existing literature and then analyse their significance in more details in the 
following sections. To date, GLI1 expression in BCCs has been analysed only in a 
few publications. Ghali et al. reported GLI1 expression in BCCs by DAB 
immunohistochemistry on wax-sections using two different antibodies, GLI1 C-18 
(which recognises the carboxyl-terminal) or GLI1 N-16 (which binds to the N-
terminus): staining was predominantly cytoplasmic. They observed stronger staining 
in BCCs using the C-terminal antibody (GLI1 C-18), and also staining of a 
subpopulation of mesenchymal cells (Ghali et al., 1999). In my experiments GLI1 C-
18 did not work consistently by immunofluorescence on frozen section, though with 
GLI1 H-300, another antibody that recognises the C-terminus of human GLI1, 
frequent stromal staining was observed. Ghali et al. did not analyse GLI1 protein 
expression in normal skin, though they argue for its absence based on a previous 
study when they detected GLI1 mRNA by RT-PCR and in-situ hybridisation in 
BCCs but not in normal skin (Green et al., 1998; Ghali et al., 1999). Of note, GLI1 
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was rarely detected in hair follicles by in-situ (Green et al., 1998; Ghali et al., 1999), 
but found to be present in the outer root sheath (ORS) of hair follicles when 
immunohistochemistry was used (Ghali et al., 1999), thus highlighting the possible 
discrepancy in results using techniques that measure either mRNA level or protein 
abundance. Notably, they describe the staining in the ORS to be considerably more 
intense than the one seen in BCC islands in the same section. Though in the BCCs 
sections I have analysed no hair follicles were present, in many sections GLI1 
intensity appeared to be stronger in the epidermis than in the BCCs, highlighting the 
possible variation in GLI1 levels between normal and neoplastic tissue.  
In the work by Dahmane et al. (Dahmane et al., 1997) GLI1 was found to be 
expressed in 6 BCCs analysed by immunofluorescence using an in-house made 
antibody against the zinc finger domain of GLI1 (aa 255-408) but again no normal 
skin was analysed for comparison. GLI1 localisation was reported to be cytoplasmic 
in the BCCs but nuclear in COS cells transfected with a GLI1 construct probed with 
the same antibody (Dahmane et al., 1997); the significance of this observation is not 
discussed in the paper. In the BCCs I have stained GLI1 is mostly cytoplasmic with 
all antibodies used. Although the predominantly cytoplasmic localisation is 
surprising for a transcription factor, GLI1 is known to shuttle between the cytoplasm 
and the nucleus (Murone et al., 2000) and is bound to the cytoskeleton when inactive. 
Dahmane et al also detected GLI1 in 47 BCCs by in-situ hybridization, though the 
level of expression varied; furthermore, GLI1 mRNA was present in the basal cell 
layer adjacent the BCCs and in some cells surrounding the tumours, but not in 
normal epidermis distant from the tumour site. In the BCCs I stained I observed 
staining in both the epidermis and the tumour masses; though surprising, this 
difference could be attributed to the different technique used. It is also possible that 
GLI1 is subject to different post-transcriptional regulation in the epidermis compared 
to the tumour, so it could be hyphothesised that, although GLI1 mRNA levels may 
be low, GLI1 protein is expressed and stabilized in the epidermis.  
SHH expression was also analysed by in-situ hybridisation by Dahmane et al; SHH 
ligand was detected at a much lower frequency compared to GLI1, which is 
consistent with what I have observed using immunofluorescent histochemistry. This 
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observation argues against a paracrine mode of Hedgehog signal in BCCs and 
suggests GLI1 expression may be regulated by other factors in the mesenchyme. 
GLI2 mRNA was shown to be present in human BCCs and also in intefollicular skin 
and outer root sheath of hair follicles by in-situ hybridization and qPCR (Bonifas et 
al., 2001; Ikram et al., 2004). Four isoforms of GLI2 have so far been described, 
GLI2 , , , and  (Tanimura et al., 1998): GLI2 isoform appear to be the most 
expressed isoform in BCCs by RT-PCR (Tojo et al., 2003). The result of the staining 
I did on normal skin and BCCs confirm GLI2 expression in the epidermis, ORS and 
BCCs; both antibody used (GLI2 H-300 and GLI2 Abcam) are predicted to recognise 
all GLI2 isoforms (see Appendix III).  
4.3.1 GLI1 antibodies staining on Normal Human Hair Bearing Skin 
Three different GLI1 antibodies were tested: GLI H-300 (sc-20687, Santa Cruz, 
polyclonal), GLI1 C-18 (sc-6152, Santa Cruz, polyclonal) and GLI1 RD (MAB3324, 
R&D Systems, monoclonal); the first two antibodies recognise an epitope located in 
a region in the C-terminal end of human GLI1, while the latter recognises a region at 
the N-terminal. For details please see Appendix III. 
When used to stain frozen human hair bearing skin by immunofluorescence, all three 
GLI1 antibodies tested gave an overall similar staining pattern, with positive staining 
in the epidermis and in the outer root sheath of hair follicles. One novel feature 
observed was the presence of GLI1 in all layers of the epidermis, since GLI1 is 
thought to be predominantly expressed in the basal layer; however, antibody against 
GLI protein have been made commercially available only recently, and most of the 
previous studies relied on RT-PCR or in-situ hybridization, which may explain the 
difference. Of note, GLI1 staining appears to be weaker in the basal layer of the 
epidermis when GLI1 H-300 antibody is used; this is also true, although to a much 
lesser extent, with GLI1 RD in some regions. GLI protein expression has been shown 
to be influenced by other cellular pathway in addiction to Hedgehog signaling (Riobo 
et al., 2006a; Lauth and Toftgard, 2007; Schnidar et al., 2009) Dennler et al., 2007; 
Dennler et al., 2009), which may be differentially activated in normal or neoplastic 
skin and this could offer a possible explanation for this observation.  
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GLI1 localisation is mainly cytoplasmic with all the antibodies, though it appears 
perinuclear or nuclear in some regions with GLI1 H-300. The skin used for staining 
was derived for an abdominoplasty surgery; skin obtained from a facelift surgery was 
also used for GLI1 H-300 and the staining pattern appears similar regardless of the 
site of origin of the skin. Positive staining in the stroma as well as in the epithelia is a 
peculiar feature of GLI1 H-300, which is also observed in some BCC samples and 
discussed later.  
4.3.2 GLI2 antibodies staining on Normal Human Hair Bearing Skin 
For the detection of GLI2 two different antibodies were tested, GLI2 H-300 (sc-
28674, Santa Cruz, polyclonal) and GLI2 Abcam (ab26056, Abcam, polyclonal); 
both antibodies recognise an epitope located in the central region of human GLI2. 
(see Appendix III). Both antibodies gave similar results on frozen section of normal 
hair bearing skin, with GLI2 staining present in the epidermis and in the outer root 
sheath of hair follicles, similar to what is known in the literature (Ikram et al., 2004). 
GLI2 staining intensity appears slightly stronger in the basal layer with GLI2 Abcam. 
GLI2 localisation is both cytoplasmic and nuclear with GLI2 H-300 and mainly 
cytoplasmic and sometimes nuclear in some areas with GLI2 Abcam.  
GLI1 and GLI2 antibodies which yielded overall reproducible results on normal skin 
(GLI1 H-300, GLI1 RD, GLI2 Abcam) were subsequently used to stain BCC 
samples.  
4.3.3 GLI1 (H300) antibody stromal staining in Basal Cell Carcinomas: 
quantitative analysis and possible explanations 
GLI1 H-300 antibody was used to stain a panel of 31 BCCs; these tumours belonged 
to different subtypes, though about 2/3 of the samples were nodular BCCs, as this 
subtype is the most abundant (Crowson, 2006). GLI1 H-300 staining is present in the 
tumour masses and is predominantly cytoplasmic with perinuclear or nuclear staining 
observed in some areas. In 23 out of 31 BCCs GLI1 is also observed in the adjacent 
stroma and its intensity appears stronger than in the epithelia; in the remaining 8 
BCCs GLI1 H-300 staining is restricted to the epithelial component of the tumour.  
 
 238 
These observations led us to speculate about the biological significance of stromal 
GLI1. Since paracrine signalling has been implied the progression of different types 
of tumors (Yauch et al., 2008; Nolan-Stevaux et al., 2009; Tian et al., 2009), it could 
be hyphothesised BCCs in which stromal GLI is present may have a distinct fate 
compared to the ones who do not: consequently, the presence of stromal GLI1 may 
be a feature of the more aggressive subtype of BCC (morphoiec), while not being so 
evident in the more indolent subtype (nodular).  
Though the number of BCCs positive for GLI1 was higher (n=23) than the number 
of BCCs which are negative (n=8), the majority of BCCs positive for stromal GLI1 
were nodular (15 out of 23) and also the majority of BCCs negative for stromal GLI1 
were nodular (7 out of 8). At the moment no strong correlation between the present 
of GLI1 staining in the stroma and BCCs subtypes can be detected, although since 
the vast majority of the samples belong to the nodular and micronodular subtypes (23 
out of 31), no definitive conclusion could be reached (BCCs positive for stromal 
staining: nodular and micronodular  n=15, nodular / morphoeic n=1, morphoeic n=2, 
infiltrative n=2, superficial n=3; BCCs negative for stromal staining, nodular and 
micronodular  n=7, infiltrative n=1); more samples would be needed to examine 
possible variations between subtypes. Whether different BCC subtypes are distinct 
from each other or nodular BCCs evolve into morphoiec to become invasive is still 
an open question in the field. It is however possible activation of GLI1 in the stroma 
of nodular BCC is a step needed in the progression from an indolent to a more 
aggressive form (morphoeic). Alternatively, stromal GLI1 could be a factor that 
facilitates tumor recurrence: this hypothesis would be ideally addressed by follow-up 
of patients and comparing the status of GLI1 activation in the stroma in the primary 
and in the recurrent tumour. This could also be tested in vitro by taking advantage of 
the DED organotypic model (see section 5.1): keratinocytes could be grown on DED 
in the presence of normal fibroblasts or GLI1-overexpessing fibroblasts, to see if the 
latter would increase the invasiveness of the keratinocytes into the dermis (a feature 
associated with malignant tumor progression). Of note, in a mice model of pancreatic 
cancer, tumour-associated fibroblasts express GLI1 and are also positive for vascular 
endothelial growth factor (VEGF) (Bailey et al., 2009). The authors suggest HH 
pathway activation in the stroma promotes angiogenesis and metastasis. 
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Because of the brightness of GLI1 H-300 staining in the stroma, we sought to 
quantify its intensity compared to the staining in the epithelial tumour using the 
Image J software and a method based on fluorescence intensity distribution. Out of 
23 samples, 17 were suitable for quantification purpose using this method: the 
remaining 6 samples showed either similar staining intensities in the stroma and in 
the epithelia (n = 4) or the stromal component was difficult to highlight (n = 2). In 
these 23 samples there seem to be a statistically significative difference (P < 0.05) 
between staining in the two tumour components, with GLI1 fluorescence intensity in 
the stroma notably higher than in the tumour.  
GLI1 staining in the stroma could be explained by the existence of a paracrine 
mechanism of HH signalling (Yauch et al., 2008; Nolan-Stevaux et al., 2009; Tian et 
al., 2009); however, from the results of SHH staining in BCC (section 4.2.11), this 
hypothesis seems unlikely. Alternatively, this could be due to non-canonical 
activation of GLI1 in the stroma: notably, non-canonical activation of GLI proteins 
by transforming growth factor beta (TGF) has recently been described in human 
keratinocytes and fibroblasts (Dennler et al., 2007; Dennler et al., 2009).  
4.3.4 Sonic Hedgehog ligand antibody staining  
To further analyse the hypothesis that GLI1 H-300 antibody stromal staining could 
be due to paracrine Hedgehog signalling, Basal Cell Carcinoma samples were stained 
with an antibody against Sonic Hedgehog ligand (SHH). It would have been ideal to 
double immunostain the same BCC section with both GLI1 H-300 and SHH. 
However, this was not possible as all commercially available antibodies against SHH 
were raised in rabbit and GLI1 H-300 is also a polyclonal rabbit antibody; a 
prerequisite for double immunostaining is that the two antibodies are raised in two 
different species. This is necessary as secondary antibodies labelled with different 
fluorochromes must be able to recognise a specific primary antibody, e.g. a green 
fluorescent anti-mouse secondary against a mouse primary antibody in conjunction 
with a red fluorescent anti-rabbit secondary against a rabbit primary antibody. A 
viable combination for double immunostaining was GLI1 RD, a rat monoclonal 
antibody, used in conjunction with a rabbit polyclonal against SHH (ab19897, 
Abcam). This combination was first tested on a frozen section of normal human hair 
bearing skin: GLI1 was present in the epidermis and in the outer root sheath of hair 
 240 
follicles and SHH in the upper layers of the epidermis and in the inner root sheath. 
Of note, SHH is also expressed in cutaneous nerve fibers, in accordance to what has 
been recently published by Brownell et al (Brownell et al., 2011). SHH from neurons 
signals in a paracrine manner to a subpopulation of responsive hair follicle bulge 
stem cells which as a result express GLI1; these cells are able to migrate into the 
epidermis upon wounding, become epidermal stem cells and contribute to wound 
healing. SHH signal from cutaneous neurons is essential to maintain bulge cells 
ability to become epidermal stem cells. This is particularly interesting as it has also 
been shown that introducing oncogenic mutations in HH pathway components in 
follicular stem cells promote the formation of BCCs after wounding (Kasper et al., 
2011; Wong and Reiter, 2011). It can therefore be speculated that alterations of 
physiological SHH signalling from cutaneous nerve fibers could result in enhanced 
susceptibility to BCC development originating from hair follicle stem cells. 
In the skin, SHH regulates the adult anagen hair cycle and controls the growth of 
multipotent progenitor cells. SHH was detected in one frozen section of normal 
human hair bearing skin used to test the antibody. Out of 13 BCC sections analysed, 
only 9 contained the epidermis: positive SHH staining was present in the epidermis 
of 5 out of these 9 BCCs. All BCCs which stained positive for SHH (n = 4) also 
presented SHH staining in the epidermis, one BCC was negative for SHH in the 
tumor mass but SHH was present in the overlying epidermis and four BCCs were 
negative for SHH in both the tumor and the epidermis. In the 9 skin-containing BCCs 
analysed, SHH presence in the epidermis seems to correlate with its presence in the 
tumor, though more samples would be needed to elaborate on the biological 
significance of this observation. Also, more normal skin samples should be analysed 
to better understand how SHH expression is regulated, which would help understand 
if SHH presence or absence in the epidermis of BCCs is related to the tumor. 
In total, 13 BCCs samples were stained with GLI1 RD and SHH (this number 
includes samples with and without overlying epidermis); 9 of them had been 
previously stained with GLI1 H-300, 4 of them being positive for GLI1 staining in 
the stroma and 5 negative. Out of these 13 BCCs samples only 4 were positive for 
SHH, and in 2 of these 4 the staining for SHH was very weak. Considering the 4 
BCCs samples previously found to be positive for GLI1 H-300 staining in the 
stroma, only one was positive for SHH. Although a bigger number of samples would 
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need to be stained to reach a definitive conclusion (especially ones displaying 
stromal GLI1 H300), it seems that the majority of BCCs analysed do not contain 
SHH ligand and therefore it is unlikely GLI1 is activated in the stroma in a paracrine 
manner. 
An alternative explanation for the pattern of GLI1 staining in human BCC samples is 
TGF mediated non-canonical activation of GLI1 in the stroma. Non-canonical 
activation of GLI proteins has been reported in vitro in keratinocytes and fibroblasts 
cell line (Dennler et al., 2007) and also been proposed to play a role in vivo in a 
murine model of pancreatic cancer (Nolan-Stevaux et al., 2009). TGF signalling 
pathway components have been reported to be present in BCC epithelial (Schmid et 
al., 1996; Verhaegh et al., 1997; Gambichler et al., 2007) and stromal components 
(Schmid et al., 1996; Furue et al., 1997). TGF ligand presence in the stroma of the 
BCCs analysed and its correlation with GLI1 expression could be addressed by 
double fluorescent immunostaining or by taking advantage of the Laser Capture 
Microdissection (LCM) technique. 
4.3.5 GLI1 (H-300), GLI1 (C-18) and GLI1 (RD) antibodies staining 
similarities and differences  
20 Basal Cell Carcinoma samples belonging to different subtypes were stained with 
GLI1 RD antibody; this number includes both samples stained with GLI1 RD alone 
or GLI1 RD in conjunction with SHH Abcam or GLI2 Abcam. Surprisingly, stromal 
staining was only present in 2 out of 20 BCCs using the GLI1 RD antibody, and 
appears to be rather weak. Of those 20 samples, 16 have also been previously stained 
with GLI1 H-300; considering these 16 samples, 10 were positive and 6 negative for 
stromal staining with GLI1 H-300 while only one was positive and the remaining 15 
negative when GLI1 RD was used; possible explanations for this observation are 
discussed further on. It should be noted both antibodies stained the tumour masses 
and the cellular localisation was similar: mainly cytoplasmic, with GLI1 H-300 
sometimes more perinuclear. Moreover, in normal human hair bearing skin the 
staining pattern is also similar using both antibodies, with GLI1 present in the outer 
root sheath of hair follicles and the epidermis, appearing slightly weaker in the basal 
layer. These observations argue for staining specificity as a similar pattern is 
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observed with two different antibodies, GLI1 H-300 and GLI1 RD; this is also 
similar to observation made in normal human bearing skin with the GLI1 C-18 
antibody.  
Although the mainly cytoplasmic localisation of GLI1 observed with different 
antibodies could be surprising considering the fact GLI1 is a transcription factor, GLI 
proteins are known to shuttle between the cytoplasm and the nucleus (Murone et al., 
2000). Moreover, cytoplasmic GLI1 localisation has been previously reported in 
BCCs using immunohistochemistry (Ghali et al., 1999).  
Both GLI1 H-300 and GLI1 C-18 recognise an epitope located in a region in the 
carboxyl-terminal end of human GLI1, while GLI1 RD recognises an epitope in a 
region of about 230 amino acids located at the amino-terminal end. The sequences 
against which GLI1 H-300 and GLI1 C-18 were raised partially overlaps; GLI1 H-
300 had been raised against a much longer sequence compared to GLI1 C-18 (300 
amino acids compared to about 50) (see Appendix III). GLI1 C-18 antibody 
presented consistency issues when different aliquots were used, and was therefore 
abandoned. Concerning GLI1 H-300, the technical support services at Santa Cruz 
stated this antibody was raised against a recombinant protein corresponding to amino 
acids 781-1080 of  GLI1 of human origin and, since the epitope was not mapped, this 
amino acid range could not be further restricted. In terms of manufacturing methods, 
the main difference between GLI1 H-300 and GLI1 RD is that the former is a rabbit 
polyclonal antibody, while the latter is a rat monoclonal one. 
Polyclonal antibodies are purified from animal serum and derived from different B 
cells; as a result they are a combination of immunoglobulin molecules secreted 
against a specific antigen, each identifying a different epitope. 
To produce monoclonal antibodies, B cells are removed from the immunized animal 
and fused with tumour cells to become hybridomas; the antibody producing 
hybridomas are cloned by isolation and cultivated, so antibodies secreted by the cells 
into the culture media can be harvested. Monoclonal antibodies are monospecific 
antibodies that are identical since they are derived from a single hybridoma clone 
(usually selected by an affinity purification procedure); these antibodies detect only 
one epitope on the selected antigen. GLI1 H-300 antigen is about 300 amino acids 
long (position 781-1080 of GLI1 of human origin, corresponding to the proline-rich 
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domain – activation domain); since the maximum epitope length is 20 amino acids in 
length, even if we assume no overlapping between their sequences, GLI1 H-300 is 
potentially composed by a mixture of at least 15 different antibodies that recognise 
15 different epitopes (300 amino acids (antigen length) / 20 amino acids (maximum 
epitope length) = 15). GLI1 RD antigen is 234 amino acids long (positions 1 – 234 of 
GLI1 of human origin, which include Sufu binding domain) but, since it is a 
monoclonal antibody, the epitope recognise will be only one and about 20 amino 
acids long; the exact sequence is not known as R&D Systems technical service was 
not able to disclose it.  
To date, different GLI1 isoforms have been described: GLI1N, generated by 
skipping exons 2 and 3 and encoding an N-terminal truncated protein (Shimokawa et 
al., 2008), and tGLI1, an in-frame deletion spanning the entire exon 3 and part of 
exon 4 (Lo et al., 2009). GLI1N present a deletion of 128 amino acids and is a less 
potent transcriptional activator compared to full-length GLI1; the expression ratios of 
the two GLI1 isoforms are greatly variable in tumour cell lines. tGLI1 results in an 
in-frame deletion of 41 amino acids, it is express in human glioblastoma multiforme 
and confers enhanced migratory properties to cells. Both GLI1N and tGLI1 
deletions are located between amino acids positions 1 – 234 of human GLI1, which 
corresponds to the antigen against which the GLI1 RD antibody was generated (for 
details please see Appendix III). Since the exact position of the epitope is unknown, 
it cannot be excluded that it falls in one of the region which differs between 
isoforms; nevertheless, if these isoforms are expressed at the same time it is not 
possible to assess their relative abundance using just one antibody; this could be done 
by qPCR using isoform-specific primers.  
Using the GLI1 H-300 antibody positive staining is present in the stroma of some 
BCCs samples, while this feature is not detected with GLI1 RD; the reason of this 
discrepancy is still unclear. Of note, positive staining was detected in cultured Basal 
Cell Carcinoma derived fibroblasts using GLI1 H-300 (J. Elliott et al., unpublished 
results), which confirms the observation made on BCCs sections. 
One possible explanation for the discrepancy observed in stromal staining is to 
postulate the existence of a novel GLI1 isoform (C-terminal deleted isoform B) that 
differs in its carboxyl-terminal end from the full-length GLI1 (here named isoform 
 244 
A) and assume these two variants are differentially expressed in the epithelia and in 
the stroma, as illustrate in Figure 4.52. Continuous line represents strong expression 
while dotted line symbolizes weak expression, GLI1 isoform B is postulated to be 
weakly expressed in the stroma. Since GLI1 H-300 epitope is located in a large 
antigen at the carboxyl-terminal end, it should be assumed this portion in deleted in 
the putative isoform B which therefore cannot be detected by this antibody. GLI1 RD 
binds to an epitope located at the amino-terminal end and therefore will detect both 
full length isoform A and carboxyl-terminal deleted isoform B. If this would be the 
case GLI1 H-300 would show fluorescent staining in both epithelia and stroma, 
while GLI1 RD signal would be present and strong in the epithelia but weaker and 
possibly below detection in the stroma. One possible way to test this hypothesis 
would be to stain the same section with both GLI1 H-300 and GLI1 RD and analyse 
the relative fluorescence intensities. However, since staining intensity could be 
influence by multiple factors (e.g. affinity of primary antibody for the epitope, type 
of fluorochrome associated with secondary antibody etc.), a better approach would 
be to design primers specific for the different isoforms and analyse their relative 
abundance in the epithelia and in the stroma using Laser Capture Microdissection. 
Another question to be considered is the function of this novel isoform: the fact that 
it would be not recognised by GLI1 H-300 implies the amino acids 781-1080 are 
missing, and therefore most of GLI1 activation domain is ablated. How this could 
reflect on the transcriptional activity of GLI1, possibly switching its function from an 




















Figure 4.52: Diagram illustrating a possible explanation for GLI1 (H-300) and 
GLI1 (RD) antibodies staining pattern in the epithelia and in the stroma of 
Basal Cell Carcinomas 
– please see text for details 
 
However, in support of this hypothesis, two novel GLI1 isoform have been described 
by transfecting full length myc-tagged GLI1 into U251 glioma cells (Altaba, 1999; 
Stecca and Ruiz i Altaba, 2009), one deleted at the amino-terminal (positions 1 – 
231) and the other missing a large portion at the carboxyl-terminal (position 515 to 
the end of the protein); the latter would not be recognised by the GLI1 H-300 
antibody and could therefore support the model highlighted in Figure 4.53. In the 
publication by Stecca et al. the author discriminate between the three GLI1 variants 
(full length, amino-terminal deleted, carboxyl-terminal deleted) by Western Blotting 
taking advantage of three GLI1 antibodies that they generated in-house (not 
commercially available): one against the N-terminus, the second against a sequence 
adjacent the zinc-finger region at the centre of the protein, and the third against the 
C-terminus.  
If we postulate the heterogeneous staining pattern observed in my staining 
experiments is due to these isoforms an antibody against the central region of GLI1 
would be essential in addition to one for the N-terminus and another for the C-
terminus. Assuming not only two GLI1 isoforms (full-length and C-terminal-deleted, 
 246 
(as outlined in Figure 4.52) but three different variant are expressed (full-length, C-
terminal-deleted, N-terminal-deleted), their discrimination by immunofluorescent 
would be extremely laborious in term of elaboration of a staining strategy, 
quantification of staining intensity would be approximate due to problems intrinsic to 
the methodology (e.g. affinity of primary antibody for the epitope, type of 
fluorochrome associated with secondary antibody etc.) and further complicated by 
the relative abundance of each isoform.  
Nonetheless, the availability of three different antibodies could allow the 
discrimination of the three variants by Western Blotting (on cells or on tissues), as in 
this technique one can rely on separation based on protein size to distinguish between 
them, while in immunofluorescent staining the antibody will bind to the epitope (if 
present) and give the same signal regardless of protein length. For these reason, 
analysis of isoform expression in Basal Cell Carcinoma sections could be better 
address by designing specific primers and using Laser Capture Microdissection 
followed by qPCR.  
Three different antibodies could be used to analyse isoform expression in 
keratinocyte cell lines upon GLI1 ectopic expression. In this case though, only GLI1 
C-18 could be used for binding at the C-terminus as both GLI1 H-300 and GLI RD 
have been shown not to be suited for Western Blot analysis, the former giving a wide 
array of different bands in GLI1 overexpressing keratinocytes while the latter is 
unable to pick up ectopic GLI1 in NEB1 or prostate cells (results by Mr Sandeep 
Nadendla, data not shown). Two new GLI1 antibodies for Western Blotting would 
therefore be needed in addition to GLI1 C-18, one binding at the amino-terminal, and 
another raised against the central region of GLI1. Figure 4.53 illustrates a schematic 
representation of GLI1 isoforms described so far, other possible combinations 







Figure 4.53: Diagram illustrating different known GLI1 isoforms and relative 
amino acids positions 
Antigens recognised by GLI1 antibodies used for staining are also highlighted – please see 
text for details  
 
Since GLI1 H300 it is a polyclonal antibody and the sequence against which it was 
generated is quite long it cannot be excluded this antibody is recognizing other 
proteins in addition to GLI1. To address this issue, inhibitors and siRNA experiments 
were carried out to validate the antibody. These experiments are at the moment not 
conclusive, although work carried out by other members of the lab supports the 
hypothesis of good antibody specificity (please see section “Analysis of antibodies 
specificity”). It should however be noted GLI antibodies described here have already 
been already used in a number of publications, which are listed in Appendix IV. 
4.3.6 Heterogeneity in staining intensity with GLI1 antibodies 
Another peculiar feature observed with both GLI1 antibodies (H-300 and RD) on 
Basal Cell Carcinoma samples is the variation in staining intensity. GLI1 staining 
appears to be weaker in the tumour compared to the overlying epidermis in about 
50% of the samples with GLI1 RD (9 out of 18) and 69% of the samples with GLI1 
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H300 (9 out of 13 – it should be noted here the total number of samples is lower). It 
is important to note it is sometimes difficult to distinguish between staining in the 
basal layer and staining in the BCC as some tumours appears as outgrowth from the 
epidermis into the dermis. Also, not all BCC samples contain overlying epidermis as 
this is dependent on the surgical technique used for removal (e.g. it is very scarce in 
punch biopsies) and on the fact that half of the BCC must be collected for diagnostic 
purpose and is usually wax-embedded; the remaining half of the BCC is collected 
and frozen for research purpose, and sometime this second half contains little or no 
epidermis. This means BCCs with epidermis are only a subset of all BCCs stained. 
Although this may appear counterintuitive as GLI1 deregulation is commonly 
associated with malignancy, this observation appears similar using two different 
antibodies and suggest further investigation to analyse its significance. Of note, a 
reduction in the level of GLI1 may be necessary to overcome GLI-promoted cell to 
cell adhesion, which has been recently described in an in vitro model of BCC based 
on GLI1-overexpressing keratinocytes (Neill et al., 2008). Moreover, 
downregulation of GLI2-responsive genes in Hacat cells appears to be required for 
invasion in a skin organotypic model (Snijders et al., 2009) and silencing of GLI2 in 
a breast cancer mouse xenograft model is associated with a more invasive tumour 
phenotype (Hu et al., 2008). All these observations suggest a complex modulation of 
HH-GLI signalling during cancer progression.  
GLI1 staining also appears in be weaker in palisading cells compared to the centre of 
the tumour in about 20% of the samples with GLI1 RD (4 out of 20) and 25% of the 
samples with GLI1 H300 (8 out of 31 – again, different number of samples stained). 
Please note for GLI1 RD all BCCs stained have been considered, regardless if they 
were stained with GLI1 RD alone or in conjunction with either SHH or GLI2 Abcam 
antibodies (for a complete list, please see Table 4.2). 
A recent paper reported an increase in the cell cycle inhibitor p16 and a decrease in 
phosphorylated Retinoblastoma protein (Rb) in the palisading cells of BCCs 
(Svensson et al., 2003), suggesting a change from proliferation to invasion at the 
edge of the tumour; it would be therefore interesting to analyse if there is a 
correlation between a reduction in GLI1 levels and the acquisition of a more invasive 
phenotype. 
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4.3.7 Comparison between immunofluorescent and DAB staining in wax-
embedded samples using GLI1 (H-300) and GLI1 (RD) antibodies 
In order to take advantage of the large number of wax embedded Basal Cell 
Carcinomas conserved in the Pathology archive, which would address the problem of 
increasing the numbers of samples belonging to the rarer superficial and morphoeic 
subtypes, as well as eliminating logistic problems associated with working with 
frozen samples, GLI antibodies were also tested on wax-embedded BCCs using the 
DAB technique.  
Optimisation of the conditions for antigen retrieval was carried out on normal skin; 
both GLI1 H-300 and GLI1 RD show diffuse staining in the epidermis, but while 
GLI1 H-300 is mainly cytoplasmic with a little nuclear staining, GLI1 RD nuclear 
staining is more pronounced. GLI2 H-300 and GLI2 Abcam were also tested: GLI2 
H-300 staining is extremely faint, nuclear and localised in the basal layer, while 
GLI2 Abcam is stronger, diffused across the epidermis and both nuclear and 
cytoplasmic. 
GLI1 staining pattern on two wax-embedded BCCs (one nodular and one infiltrative) 
was compared using either immunofluorescence or DAB staining with either GLI1 
H-300 (carboxyl-terminal epitope) or GLI1 RD (amino-terminal epitope); staining 
pattern appears to be overall similar with both techniques. Furthermore, there seem 
not to be significative differences between the two BCCs analysed, which belonged 
to two different subtypes (nodular and infiltrative). 
GLI1 H-300 staining is diffused throughout the epidermis and the BCCs, in both 
nucleus and cytoplasm; DAB staining appears fainter compared to 
immunofluorescence. GLI1 H-300 immunofluorescent staining intensity on wax 
sections appears weaker when compared to immunofluorescent staining on frozen 
sections. Stromal GLI1 H-300 staining which is diffuse and very bright in most BCC 
frozen sections by immunofluorescence is very limited in wax BCC sections, either 
by immunofluorescence or by DAB staining (although it should be noted only two 
wax-embedded BCCs were analysed, and it is possible these two BCCs do not 
express stromal GLI1).  
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GLI1 RD staining is present in the BCCs and in the overlying epidermis, although 
with this antibody localisation appears mostly nuclear; it is also present in the stroma 
when DAB chemistry is used, while this is not so evident using immunofluorescence. 
Conversely, in frozen sections GLI1 RD staining was restricted to the epithelia in 
nearly all samples analysed (it should be noted however only two wax-embedded 
BCCs were stained compared to 20 frozen BCCs and this could be the reason of the 
discrepancy). The reason why GLI1 RD is more nuclear in wax sections (DAB and 
immunofluorescence) compared to frozen ones (immunofluorescence) is not clear; it 
may be GLI1 is predominantly nuclear in the wax sections analysed (one normal skin 
and two BCCs) or this could be due to the different techniques used. It should be 
noted for wax sections an antigen retrieval step is required to remove the cross-
linking of the amino groups of proteins that result from fixing with 
paraformaldehyde: it may be antigen retrieval treatment allows recognition of the 
epitope also in the nucleus. This is counterintuitive as amino groups in frozen 
sections are not subject to modification (fixing and permeabilization is achieved with 
acetone) and therefore there is supposed to be no hindrance to epitope recognition. 
However, it is possible this treatment is not suited for the recognition of the epitope 
also in the nucleus; moreover, it is not known how the thawing process required for 
staining frozen sections affects protein conformation and stability. Conceding the 
fact that nuclear GLI1 may be underestimated when immunofluorescence in frozen 
sections is used, it should be stressed this is a comparison between two different 
techniques and therefore the reason could be due to the different methods employed.      
4.3.8 GLI1 and GLI2 antibodies double immunofluorescent staining 
To analyse GLI1 - GLI2 interplay a strategy for double immunofluorescent staining 
was developed. Antibodies that gave inconsistent results depending on the batch used 
(GLI1 C-18, GLI2 H-300) were excluded; although GLI1 H-300 antibody has been 
used to stain the vast majority of Basal Cell Carcinoma samples, it is a rabbit 
polyclonal antibody like GLI2 Abcam and for this reason the two cannot be used 
together. Therefore, the only viable combination was GLI RD (rat monoclonal) with 
GLI2 Abcam (rabbit polyclonal).  In a sample of normal human hair bearing skin, 
GLI1 and GLI2 staining is present throughout the epidermis and in the outer root 
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sheath of the hair follicle; GLI2 staining appears slightly stronger in the basal cell 
layer. 
A panel of 18 BCCs, mostly belonging to the nodular subtype, was also stained with 
GLI1 RD in combination with GLI2 Abcam. In most samples GLI1 and GLI2 show 
extensive areas of co-expression, as well of areas where one protein appears to be 
more abundant than the other. As previously discussed (section 4.3.6), GLI1 RD 
staining appears to be diffuse but sometime weaker and at the invading front of the 
tumour (palisading cells) and also in some samples weaker in the tumour compared 
to the overlying epidermis. GLI2 on the other hand is stronger and more defined in 
the basal layer in 5 out of 17 BCCs (30%) in which the epidermis is present, though 
it should be noted this is sometime hyperplastic skin. In 4 out of these 5 samples 
GLI1 staining appears uniform throughout the epidermis. Although a positive 
feedback loop at mRNA level between GLI1 and GLI2 has been described human 
keratinocytes (Regl et al., 2002) and therefore one would expect GLI1 and GLI2 
staining to be superimposable, double immunofluorescent staining for GLI1 and 
GLI2 in BCCs samples reveal areas of co-expression as well as areas when one or 
the other protein is more abundant; this highlights how the GLI1 - GLI2 interplay 
could be more complex that previously hyphothesised and is consistent with the 
putative inhibitory effect of ectopic GLI1 on GLI2 expression described in Chapter 
3. GLI1 and GLI2 relative abundance could be further and more quantitatively 
analysed by using Laser Capture Microdissection (LCM) followed by qPCR.  
4.3.9 Analysis of antibodies specificity in cultured cell lines 
Due to the heterogeneity of the staining results observed, we decided to try and 
validate the GLI antibodies. It should be noted, however, that the GLI antibodies 
used for staining in this thesis have already been employed in a number of 
publications, which are listed in Appendix IV. Antibody specificity was analysed by 
immunofluorescence using NEB1 keratinocytes exposed to SMO inhibitors KAAD-
cyclopamine (KAAD-cyc) and SANT-1. Exposure of keratinocytes to SMO 
antagonists should decrease GLI1 expression and a corresponding reduction in GLI1 
fluorescence would support the notion of good antibody specificity. Previous work in 
the lab performed by Mr Muhammad Rahman had shown that GLI1 H-300 
fluorescence is reduced upon 24 hours treatment with KAAD-cyc and SANT-1 in 
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NEB1 keratinocytes; this is concomitant with a reduction of about 50% in GLI1 
mRNA by qPCR (M. Rahman et al., unpublished results). I repeated the experiment 
on NEB1 wild-type keratinocytes which had been shown to express GLI1 (M. 
Rahman et al, unpublished results) and also analysed NEB1 PTCH1 knockdown 
keratinocytes, in which GLI1 has been shown to be upregulated (M. Rahman et al, 
unpublished results). NEB1 keratinocytes were exposed to either KAAD-
cyclopamine (100 nm) or SANT-1 (100 nm) for 24 hours then fixed and stained with 
either GLI1 RD or GLI1 H-300 antibody; staining intensity was then measured using 
the ImageJ software. No significative difference in fluorescence intensity was 
observed upon treatment with SMO inhibitors; this could be due to the fact different 
aliquots of inhibitors were used as it had also been noted by other group members 
that some batches did not suppress GLI expression as efficiently as others. 
Because of the unexpected results of these two experiments, we decide to try and 
address GLI antibody specificity by using short interfering RNA (siRNA). 
Conditions for GLI1 siRNA were optimised by Mr Sandeep Nadendla, who observed 
ectopic GLI1 mRNA was maximally suppressed in LNCaP-GLI1 prostate cancer 
cells 96 hours post-transfection and, similarly, endogenous GLI1 mRNA levels were 
reduced in DU145 and PC-3 prostate cancer cells at 96 hours post-transfection 
(Nadendla et al., 2011). I therefore tested two different commercially available 
siRNAs (si5815 and si5816, Ambion) against GLI1 in NEB 1 keratinocytes using a 
96 hours timepoint and 30 nM final concentration as a starting point. Cells were 
transfected, grown for 96 hours, fixed and stained with GLI1 RD antibody; no 
significative reduction in staining intensity with either antibody was observed in 
GLI1 silenced cells. Lack of reduction in fluorescence levels in GLI1 siRNA cells 
could be due to inefficient silencing, therefore in the subsequent experiments GLI1 
mRNA and protein levels were analysed before staining for GLI1. Since NEB1 
keratinocytes have been shown to be quite difficult to transfect (M. Rahman et al., 
unpublished data), Hacat keratinocytes and more easily transfectable prostate cancer 
cell lines were used. Levels of messenger RNA (mRNA) for Cyclophilin B and for 
GLI1 were measured in Hacat transfected cells. Cyclophilin B mRNA levels are 
reduced, indicating successful transfection; GLI1 mRNA levels appear reduced with 
siRNA 5815 but are increased with siRNA 5816. This preliminary result is 
unexpected and need to be further investigated to assess its reproducibility; in the 
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following experiments it would be useful to also analyse GLI1 silenced cells by 
immunofluorescence. 
In parallel to this work, similar validation was carried out to validate GLI2 Abcam 
antibody using two commercially available siRNA against GLI2, si5817 (Ambion) 
and si44 (Qiagen) (please see Materials and Methods sections for details). Conditions 
for GLI2 siRNA were optimised by Mr Sandeep Nadendla, who observed a reduction 
in the levels of endogenous GLI2 mRNA at 96 hours post-transfection in DU145 and 
PC-3 prostate cancer cells (Nadendla et al., 2011); he used a commercially available 
siRNA against GLI2 (si5817, Ambion) at 30 nM concentration. Du145 prostate 
cancer cells or Hacat keratinocytes were transfected with siRNAs at 30 nM final 
concentration and after 96 hours cells were harvested and analysed. GLI2 H-300 has 
been validated for immunofluorescence in a recent publication (Bishop et al., 2010) 
and was used as a positive control. Although Cyclophilin B mRNA levels appear 
decreased in both cell types, GLI2 levels are reduced by half in Du145 but only by 
about 15% in Hacat cells. Western Blot using the GLI2 H300 antibody revealed a 
decrease in GLI2 levels using si17, though GLI2 levels in the controls raise some 
concerns as they seem to vary in Du145 cells, while in Hacat keratinocytes GLI2 
levels in siGlo and siAmb are very similar to si17. No significative differences in 
staining intensity were observed by immunofluorescence in knockdown cells 
compared to control with either GLI2 H300 or GLI2 Abcam antibody. The 
experiment was repeated using a second siRNA against GLI2, si44, in addition to 
si17. Though Cyclophilin B mRNA levels are reduced in all cell types, GLI2 
silencing looks effective only in Du145, with si17 giving the best results; in Hacat 
keratinocytes GLI2 mRNA levels are not decrease with si17 and paradoxically 
increased by si44. No significative difference was detected by Western Blotting 
using the GLI2 H-300 antibody in either cell line. The lower molecular band detected 
in the LnCap and PC3 prostate cancer cell lines (included for comparison) is 
consistent with the hypothesis that different isoforms or differently cleaved products 
of GLI2 may be expressed by different cell types. No significative difference in 
staining intensity was observed with either antibody in silenced cells compared to 
controls. 
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In conclusion, although the transfection protocol seem to be working judging by the 
reduction in Cyclophilin B levels, it is difficult to see a correlation between qPCR,  
Western Blotting and staining data when cells are silenced for either GLI1 or GLI2.  
One possible explanation is the conditions used (30 nM concentration, 96 hours 
timepoint) has been shown to be optimal for prostate cells but may be not be ideal for 
skin cells, in which different concentrations and timepoints would need to be tested. 
From the data obtained so far, it cannot be concluded GLI1 RD and GLI2 Abcam 
antibodies are 100% specific as the siRNA results are inconclusive and no clear 
reduction of GLI expression could be consistently detected. 
4.3.10 Conclusions  
Previous studies that analysed either GLI1 or GLI2 levels in human BCC relied 
almost exclusively on measurement of messenger RNA: this is based on the 
assumption mRNA is always translated to yield a functional protein, not taking into 
account possible post-transcriptional regulation mechanisms. Moreover, in situ 
hybridization does not allow co-expression studies (in situ co-hybridization is not a 
widely used and established technique). Immunohistochemical double-staining was 
therefore chosen as a feasible approach to characterise GLI1 and GLI2 expression 
pattern at the protein level in a panel of human BCC samples.  
Antibodies against the GLI proteins have been made commercially available only 
recently; some of them presented reproducibility issues, as described in the previous 
sections, and were therefore dismissed. The GLI antibodies that worked consistently 
highlighted a widespread heterogeneity in the pattern of GLI1 and GLI2 expression: 
this result could be related to non-canonical activation of GLI proteins. In addition to 
that, difference in staining pattern using different GLI1 antibodies was observed: the 
different patterns could be due to different isoforms; an antibody will bind to a GLI1 
isoform only if the epitope is present (Fig 4.53). GLI1 isoforms had been described 
in vitro (by transfecting full length GLI1 into glioma cells) (Altaba, 1999; Stecca and 
Ruiz i Altaba, 2009), but not until very recently they have been reported in human 
tissues (including lung, kidney, pancreas, and ovary) (Shimokawa et al., 2008) and in 
human glioblastoma multiforme samples (Lo et al., 2009). As such, these isoforms 
were not taken into account when commercially available antibodies were designed, 
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and this could in part account for the heterogeneity and discrepancies observed in the 
BCC staining results. Based on currently available information, to detect all the 
known GLI1 isoforms, an antibody should be generated against an epitope between 
amino-acids position 231 – 515 (Fig 4.53), and none of the antibodies used in this 
thesis satisfy this condition. To take into account this unexpected novel complexity 
of the HH-GLI signalling, highlighted by the staining results, GLI1 isoforms 
expression pattern in BCC are to be identified using LCM at mRNA level, then 
isoform-specific antibodies could be generated to see if this is reflected in GLI1 – 
GLI2 protein expression.  Given these assumption, it is difficult to say which 
antibody is the best or more specific one for BCC staining. GLI antibodies used for 
staining in this thesis have already been employed in a number of publications, listed 
in Appendix IV. However, due to the heterogeneity of the staining results observed, 
(see section 4.3.9), we tried to validate the antibodies by using SMO inhibitors and 
subsequently by siRNA technology. Unfortunately, from the data obtained so far, it 
cannot be concluded that GLI1 RD and GLI2 Abcam antibodies are unequivocally 
specific as the results have been inconclusive and further troubleshooting could not 
be carried out due to time constraints. The reason for incorporating these 
inconclusive results is that they represent the starting point for further validation 
work. Since the lack of difference in fluorescence intensity observed upon treatment 
with SMO inhibitors could be due to the different aliquots of inhibitors used, a 
positive control for testing the efficacy of the inhibitors is needed. An ideal solution 
would be a cell line incorporating a GLI luciferase reporter, similar to the one 
employed by Taipale et al. (Taipale et al., 2000); if treatment of cells with 
cyclopamine significantly reduces GLI reporter activity we could be confident about 
the effectiveness of those inhibitors. An alternative approach for validating the 
antibodies is the use of short interfering RNA (siRNA) technology. We tested the 
cells by qPCR and by Western Blotting as methods to check siRNA efficacy in 
parallel with immunofluorescent cytochemistry analysis. No clear correlation 
between qPCR, Western Blotting and fluorescent staining data was observed, and 
further optimisation is needed, specifically testing different siRNA concentrations 
and timepoints for harvesting. Results obtained by other PhD students in the lab (J. 
Elliott et al. and M. Rahman et al., unpublished data) support GLI1 H-300 
 256 
specificity, while GLI2 H-300 was validated for use in immunofluorescence in a 
recent publication by Bishop et al. (Bishop et al., 2010).  
The majority of the immunochemistry work described in this thesis was carried out 
using frozen specimens and immunofluorescent detection. When 
immunofluorescence is used the structure of the tissue stained is not readily evident, 
for the purpose of clearly identifying tissue morphology histochemical staining 
(DAB) is a better technique. Immunofluorescent staining using GLI1 H-300 antibody 
revealed positive staining the stroma of some BCC samples: we speculated DAB 
staining would be more informative in trying to identify the location and cell type 
that stained positive for GLI1. In addition to this, we thought it was useful to test 
how these GLI antibodies performed in DAB staining (limited data was available in 
the literature as they had been made commercially available only recently). DAB 
staining is most widely used on wax-embedded tissues: we also could have taken 
advantage of the large number of wax embedded BCCs conserved in the Pathology 
archive and therefore address the problem of increasing the numbers of samples 
belonging to the rarer superficial and morphoeic BCC subtypes.  
GLI2 antibodies (GLI2 H-300 and GLI2 Abcam) gave similar staining patterns in 
normal skin using wax sections and DAB detection and frozen sections and 
immunofluorescent detection, while GLI1 antibodies presented some differences. 
GLI1 RD is more nuclear in wax sections (DAB and immunofluorescence) compared 
to frozen ones (immunofluorescence) though the reason for this is not clear; it may 
be GLI1 is predominantly nuclear in the wax sections analysed (one normal skin and 
two BCCs) or this could be due to the different techniques used. GLI1 H-300 
staining intensity is weaker in BCC wax sections (both by DAB and by 
immunofluorescence) when compared to immunofluorescent staining on frozen 
sections. Unfortunately GLI1 H-300 stromal staining was not evident in wax-
embedded BCCs, either by DAB or by immunofluorescence (two BCCs analysed); 
this could be due to the fact an antigen-retrieval step is required. We decided to 
continue with immunofluorescent staining in frozen BCC sections in parallel with 
experiments aimed at validating the antibodies used.  The main advantage of 
immunofluorescence is the possibility of performing double staining for two 
different proteins using different fluorochromes. This peculiarity was exploited in 
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double staining for GLI1 and SHH, aimed at investigating a possible paracrine 
mechanism of HH signalling and in double staining for GLI1 and GLI2, to analyse 
their pattern of expression. Paracrine HH signalling has been described in different 
kind of cancers (Yauch et al., 2008; Nolan-Stevaux et al., 2009; Tian et al., 2009) 
and has been linked to tumor progression, possibly by secretion of chemokines and 
growth-promoting factors. This was an attractive hypothesis to explain GLI1 staining 
in the stroma and could explain why BCC explants are difficult to culture in vitro 
once they are separated from the mesenchyme (Asada et al., 1992; Grando et al., 
1996). However, since only a very small minority of BCC samples were positive for 
SHH staining (section 4.2.11), this seems unlikely. An alternative hypothesis is non-
canonical activation of GLI proteins in the stroma by transforming growth factor beta 
(TGF) (Dennler et al., 2007; Dennler et al., 2009), which could be tested by staining 
or by using laser capture microdissection (LCM).  
Several studies have shown that the GLI1 and GLI2 transcription factors are 
frequently upregulated in Basal Cell Carcinoma and this is linked with inappropriate 
Hedgehog pathway activation (Dahmane et al., 1997; Green et al., 1998; Ghali et al., 
1999; Bonifas et al., 2001; Ikram et al., 2004; Hatta et al., 2005) However, the data 
presented here suggests the expression of GLI1 and GLI2 is considerably more 
complex than previously documented. For example, by specifically assessing protein 
expression using immunohistochemistry, it is apparent that there is a great deal of 
heterogeneity with regard to the level and pattern of GLI1 and GLI2 in human BCC. 
This is compounded by the fact that other research in the group has demonstrated 
that PTCH1 suppression (by siRNA) leads to an increase of GLI1 but not GLI2 
mRNA expression in human keratinocyte cell lines (M. Rahman et al., unpublished 
data). As such, it is not possible to state that BCCs have a uniform increase in 
epithelial GLI expression as a result of ligand-independent HH signalling that stems 
from a loss of PTCH1 function or a gain of SMO function. Therefore, the role of the 
GLI transcription factors in BCC biology requires further evaluation. Moreover, 
preliminary data also question the presence of a positive GLI1-GLI2 feedback loop 
in cultured keratinocytes, although how this relates to Basal Cell Carcinoma 


























5 Effect of over expression of constitutively active GLI2 in 
organotypics models 
 
5.1 Introduction  
Cells are usually grown completely submerged by culture media on treated plastic 
dishes or flasks. While this approach is suitable for the vast majority of cell types, a 
different type of culture condition has been found to be useful in studying cellular 
process that are peculiar to keratinocytes. The epidermis is composed of 
keratinocytes, and these cells are normally exposed to the air as they give rise to the 
upper layer of the skin; keratinocytes grown in submerged culture show signs of 
differentiation though they cannot fully differentiate, probably due to conditions that 
are quite different to an in vivo setting. Different models of skin equivalents in which 
cells are grown at the liquid-air interface have been proposed (Prunieras et al., 1983): 
the most widely used are de-epidermalised dermis (DED) and collagen or collagen-
matrigel gels. These models are useful in studying keratinocytes differentiation and 
also processes in which cell-extracellular matrix interactions are involved, such as 
migration and invasion. 
GLI2N is a constitutively active form of GLI2 lacking the amino-terminal repressor 
domain (Roessler et al., 2005). This truncated form of GLI2 (previously thought to 
be the whole protein) has been shown to be a more potent activator than the full-
length GLI2, and has been previously used in cancer studies. A stable-expressing 
GLI2N cell line has been previously generated and characterised in the lab (E. 
Pantazi et al., unpublished results): this has been achieved by transducing a GLI2N 
overexpression vector into the immortalized human keratinocytes cell line N/Tert-1 
as a GFP fusion protein. Human telomerase (h/TERT)-immortalised N/Tert-1 
keratinocytes have functional p53/p21WAF1/CIP1 and have been shown to retain normal 
epidermal keratinocyte differentiation in organotypic cultures (Dickson et al., 2000). 
Cross talk between the Hedgehog and WNT pathways has been suggested to be 
implicated in Basal Cell Carcinoma pathogenesis. In a mouse model of skin cancer, 
WNT signalling is necessary for the development of follicular hamartomas, a type of 
benign tumour associated with deregulated HH signalling (Yang et al., 2008). 
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Intriguingly, this suggests HH-WNT cross-talk could also be important for BCC 
development. Notably, upregulation of WNT-family proteins WNT5a, WNT7a and 
WNT11 has been detected in GLI2N cell line by qPCR (Pantazi E. et al, 
unpublished data). WNT5a, WNT7a and WNT11 are secreted ligands and had been 
shown to play a role in cell migration (Weeraratna et al., 2002; Ouko et al., 2004; 
Lyu and Joo, 2005; Kurayoshi et al., 2006; Pukrop et al., 2006). The aim of this 
chapter is to test if GLI2N keratinocytes have enhanced migratory and/or invasive 
properties as a consequence of upregulation of specific WNT proteins. We used two 
different organotypic model of human skin, de-epidermalised dermis (DED) and 
collagen-matrigel gels; both these models have been previously used to assess 
invasion (Akgul et al., 2005; Nystrom et al., 2005). BCCs are slow growing tumors, 
and it is not clear how they switch from being indolent to a more aggressive and 
metastatic phenotype: upregulation of migratory WNT proteins could be a possible 
mechanism that contributes to this transition. Would this proven to be true, the use of 




















5.2.1 De-epidermalised dermis (DED) organotypic model 
5.2.1.1 N/Tert-1 GLI2N keratinocytes grown on De-epidermalised dermis 
(DED) organotypic model (first experiment) 
 
N/Tert-1, N/Tert-1 GFP or N/Tert-1 GLI2N keratinocytes were plated on the 
papillary surface of DEDs containing human dermal fibroblasts on its reticular 
surface. These organotypic cultures were grown on a stainless-steel grid and supplied 
with medium from below for 18 days; the tissue was then fixed and processed as 
detailed in the Materials and Methods section. 
Hematoxylin and eosin staining of organotypic sections show how keratinocytes 
were able to attach and grown on the DED surface (Fig. 5.1 - 5.3). The staining of 
sections also highlighted how N/Tert-1 GLI2N keratinocytes invade into the dermis 
(Fig. 5.3), a characteristic feature not observed in N/Tert-1and N/Tert-1 GFP 
keratinocytes (Fig. 5.1 and 5.2). Keratinocytes seem to invade in small groups, 
sometimes resembling string-like structures; it is interesting to note this feature is 
also characteristic of Basal Cell Carcinomas belonging to the infiltrative / morphoeic 
subtype, which often present thin strands of basaloid cells extending into the 
underlying dermis. 
GLI2N keratinocytes also display a peculiar morphology and appear to be less 
differentiated than their N/Tert-1 and N/Tert-1 GFP counterparts as denoted by the 
lack of a visible cornified layer and, more generally, by the apparent lack of stratified 
organisation (Fig. 5.3). This observation is consistent with a previous report that 
shows how GLI2N overexpression is associated with repression of epidermal 
differentiation markers in vitro (Regl et al., 2004a). As a negative control N/Tert-1 
cells were seeded on a DED lacking fibroblasts on the reticular side; here 
keratinocytes seem to have attached but not able to fully differentiate (Fig. 5.4).  
These data suggest GLI2N overexpression in keratinocytes promotes invasion and 
disorganised differentiation in a DED organotypic model system. We therefore 





Figure 5.1: N/Tert-1 keratinocytes organotypic raft cultures 
Haematoxylin and eosin stained transverse section of organotypic cultures of keratinocytes 
on De-Epidermalized Dermis (DED). N/Tert-1 keratinocytes were plated on top of DED and 
grown at the air-liquid interface for 18 days. Representative images are shown (a, c), with 
respective higher magnification pictures shown on the right (b, d). Scale bar represents 200 










Figure 5.2: N/Tert-1 GFP keratinocytes organotypic raft cultures 
Haematoxylin and eosin stained transverse section of organotypic cultures of keratinocytes 
on De-Epidermalized Dermis (DED). N/Tert-1 GFP keratinocytes were plated on top of 
DED and grown at the air-liquid interface for 18 days. Representative images are shown (a, 
c), with respective higher magnification pictures shown on the right (b, d). Scale bar 










Figure 5.3: N/Tert-1 GLI2N keratinocytes organotypic raft cultures  
Haematoxylin and eosin stained transverse section of organotypic cultures of keratinocytes 
on De-Epidermalized Dermis (DED). N/Tert-1 GLI2N keratinocytes were plated on top of 
DED and grown at the air-liquid interface for 18 days. Representative images are shown (a, 
c), with respective higher magnification pictures shown on the right (b, d). Invading cells 
display a peculiar string-like morphology (e, f). Scale bar represents 200 µm in (a, c,) and 50 




Figure 5.4: N/Tert-1 keratinocytes organotypic raft cultures grown in the 
absence of fibroblasts (negative control) 
Haematoxylin and eosin stained transverse section of organotypic cultures of keratinocytes 
on De-Epidermalized Dermis (DED). N/Tert-1 keratinocytes were plated on top of DED and 
grown at the air-liquid interface for 18 days. As a negative control, no fibroblasts had been 
seeded in the reticular side of the de-epidermalised human skin (see text for details). 
Representative images are shown (a), with respective higher magnification pictures shown 














5.2.1.2 N/Tert-1 GLI2N keratinocytes grown on De-epidermalised dermis 
organotypic model (second experiment) 
N/Tert-1, N/Tert-1 GFP or N/Tert-1 GLI2N keratinocytes were plated on the 
papillary surface of DEDs containing human dermal fibroblasts on its reticular 
surface. These organotypic cultures were grown on a stainless-steel grid and fed with 
medium from below for 10 days; the tissue was then fixed and processed as detailed 
in the Materials and Methods. Hematoxylin and eosin staining of organotypic 
sections revealed how keratinocytes were able to attach and grown on the DED 
surface (Fig. 5.5); a thicker layer of epidermis was formed compared to the one 
observed in the previous experiment (Fig. 5.1 - 5.3): this could be due to a better 
ability to attach and / or proliferate.  
N/Tert-1 and N/Tert-1 GFP keratinocytes appear to have at least partly differentiated 
on DEDs (Fig. 5.5 a, b, c, d), while this feature seems less pronounced in the N/Tert-
1 GLI2N DED (Fig. 5.5 e, f). GLI2N keratinocytes also seem to have a more 
cuboidal shape compared to the more rounded N/Tert-1 and N/Tert-1 GFP; 
moreover, they seem to be less able to adhere to each other as judged by the wide 
crack-like gaps present in the epidermis structure (Fig. 5.5 e, f). 
No overt invasion into the underlying dermis was seen in the GLI2N keratinocytes 
DEDs, contrary to what was observed in the previous experiment. GLI2N 
keratinocytes may, however, have invasive potential that could be revealed by 
staining for component of the basement membrane. Enzymatic breakdown of the 
basement membrane is necessary for keratinocytes invasion into the underlying 
dermis. Collagen type IV and collagen type VII are primarily expressed in the 
basement zone underlying epithelia; if an aberrant pattern expression of these 
proteins would be seen in the GLI2N DEDs this would support the notion of a more 
invasive capacity. Of note, Hacat GLI2N collagen organotypics has been 
previously reported to show reduced epithelial differentiation and an abnormal 
basement membrane zone (Regl et al., 2004a; Regl et al., 2004b; Kump et al., 2008; 
Marsh et al., 2008; Snijders et al., 2009). 
Overexpression of GLI2N has also been associated with repression of epidermal 
differentiation markers in vitro (Regl et al., 2004a), and in both DEDs experiments 
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N/Tert-1 GLI2N keratinocytes appear morphologically less differentiated than their 
N/Tert-1 and N/Tert-1 GFP counterparts. To further extend this observation, DEDs 
sections have been stained with markers of epithelial differentiation (see section 
5.2.1.3). 
As a negative control N/Tert-1 GFP and N/Tert-1 GLI2N cells were also seeded on 
a DED lacking fibroblasts on the reticular side; surprisingly cells seem to have 
attached even in the absence of fibroblast, though keratinocytes seem to be less 
compact and gaps between cells are seen not only in the N/Tert-1 GLI2N DED but 






Figure 5.5: N-Tert-1, N/Tert-1 GFP and N/Tert-1 GLI2N keratinocytes in 
organotypic raft cultures 
Haematoxylin and eosin stained transverse section of organotypic cultures of keratinocytes 
on De-Epidermalized Dermis (DED). N-Tert-1 (a, b), N/Tert-1 GFP (c, d) or N/Tert-1 
GLI2N keratinocytes (e, f) were plated on top of DED and grown at the air-liquid interface 
for 10 days. Representative images are shown (a, c, e), with respective higher magnification 








Figure 5.6: N/Tert-1 GFP and N/Tert-1 GLI2N keratinocytes organotypic raft 
cultures grown in the absence of fibroblasts (negative control). 
Haematoxylin and eosin stained transverse section of organotypic cultures of keratinocytes 
on De-Epidermalized Dermis (DED). N/Tert-1 GFP (a, b) or N/Tert-1 GLI2N (c, d) 
keratinocytes were plated on top of DED and grown at the air-liquid interface for 10 days. 
As a negative control, no fibroblasts had been seeded in the reticular side of the de-
epidermalised human skin. Representative images are shown (a, c), with respective higher 











5.2.1.3 Keratin 1, Involucrin, Loricrin and E-cadherin expression pattern in N-
Tert-1, N/Tert-1 GFP and N/Tert-1 GLI2N De-epidermalised dermis 
(DED) organotypic model  
To analyse the effect of GLI2N overexpression on differentiation and adhesion, 
N/Tert-1, N/Tert-1 GFP and N/Tert-1 GLI2N wax-embedded DED sections were 
stained were stained with differentiation markers Keratin 1, Involucrin (two different 
antibodies), Loricrin and with an antibody against E-cadherin.  
N/Tert-1 and N/Tert-1 GFP DEDs were positive for Keratin 1 filaments (a marker of 
the spinous layer), while they appear to be absent in the N/Tert-1 GLI2N DED (Fig. 
5.7). Involucrin and Loricrin expression, both markers of keratinocyte terminal 
differentiation, are normally expressed in the suprabasal layers of stratified epithelia. 
Involucrin staining is observed in the upper layers of both N-Tert-1 and N/Tert-1 
GFP DEDs using antibody SY7 (Fig 5.8), while a similar pattern is absent in the 
N/Tert-1 GLI2N DED; the same result is obtained using a second Involucrin 
antibody (SY5)(Fig 5.9). Strong Loricrin staining is present in N/Tert-1 and also, 
albeit slightly less evident, in N/Tert-1 GFP DED, while it is rarely present in 
N/Tert-1 GLI2N DED (Fig 5.10).. E-cadherin is a component of adherence 
junctions which plays a crucial role in epithelial cell-cell adhesion; down-regulation 
of E-cadherin expression is linked with increased invasive potential of epithelial 
carcinomas. There seem to be no significative difference in E-cadherin expression in 













Figure 5.7: Keratin 1 staining of N-Tert-1, N/Tert-1 GFP and N/Tert-1 GLI2N 
keratinocytes in organotypic raft cultures  
N-Tert-1 (a), N/Tert-1 GFP (b) or N/Tert-1 GLI2N keratinocytes (c) wax-embedded DED 
sections were stained with an antibody against Keratin 1. Scale bar represents 50 µm. 
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Figure 5.8: Involucrin (SY7) staining of N-Tert-1, N/Tert-1 GFP and N/Tert-1 
GLI2N keratinocytes in organotypic raft cultures  
N-Tert-1 (a), N/Tert-1 GFP (b) or N/Tert-1 GLI2N keratinocytes (c) wax-embedded DED 
sections were stained with an antibody against Involucrin (SY7). Scale bar represents 50 µm. 
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Figure 5.9: Involucrin (SY5) staining of N-Tert-1, N/Tert-1 GFP and N/Tert-1 
GLI2N keratinocytes in organotypic raft cultures  
N-Tert-1 (a), N/Tert-1 GFP (b) or N/Tert-1 GLI2N keratinocytes (c) wax-embedded DED 




Figure 5.10: Loricrin staining of N-Tert-1, N/Tert-1 GFP and N/Tert-1 GLI2N 
keratinocytes in organotypic raft cultures  
N-Tert-1 (a), N/Tert-1 GFP (b) or N/Tert-1 GLI2N keratinocytes (c) wax-embedded DED 




Figure 5.11: E-cadherin staining of N-Tert-1, N/Tert-1 GFP and N/Tert-1 
GLI2N keratinocytes in organotypic raft cultures  
N-Tert-1 (a), N/Tert-1 GFP (b) or N/Tert-1 GLI2N keratinocytes (c) wax-embedded DED 
sections were stained with an antibody against E-cadherin. Scale bar represents 50 µm. 
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5.2.2 Collagen-matrigel gels organotypic model 
The dermis is composed for more than 70% of collagen, which is synthetised and 
organised by dermal fibroblasts; collagen or collagen-matrigel gels embedded with 
fibroblasts are widely used as a skin substitute to investigate cell invasion ((Akgul et 
al., 2005; Nystrom et al., 2005). Matrigel is an extracellular matrix preparation 
derived from a mouse sarcoma; this mixture includes high levels of collagen IV and 
laminin, as well as different growth factors, which make this composition more 
similar to the physiological in vivo setting.  
To test if GLI2N overexpression in N/Tert-1 keratinocytes has an effect on cell 
invasion, in N/Tert-1, N/Tert-1 GFP or N/Tert-1 GLI2N keratinocytes (5 × 105 cells 
for each type) were plated on top of collagen-matrigel gels (50%-50%) with 
incorporated fibroblasts (5 × 105 fibroblasts per gel). Organotypic cultures were 
grown on a stainless-steel grid and fed with medium from below for 14 days; the 
tissue was then fixed and processed (see Materials and Methods). Although these 
gels seem to present some technical issues (which it is reflected in their histology) 
probably due to the fact they tend to lose compactness during culture and are 
therefore difficult to separate from the grids in order to be processed, cells appear to 
have been able to attach and proliferate (Fig. 5.17). GLI2N keratinocytes seem to 
display increased invasion into the gel compared to N/Tert-1 and N/Tert-1 GFP 
keratinocytes, as shown by hematoxylin and eosin staining of organotypic sections 
(Fig. 5.17 c). This is similar to what we observed using the DED organotypic model, 
and consistent with data previously generated in the lab (Bahta A. et al., unpublished 
results). Notably, similar results have been recently obtained in the lab by Miss Eleni 
Pantazi using collagen-matrigel organotypics gels kept in culture for 13 days (E. 
Pantazi et al., unpublished results). This peculiar behavior of GLI2N keratinocytes 
in organotypic cultures is consistent with the hypothesis that GLI2 could activate 
















Figure 5.12: GLI2N overexpression in N/Tert-1 keratinocytes increases 
invasion in collagen-matrigel organotypic cultures 
Haematoxylin and eosin stained transverse section of organotypic cultures of keratinocytes 
on collagen-matrigel gels. N/Tert-1, N/Tert-1 GFP or N/Tert-1 GLI2N keratinocytes were 
plated on collagen-matrigel gels with incorporated fibroblasts and grown at the air-liquid 
interface for 14 days. (a) N/Tert-1 organotypic gel (b) N/Tert-1 GFP organotypic gel (c) 









5.2.3 Effect of over expression of constitutively active GLI2 in adhesion and 
migration assays 
As organotypics models take a long time to establish we tried to find a faster and 
more reproducible assay, and decided to investigate GLI2N invasive properties 
using adhesion and transwell migration assays. With these assays it is possible to test 
the effect of specific matrix macromolecules on cell migratory behavior and also to 
investigate effects of gene silencing using siRNA as well as drug treatment of cells. 
Collagen is the major constituent of the extracellular matrix, while fibronectin is a 
matrix glycoprotein involved in many cellular processes, including wound repair, 
cell migration and cell adhesion. For the cell adhesion assay serum-starved cells were 
plated in 96 wells pre-coated with either type I collagen (100 g / ml) or fibronectin 
(10 g / ml) and cultured for different amounts of time (1, 15, 30 or 45 minutes). 
Adherent cells were stained with crystal violet and then washed with SDS which 
leads to dye elution from stained cells into the supernatant. Cell adhesion can be 
quantified using a spectrophotometer by reading absorbance at 550 nm: the amount 
of dye is directly proportional to the number of cells. For the cell migration assay 
serum-starved cells were placed in the upper chamber of a transwell, on top of a 
permeable membrane pre-coated with either type I collagen (100 g / ml) or 
fibronectin (10 g / ml). After 4 hours cells that had not migrated were removed 
while migrated cells were fixed, stained with crystal violet and counted. 
N/Tert-1 GLI2N keratinocytes appear to be more adhesive compared to N/Tert-1 
GFP on collagen substrate (Fig. 5.13), while this difference is not so evident when 
fibronectin is used as a substrate (Fig. 5.14). No difference in adhesion is seen as 
expected in the BSA negative control (Fig. 5.15).  
In transwell assays more N/Tert-1 GFP cells migrate toward collagen compared to 
N/Tert-1 GLI2N cells (Fig. 5.16); this is also true for migration on fibronectin 
substrate (Fig. 5.17). Collagen appears to be in general a more attractive substrate as 
about double the number of cells are able to migrate toward collagen compared to 
fibronectin. As we initially hyphothesised N/Tert-1 GLI2N keratinocytes may be 
more migratory and therefore possibly less adhesive compared to N/Tert-1 GFP this 
was unexpected. Since GLI1 has been shown to enhanced cell–cell adhesion (Neill et 
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al., 2008), this could also potentially be true for GLI2N. Another possibility is this 
result is due to the fact these assays offer a quick but oversimplified way to test cells 
invasive properties compared to organotypics models; specifically, keratinocytes are 
seeded on artificial plastic substrates and left in culture for a short period of time. 
The invasive phenotype of keratinocytes observed in organotypics models could be 
due to complex paracrine interactions between the keratinocytes and the surrounding 













































Figure 5.13: Adhesion assay of N/Tert-1 GFP and N/Tert-1 GLIN 
keratinocytes in the presence of collagen substrate 
Cell adhesion assay performed on N/Tert-1 GFP and N/Tert-1 GLI2N keratinocytes. 10000 
cells were seeded on 96-well plates coated with collagen (100 g / ml) and incubated for 1, 
15, 30 or 45 minutes. The amount of adherent cells was determined by staining cells with 
crystal violet and measurements of absorbance values at 550 nm. Data are expressed as  











































Figure 5.14: Adhesion assay of N/Tert-1 GFP and N/Tert-1 GLIN 
keratinocytes in the presence of fibronectin substrate 
Cell adhesion assay performed on N/Tert-1 GFP and N/Tert-1 GLI2N keratinocytes. 10000 
cells were seeded on 96-well plates coated with fibronectin (10 g / ml) and incubated for 1, 
15, 30 or 45 minutes. The amount of adherent cells was determined by staining cells with 
crystal violet and measurements of absorbance values at 550 nm. Data are expressed as  











































Figure 5.15: Adhesion assay of N/Tert-1 GFP and N/Tert-1 GLIN 
keratinocytes in the presence of BSA (negative control) 
Cell adhesion assay performed on N/Tert-1 GFP and N/Tert-1 GLI2N keratinocytes. 10000 
cells were seeded on 96-well plates coated with BSA (Bovine Serum Albumin) as a negative 
control and incubated for 1, 15, 30 or 45 minutes. The amount of adherent cells was 
determined by staining cells with crystal violet and measurements of absorbance values at 
550 nm. Data are expressed as mean ± standard error, representative of four independent 






Figure 5.16: Migration assay of N/Tert-1 GFP and N/Tert-1 GLIN 
keratinocytes in the presence of collagen substrate 
Transwell migration assay performed on N/Tert-1 GFP and N/Tert-1 GLI2N keratinocytes. 
Cells were tested for their ability to migrate in a transwell assay in response to collagen (100 
g / ml) after being serum starved overnight (30000 cells per well). After 4 hours migrated 
cells were fixed, stained with crystal violet and counted. A statistically significative 
difference (P < 0.05) is present, with N/Tert-1 GLI2N cells less migratory than N/Tert-1 
GFP. Student’s t-Test (two-sample assuming equal variance) was used, data are expressed as 











Figure 5.17: Migration assay of N/Tert-1 GFP and N/Tert-1 GLIN 
keratinocytes in the presence of fibronectin substrate  
Transwell migration assay performed on N/Tert-1 GFP and N/Tert-1 GLI2N keratinocytes. 
Cells were tested for their ability to migrate in a transwell assay in response to fibronectin 
(10 g / ml) after being serum starved overnight (30000 cells per well). After 4 hours 
migrated cells were fixed, stained with crystal violet and counted. A statistically significative 
difference (P < 0.05) is present, with N/Tert-1 GLI2N cells less migratory than N/Tert-1 
GFP. Student’s t-Test (two-sample assuming equal variance) was used, data are expressed as 













5.3 Discussion  
Keratinocytes are routinely grown in submerged cultures on plastic substrates; 
although these conditions are fine for most biochemical studies, a more physiological 
relevant model is represented by organotypic skin cultures, in which keratinocytes 
are grown on dermal equivalents in a three-dimensional state. Exposure to air permits 
keratinocytes differentiation and culture with dermal components (e.g. fibroblasts) 
allows the study of epidermal - dermal interactions which are not possible in 
monolayer cell culture models. Organotypics models are also a useful tool in cancer 
studies as the process of cell invasion is a hallmark of malignancy. 
The two most widely used organotypic model of human skin are de-epidermalised 
dermis (DED) and collagen-matrigel gels. The DED method is based on the 
reconstruction of the epidermis using cadaveric skin in which keratinocytes are 
removed and replaced with the keratinocytes of interest; collagen or collagen-
matrigel gels are mixtures of dermal components on top of which keratinocytes are 
seeded; both models have been used to asses invasion (Akgul et al., 2005; Nystrom 
et al., 2005; Martins et al., 2009). The two major differences between these methods 
are fibroblasts location and the presence of an intact basement membrane. In DEDs 
fibroblasts are seeded on the reticular surface of the skin and lay at the bottom of the 
skin preparation, while in collagen-based preparations fibroblasts are embedded into 
the gel. In DEDs the original keratinocytes that compose the epidermis are removed 
but the underlying basement membrane is supposed to be kept intact: this is relevant 
as basement membrane breakdown is required in vivo for cells to invade into the 
dermis and this event is characteristic of malignant tumour behavior (Hagedorn et 
al., 1998). In collagen gels there is not a specific barrier to be crossed for cells to 
invade, although different basal membrane and extracellular matrix components such 
as laminin, collagen IV, proteoglycans and various growth factors are present in the 
preparation.  
Because of the cost and technical difficulties associated with the production of 
organotypic skin models, cell migration and invasion is also sometime studied using 
artificial substrates, such as Transwells. The Transwell chamber (or Boyden 
chamber) consists of two compartments separated by a membrane which the cells 
need to cross to move from the upper to the lower compartment. Cells seeded in the 
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top chamber migrate towards a chemotactic stimulus present in the lower chamber; 
the porous membrane can also be coated with Matrigel or with specific extracellular 
matrix components. After an appropriate incubation time the cells that have crossed 
the membrane can be fixed and counted. Transwell assays are often performed in 
conjunction with adhesion assay to investigate the adhesive properties of cells. In an 
adhesion assay cells are plated in wells coated with an extracellular protein of choice 
and incubated for different amounts of time. The amount of cells bound to the 
substrate is then evaluated by colorimetric measurement using crystal violet staining 
(see Materials and Methods).  
The invasive properties of N/Tert-1 keratinocytes expressing a constitutively active 
form of GLI2 (GLI2N) were tested using DEDs, collagen-matrigel gels and 
Transwell assay. Upregulation of WNT-family members proteins WNT5a, WNT7a 
and WNT11 has been detected by qPCR in GLI2N cell line (Pantazi E. et al, 
unpublished data). These secreted WNT proteins had been shown to play a role in 
cell migration; moreover, cross talk between the Hedgehog and WNT pathways has 
been suggested to be implicated in BCC pathogenesis (Yang et al., 2008). For these 
reasons, N/Tert-1 GLI2N keratinocytes behavior was tested in organotypics 
models.   
To determine the best conditions for keratinocytes growth on DEDs the epidermis 
was removed by either enzymatic treatment (Dispase) or by PBS soaking; 
additionally, the DEDs where fed using media with or without the RM+ supplement 
(please see section 2.2.1.1 'DED optimisation' in Materials and Methods). Primary 
human keratinocytes were used in this experiment, and four different DEDs were 
generated. Primary keratinocytes attached to the dermis and a stratum corneum is 
clearly visible when epidermis removed with PBS soaking and DED is fed with RM+ 
media (Fig. 2.1 d). When Dispase treatment was used no cell attachment was 
observed (Fig. 2.1 a, b); although it cannot be excluded further optimisation of 
enzyme concentration or time of incubation may give better results. Dispase, a 
bacterial neutral protease, is widely used to separate epidermis from the dermis as it 
cleaves fibronectin, type IV collagen and, to a lesser extent, type I collagen (Stenn et 
al., 1989); it is possible the condition used were too harsh and led to excessive 
degradation of these molecules on the dermis surface, impairing keratinocytes 
 287 
attachment. The effect of growth supplement media was also tested: some of the 
DEDs were fed with RM+ supplemented media (see Appendix I for details), while 
the others were fed with the same media but lacking the RM+ supplement. The RM+ 
supplement contains epidermal growth factor (EGF) and cholera toxin, which had 
been shown to stimulate the growth of human epidermal cells in culture but also to 
inhibit their terminal differentiation (Jensen et al., 1985). In the absence of RM+ 
supplement cells were not able to grow on a DEDs; as primary keratinocytes fully 
differentiate when the DED was fed with RM+ containing media (Fig. 2.1 d), 
concerns about terminal differentiation inhibition were dismissed. We therefore 
decided to use PBS soaking as the method for epidermis removal and feeding with 
RM+ media in the following experiments with N/Tert-1 cells; primary keratinocytes 
were also included as a positive control, to check if the conditions of the experiment 
would allow for stratification.  
DEDs experiments were characterised by a certain amount of variability in the 
results. In the first experiment N/Tert-1 GLI2N keratinocytes appear less 
differentiated and more invasive compared to N/Tert-1 GFP and untransduced 
N/Tert-1 (Fig. 5.1-5.3). 
The appearance of well defined clear stratum corneum is not observed when N/Tert-
1 keratinocytes were used, although they display some evidence of stratification; 
therefore they are able to differentiate, albeit to a lesser extent compared to primary 
keratinocytes. N/Tert-1 cells are human epidermal keratinocytes immortalised by 
ectopic expression of the telomerase catalytic subunit hTERT (Dickson et al., 2000); 
it could he hyphothesised this alters the balance between proliferation and 
differentiation which is needed for the formation of a stratified epithelia.  
The less differentiated phenotype of GLI2N cells (Fig. 5.3) is consistent with GLI2 
role in repressing genes associated with epidermal differentiation (Regl et al., 2004a) 
and has also been observed in collagen-based organotypic models using an inducible 
GLI2 Hacat cell line (Snijders A. et al., 2009).  
Subsequent DEDs experiments were hindered by yeast contaminations or by lack or 
incomplete adhesion of keratinocytes to the dermal substrate (data not shown).  
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A further DEDs experiment was then performed using the optimised conditions, 
namely epidermis removal by PBS soaking and DED feeding with RM+ media. In 
order to avoid possible contamination problems these DEDs were kept in culture for 
a shorter amount of time (10 days compared to 18; the right time to harvest was 
determined by observing the appearance of the stratum corneum on the primary 
keratinocytes DEDs as it can be usually seen by naked eye). 
Keratinocytes were able to attach to the DED surface and generated a thicker layer of 
epidermis compared to the one observed in the previous successful experiment (Fig. 
5.5). Though no clear stratum corneum was observed, N/Tert-1 and N/Tert-1 GFP 
keratinocytes appear to have at least partly differentiated on DEDs (Fig. 5.5 a, b, c, 
d), while this feature is almost absent in the N/Tert-1 GLI2N DED (Fig. 5.5 e, f). In 
addition to that, GLI2N keratinocytes are not able to adhere properly to each other, 
as highlighted by the cracks and gaps present in the epidermis structure (Fig. 5.5 e, 
f). The cuboidal morphology of GLI2N cells also suggest they may be less 
differentiated, which is in accordance with previously published studies (Regl et al., 
2004a); this seems to confirmed by the fact markers of epithelial differentiation 
appear to be lacking in the N/Tert-1 GLI2N DED compared to N/Tert-1 and 
N/Tert-1 GFP DEDs (Fig 5.7 – 5.10).  
Although no overt invasion into the underlying dermis was seen in the GLI2N 
keratinocytes DEDs (contrary to what was observed in the previous experiment), it 
cannot be excluded GLI2N may have invasive potential. No difference in E-
cadherin staining was observed in N/Tert-1 GLI2N DED compared to N/Tert-1 and 
N/Tert-1 GFP DEDs (Fig 5.11), which seems to argue against this hypothesis. Since 
GLI1 has been shown to enhanced cell–cell adhesion (Neill et al., 2008), this could 
also potentially be true for GLI2N. Analysis of more invasion more markers will be 
required to ascern the impact of this event on GLI2N cells invasive potential, as 
well as further confirmation of the invasive phenotype in future DEDs experiments. 
In the paper published by Snijders et al., collagen organotypics models of Hacat 
GLI2N keratinocytes were also shown to display an altered basement zone with 
abnormal expression of adhesion proteins, like integrin 4, which normally anchor 
the epithelia to the underlying dermis. To investigate this possibility, DEDs sections 
 289 
could be stained for markers of the basement membrane. Keratinocytes are linked to 
each other via the desmosomes and basal keratinocytes are anchored to the basement 
membrane and extracellular matrix through hemidesmosomes. In hemidesmosomes 
the 64 integrin receptor expressed on basal keratinocytes interacts with laminin 5 
and fibronectin present in the basement membrane. During malignant tumour 
progression cells begin to invade the surrounding tissues; keratinocytes acquire the 
ability to cross the basement membrane barrier by promoting extracellular matrix 
degradation and activating cell motility mechanisms (Liotta and Kohn, 2001). 
Degradation of basement membranes components is achieved by secretion of matrix 
metalloproteinase (MMP), while extracellular-matrix signals cause cytoskeletal 
changes that favour migratory movement. Abnormal distribution of collagen type IV 
and collagen type VII, primarily expressed in the basement zone, or an aberrant 
pattern of integrin and laminin expression would support the notion of GLI2N 
keratinocytes more invasive capacity.  
To further investigate invasion I also used a collagen-matrigel assay. In a preliminary 
experiment, GLI2N keratinocytes appeared to be more invasive compared to empty 
vector and untransduced controls in collagen-matrigel gel (Fig. 5.12), in line with 
data previously generated in the lab (Bahta A. et al., unpublished results) and 
recently confirmed by Miss Eleni Pantazi (E. Pantazi et al., unpublished results).  
The adhesive and migratory properties of N/Tert-1 GLI2N were also tested using 
adhesion and Transwell assays, respectively. Collagen and fibronectin were chosen 
as ligands for coating as interaction between these extracellular matrix components 
and integrins present on the cell surface is known to regulate adhesion between the 
basal keratinocytes and the dermis; these interactions are altered during cancer 
progression resulting in invasion into the underlying dermis.  
N/Tert-1 GLI2N keratinocytes seem to be more adhesive compared to N/Tert-1 
GFP on collagen substrate (Fig. 5.13), while this difference is not so evident on 
fibronectin (Fig. 5.14). No difference in adhesion is seen as expected in the BSA 
negative control (Fig. 5.15). On collagen substrate, the difference in adhesion 
between GLI2N and GFP control cells is most evident after 30 minutes, where 
GLI2N keratinocytes appear to be roughly 50% more adhesive compared to GFP. 
At 45 minutes this difference in adhesion is reduced; to determine if enhanced GLI2 
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adhesion is a transient effect it would be useful to repeat the experiment including 
also later timepoints.   
For Transwell assay, keratinocytes were serum-starved for 24 hours and then seeded 
in the upper chamber of Transwells whose porous membranes had been previously 
coated with either collagen or fibronectin; the lower chamber was filled with serum-
containing media as a chemoattractant. This system investigates the ability of cells to 
migrate toward serum and helps determine if a specific stimulus (e.g. collagen or 
fibronectin) facilitate this process. This migration assay differs from an invasion 
assay where the porous membrane is coated with Matrigel, assessing the ability of 
cells to degrade Matrigel components in order to access into the lower chamber.  
Since only a minor fraction of the cells seeded were able to migrate into the lower 
chamber in migration assays, invasion assays were not performed because they are 
characterised by more stringent conditions.  
In transwell migration N/Tert-1 GLI2N keratinocytes appear less migratory than 
N/Tert-1 GFP on both collagen and fibronectin substrate (Fig. 5.16 - 5.17). 
Specifically, N/Tert-1 GLI2N keratinocytes are about 40% less migratory than 
N/Tert-1 GFP on collagen and about 60% less migratory on fibronectin. Collagen 
seems to be a more attractive substrate as about double the number of keratinocytes 
are able to migrate toward collagen compared to fibronectin. 
In the initial hypothesis, N/Tert-1 GLI2N keratinocytes were postulated to be more 
migratory and consequently less adhesive compared to N/Tert-1 GFP: therefore the 
results of adhesive and Transwell migration assays were unexpected. However, it 
should be noted these assays are conducted on a short timescale (45 minutes for 
adhesion and 4 hours for Transwells) compared to organotypics models, and they 
rely on artificial plastic-based substrates. These assays offer a quick but possibly 
oversimplified way to test cells migratory behavior compared to organotypics 
models. The invasive phenotype of keratinocytes observed in organotypics models 
(should it be confirmed by staining with components of the basement membrane) 
could be due to complex paracrine interactions between the keratinocytes and the 
surrounding mesenchyme that cannot be recreated using these assays. In conclusion, 
judging by their morphology and by staining with differentiation markers antibodies, 
GLI2N keratinocytes appear de-differentiated compared to controls; the invasive 
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phenotype of GLI2N keratinocytes, on the other hand, is less reproducible. Both 
observations will require a more in-depth analysis for validation. DEDs and 
collagen-matrigel organotypics sections could be stained for markers of cell invasion 
such as MMPs, and the expression of collagen type IV and collagen type VII could 
be analysed to validate the hypothesis of GLI2N keratinocytes more invasive 
capacity. Preliminary experiments with differentiation markers antibodies suggest 
GLI2N keratinocytes are impaired in their ability to differentiate. 
Organotypic skin cultures allow the study of differentiation, cell-matrix interactions 
and keratinocyte-fibroblast paracrine communications; all of these processes are 
relevant for cancer studies. Basal cell carcinoma are often composed of  a large 
amount of undifferentiated cells (Miller, 1995) and GLI2 overexpression has been 
shown to repress genes involved in epidermal differentiation (Regl et al., 2004a), 
which appears to be confirmed from the organotypic experiments described in this 
thesis. Invasion is a hallmark of malignancy, and organotypics models could be 
useful in understanding the molecular mechanisms that are responsible for the 
conversion of BCCs, which are usually indolent tumours, into metastatic ones. 
Should the invasive phenotype of GLI2 keratinocytes be confirmed, it could be 
analysed if cell invasion is dependent on WNT pathway activation by treating the 
organotypics with WNT pathway inhibitors (e.g. Dkk1, which inhibits canonical 
WNT pathway, or sFRPs which inhibit both WNT canonical and non-canonical 
pathways). Alternatively, siRNA technology could be employed to silence specific 
WNTs in GLI2 keratinocytes before they are seeded onto the organotypic rafts, to 
see if this is sufficient to abolish the invasive phenotype. The results of these 
experiments could lead to the use of antagonists of WNT pathways as a treatment for 
BCCs. GLI1 expression has been detected by immunofluorescence in a number of 
BCC samples using the GLI1 H-300 antibody (see section 4.2.2) and also in BCC 
fibroblasts derived from tumour explants (J. Elliott et al., unpublished results). 
Although it is not yet clear whether GLI1 activation in the stroma occurs via a 
canonical or non-canonical mechanism, it could be hyphothesised this event has an 
influence on the tumour development. GLI1 overexpressing fibroblasts could be 
compared to normal dermal fibroblasts in organotypic models to see if mesenchymal 
GLI1 expression promotes keratinocytes invasion into the dermis (e.g. via 
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6 Discussion and future research  
 
The transcription factors GLI1 and GLI2 have been proposed to be part of a positive 
feedback mechanism in BCC, although the exact sequence of Gli gene activation is 
not clear (Regl et al., 2002). It should be noted the complete GLI2 mRNA sequence  
was only discovered in 2005 (Roessler et al., 2005) and these experiments rely on an 
amino-terminal deleted version of GLI2 (GLI2N) which has been shown to be a 
more potent transcriptional activator than full-length GLI2. Based upon the kinetics 
of transcript expression compared to the induction of PTCH1 mRNA, GLI1 is 
thought to be a direct transcriptional target of GLI2N in human keratinocytes; 
moreover GLI2N binds to the human GLI1 promoter (Bonifas et al., 2001; Ikram et 
al., 2004). On the other hand, GLI2 appears to be an indirect target of GLI1 (Regl et 
al., 2002). In contrast to these studies based on mRNA levels, previous work in the 
lab and my preliminary experiments suggest that endogenous GLI2 protein is 
suppressed by ectopic GLI1 in both prostate cells and immortalised keratinocytes. 
Moreover, another project in the group (M. Rahman et al., unpublished results) has 
shown that PTCH1 suppression in NEB1 human keratinocytes leads to an increase of 
GLI1 but not GLI2 mRNA  
In order to address the biological relevance of these results, expression of GLI1 and 
GLI2 was analysed ex-vivo by immunostaining of normal human skin and Basal Cell 
Carcinoma samples. Immunohistochemical analysis of BCCs revealed areas of co-
expression of GLI factors as well as areas where one protein appears to be more 
abundant than the other. A great deal of heterogeneity in the expression pattern of 
GLI1 and GLI2 in human BCCs was observed, which questions the presence of a 
positive GLI1-GLI2 feedback loop. This also seems to question the hypothesis that 
BCCs have a uniform increase in epithelial GLI expression as a result of ligand-
independent HH signalling and other factors should be taking into account, including 
the recently described negative feedback loop of PTCH1 on GLI1 (Rahnama et al., 
2006) and the role played by non-canonical activation of GLI factors such as TGF 
and activated K-Ras (Dennler et al., 2007; Dennler et al., 2009; (Nolan-Stevaux et 
al., 2009). 
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Rahnama et al. co-transfection experiments in HEK-293 cells have shown how GLI1 
activation of a luciferase reporter construct is inhibited by PTCH1: this effect is 
observed with amounts of PTCH1 at least three times higher than that of GLI1. GLI1 
expression is also inhibited by PTCH1 in transfection experiments using 3T3 cells: 
this effect is observed even in the presence of cyclopamine and moreover PTCH1 C-
terminal region (proposed to play a role in HH/SMO signalling) is dispensable for 
this inhibition (Rahnama et al., 2006). It can therefore be hypothesized mutated 
PTCH1 has lost its ability to repress SMO (resulting in GLI factor activation) but has 
retained its SMO-independent ability to inhibit GLI1. 
A possible model to describe the complex network of interactions that governs GLI 
expression (both canonical and non-canonical) in vivo and how this could be 
modeled in vitro is outlined in Figure 6.1. For simplicity, it is assumed all positive 
and negative inputs that regulate GLI expression assume the same importance; it is 
however likely that some may have stronger effects than others.  
When PTCH1 is mutated in vivo (Fig. 6.1 a), GLI1 is positively upregulated via 
SMO, the GLI2 positive feedback and potentially non-canonical signalling (e.g. via 
TGF or KRAS) and negatively regulated by PTCH1; similarly, GLI2 is upregulated 
via SMO and non-canonical signalling and downregulated by GLI1.  
On the other hand, when PTCH1 is wild-type in vivo (Fig. 6.1 c), GLI1 is 
upregulated only by GLI2 and non-canonical signalling and downregulated by 
PTCH1; GLI2 is activated via non-canonical signalling and downregulated by GLI1. 
This could help explain the different intensities and heterogeneity observed in 
immunohistochemistry staining for GLI factors (see Chapter 4), as they would be the 
sum of canonical and non-canonical induction if PTCH1 is mutated but only due to 
non-canonical signalling if PTCH1 were wild-type. To further explore this 
hypothesis in future studies it would be useful to determine PTCH1 mutational status 
of the BCC before immunohistochemical analysis to see if there is a correlation 
between PTCH1 status and GLI proteins expression.  
GLI1 overexpression in N/Tert-1 human keratinocytes has been used as an in vitro 
model of BCCs (Fig. 6.1 b); it should be noted in this system levels of GLI1 may be 
significantly different from physiological levels. From the literature it is known how 
transfection of 3T3 cells with ectopic GLI1 induces endogenous expression of the 
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GLI1 mRNA, though this event is inhibited when GLI1 is co-transfected with 
PTCH1. This highlights how PTCH1 could also affect GLI1 endogenous gene 
expression (Rahnama et al., 2006). Therefore, it is conceivable ectopic GLI1 may 
lead to a significative increase of PTCH1 levels that in turn would reduce 
endogenous GLI1 expression. 
Ectopic GLI2N overexpression in vitro (Fig. 6.1 d) may also suppress endogenous 
GLI1 due to high levels of PTCH1 induction but this is counteracted by the fact that 
GLI2N directly activates GLI1; it remains to be determined if the putative new 
GLI2 isoforms / degradation products  (see Chapter 3) are also able to induce GLI1. 
To explore this possibility, they would need to be first isolated, cloned and then 
overexpressed in human keratinocytes.  
A more relevant model of BCCs development could be the NEB1 PTCH1 
knockdown cell line which has been recently created in the lab by Mr Muhammad 
Rahman (Fig. 6.1 e). In this system, GLI1 mRNA expression is increased but this is 
not associated with an increase of GLI2 expression. This further supports the 
hypothesis that GLI2 may be activated by HH-independent mechanisms in BCC. In 
addition, the role of SMO in regulating GLI1 expression is unclear and currently 
under investigation by Mr Muhammad Rahman.  
Regulation of GLI factor expression appears to be more complex than previously 
thought. Laser Capture Microdissection technology could be used to assess the 
mRNA levels of GLI and their isoforms in BCCs samples. To help dissect the 
contribution of canonical vs. non-canonical signalling on GLI factors expression 
PTCH1 knockdown cells could be exposed to TGF or treated with SMO inhibitors.  
GLI1 staining intensity appeared sometime reduced in the BCCs compared to the 
overlying epidermis; in some samples its intensity is also reduced in palisading cells 
compared to the centre of the tumour (see Chapter 4). Although this could be 
surprising as GLI deregulation is commonly associated with malignancy, a reduction 
in the level of GLI1 may be necessary to overcome GLI-promoted cell to cell 
adhesion and the acquisition of invasive properties (Neill et al., 2008). Furthermore, 
GLI2-responsive genes downregulation appears to be required for invasion of Hacat 
cells in a skin organotypic model (Snijders et al., 2009). Also stemming from this 
observation it would be interesting to confirm the invasive phenotype of N/Tert-1 
 297 
GLI2N keratinocytes in organotypics models (see Chapter 5) and see if there is a 









































Figure 6.1: Diagram illustrating the potential complex network of interactions 
that governs GLI expression (both canonical and non-canonical) in vivo and in 
vitro  





Ectopic overexpression of GLI1 or GLI2N in mouse models result in BCC-like 
tumour formation, while in the experiment I performed levels of GLI in human 
BCCs appear heterogeneous seem to bear no correlation with tumour subtype and 
aggressiveness. This could be due to the differences between human and mice 
tumorigenesis processes; moreover, overexpression of GLI1 or GLI2N could 
significantly alter the balance and feedback loops previously described (Fig. 6.1).  
The majority of sporadic BCCs display loss of heterozigosity for PTCH1 and this 
historically suggested its inactivation is an important step in BCC formation (Gailani 
et al., 1996a). However, an extensive analysis of PTCH1 mutation status in 
correlation with GLI levels in BCCs has not yet been reported. Different PTCH1 
mutations have been described, which may affect one portion of the protein but leave 
the rest intact. A role for PTCH1 in cell cycle control by means of interaction with 
cyclin B has been reported (Barnes et al., 2001); moreover, PTCH1 has been recently 
shown to reduce GLI1 levels, and this function appears not to involve HHG 
signalling (Rahnama et al., 2006). It is therefore conceivable that PTCH1 could exert 
some of its activity even if mutated, in addition to the fact that in case of PTCH1 
heterozygosity one allele would be fully functional.  
Different mouse models of BCCs have been proposed, although it is still debated 
how closely these mice tumours can mimic their human counterparts. PTCH1 
knockout mice (Ptch1 -/-) are not viable; PTCH1 (Ptch1 +/-) heterozygous mice 
develop tumours similar to human trichoblastomas, and only if irradiated with U.V. 
or ionizing radiation develop tumours histologically similar to BCCs (Aszterbaum et 
al., 1999; Mancuso et al., 2004); the issue of how these radiation can influence 
tumour development has never been fully addressed. Ectopic expression of GLI1 or 
GLI2N in mouse skin result in BCC-like tumour formation, though in this case the 
physiological relevance of the high levels of GLI that are induced should be taken 
into account, as well as the differences between the human and the mice 
tumorigenesis processes. As discussed above, overexpression of GLI1 or GLI2N 
could significantly perturb feedback loops (Fig. 6.1). Moreover, only a small fraction 
of human BCCs is caused by gain-of-function mutation in GLI factors (Khavari, 
2006). Anti-SMO inhibitors appear to be effective in reducing mouse BCC tumour 
growth but have limited success in humans (Williams et al., 2003; Tang et al., 2011). 
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This may be due to the fact that in mouse BCC-like tumours the canonical HH 
signalling may be prevalent and series of complex positive and negative loops 
present in human tumours may be lost. 
In summary, this project has shown that GLI regulation and expression are more 
complex than previous studies have suggested and that further research is necessary 
in order to provide better therapies for the treatment of BCCs and possibly other 
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Appendix I  
Standard buffers, reagents and cell culture media 
 
Phosphate buffered saline (PBS) 
Dulbecco's PBS (1x) without Ca2+ & Mg2+ (PAA Laboratories GmbH, Austria) 
 
Trypsin 
Trypsin – EDTA (0.05% - 0.02% in D-PBS), (PAA Laboratories GmbH, Austria) 
 
Versene  
Versene 0.2 g/l (0.53 mM) in an isotonically buffered saline (Invitrogen, U.K.) 
 
DMEM Medium 
DMEM (PAA Laboratories GmbH, Austria) 
10% (v/v) fetal bovine serum (FBS) (Biosera, U.K.)  
1% (v/v) L-glutamine (PAA Laboratories GmbH, Austria) 
1% (v/v) Penicillin / Streptomycin (PAA Laboratories GmbH, Austria) 
 
RM+ Medium 
DMEM: Ham’s F12 3:1 (v/v), custom made, (PAA Laboratories GmbH, Austria)  
10% (v/v) fetal bovine serum (FBS) (Biosera, U.K.)  
1% (v/v) L-glutamine (PAA Laboratories GmbH, Austria) 
1% (v/v) Penicillin / Streptomycin (PAA Laboratories GmbH, Austria) 
RM+ supplement: 
5 g/ml insulin 
0.4 g/ml hydrocortisone 
10 ng/ml epidermal growth factor  
5 g/ml transferrin 
20 pM L-lyothyronine.  
1 nM cholera toxin (Sigma, U.K.) 
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Keratinocyte Growth Medium (KGM) 
-MEM (Lonza, U.K.)  
10% (v/v) fetal bovine serum (FBS) (Lonza, U.K.)  
1% (v/v) L-glutamine (PAA Laboratories GmbH, Austria) 
1% (v/v) Penicillin / Streptomycin (PAA Laboratories GmbH, Austria) 
1.8 X 10-4  M adenine 
1 X 10-10 M cholera toxin 
5 g/ml insulin 
0.4 g/ml hydrocortisone 
10 ng/ml epidermal growth factor  
(Sigma, U.K.) 
 
RPMI 1640 Medium 
RPMI 1640 (PAA Laboratories GmbH, Austria) 
10% (v/v) fetal bovine serum (FBS) (Biosera, U.K.)  
1% (v/v) L-glutamine (PAA Laboratories GmbH, Austria) 
1% (v/v) Penicillin / Streptomycin (PAA Laboratories GmbH, Austria) 
 
Freezing solution 
10% (v/v) Dimethyl sulphoxide (DMSO)(BDH Laboratory Supplies, U.K.) in fetal 
bovine serum (FBS) (Biosera, U.K.)  
 
Antibiotics and Antimycotics 
Antibiotic-Antimycotic Solution  
(Penicillin 10.000 U/ml, Streptomycin Sulphate 10 mg/ml, Amphotericin B 25 µg/ml 
in 0.9 % NaCl) (PAA Laboratories GmbH, Austria). 
Solution was diluted 1:100 in sterile PBS prior to use 
 
Paraformaldehyde fixative solution (PFA, 1L) pH 7.6 
1.3 M Paraformaldehyde (40 g), equal to 4% Paraformaldehyde (w/v)  
Paraformaldehyde powder and one pellet of NaOH was dissolved into 1L of distilled 
water on heating plate at 60°C with a magnetic stirrer; the pH of the solution was 
then adjusted to 7.6, followed by filtering and storing at +4°C 
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Scott’s tap water (10x, 1L) 
811 mM Magnesium sulphate (200g) 
238 mM Sodium bicarbonate (20g) 
All the reagents were dissolved in 1L of distilled water 
 
Tris buffered saline (TBS, 10x, 1L) pH 7.4 
200 mM Tris base (24.2 g) 
1.37 M  NaCl (80 g) 
All the reagents were dissolved in 1L of distilled water, pH adjusted to 7.4 and stored 
at RT. TBS-T solution was made by adding 0.1% (v/v) Tween 20 (BDH Laboratory 
Supplies, U.K.) to 1x TBS. 
 
TAE (tris-acetate ethylediaminetetra-acetic acid) buffer (50 x, 1L) 
2M Tris base (242 g) 
57.1 ml glacial acetic acid 
100 mL of 0.5 M EDTA (pH 8.0) 
 
Buffers for Western Blotting 
Running buffer (10x, 1L) 
0.25 M Tris base (30.29g)  
1.92 M Glycine (144.13g) 
1 % SDS (10g)  
All the reagents were dissolved in 1L of distilled water and stored at RT 
 
Transfer Buffer (10x, 1L)  
0.25 M Tris base (30.29g) 
1.92 M Glycine (144.13g) 
10 % (v/v) Methanol 
Tris base and Glycine were dissolved in 1L of distilled water and stored at RT;  
Transfer buffer 1x was prepared before use by diluting this solution 1:10 and adding 
10 % (v/v) Methanol. 
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10 % Polyacrylamide Resolving Gel for SDS Gel Electrophoresis (10ml) 
4.0 ml dd H2O 
3.3 ml Acrylamide/Bis acrylamide mix (30% (w/v) Acrylamide / 0.8% (w/v) Bis 
acrylamide) 
2.5 ml 1.5 mM Tris HCl (pH 8.8)  
100 l 10% SDS 
100 l 10% Ammonium persulfate 
4 l Tetramethylethylenediamine (TEMED)  
 
5 % Polyacrylamide Stacking Gel for SDS Gel Electrophoresis (5ml) 
3.4 ml dd H2O 
830 l Acrylamide/Bis acrylamide mix (30% (w/v) Acrylamide / 0.8% (w/v) Bis 
acrylamide) 
630 l 1.5 mM Tris HCl (pH 6.8)  
50 l 10% SDS 
50 l 10% Ammonium persulfate 
5 l Tetramethylethylenediamine (TEMED)  
 
Lysis buffer boiling buffer A  
50 mM Tris HCl pH 8.0 
2% (w/v) SDS 
1 mM Na3OV4 
 
Laemmli buffer (2x) 
0.1 M Tris HCl pH 6.8 
0.2 M Dithiothreitol (DTT) 
4 % (w/v) SDS  
0.2% (w/v) Bromophenol blue 






Loading buffer (5x)  
125 mM Tris HCl pH 6.8  
5% (v/v) -mercaptoethanol  
20 % (v/v) Glycerol  
4% (w/v) SDS  
0.02% (w/v) Bromophenol blue 
 
Tris buffered saline (TBS, 10x, 1L) pH 7.4 
200 mM Tris base (24.2g) 
1.37 M  NaCl (80g) 
All the reagents were dissolved in 1L of distilled water, pH adjusted to 7.4 and stored 
at RT. TBS-T solution was made by adding 0.1%-0.5% (v/v) Tween 20 (BDH 





















Appendix II  
List of RNAi sequences 
 
 
GLI1 si15 (s5815, Silencer Select siRNA, Ambion, U.K.) 
Sequence 5’ 3’ 
Sense            CCAACUUGCCCAAUCACAAtt 
Antisense     UUGUGAUUGGGCAAGUUGGgt 
 
GLI1 si16 (s5816, Silencer Select siRNA, Ambion, U.K.) 
Sequence 5’ 3’ 
Sense           AGACAGUGCAUGGUCCUGAtt 
Antisense    UCAGGACCAUGCACUGUCUtg 
 
GLI2  si17 (s5817, Silencer Select siRNA, Ambion, U.K.) 
Sequence 5’ 3’ 
Sense           GGUUCGAGCAGCUCAAGAAtt 
Antisense    UUCUUGAGCUGCUCGAACCgg 
 
GLI2 si44 (FlexiTube siRNA SI00074844, Qiagen, U.K.) 
 
Sequence 5’ 3’ 
Target Sequence  TAGGGAGCATTTGGGTTTGAA 
 
Sense                     GGGAGCAUUUGGGUUUGAATT 









Appendix III  





GLI1 H-300 antibody (GLI1 (H-300) sc-20687, Santa Cruz) was raised against a 
recombinant protein corresponding to amino acids 781-1080 of GLI1 of human 
origin (acc# P08151). 
The epitope of GLI1 C-18 (GLI1 (C-18) sc-6152, Santa Cruz) maps within the range 
of amino acids1056-1106 of GLI1 of human origin (acc# P08151). 
The GLI1 RD (MAB3324, R&D Systems) antibody was produced using a 
hybridoma elicited from a rat immunized with purified, E. coli-derived recombinant 
human GLI1 (aa 1 - 234; Accession # P08151).  
The epitope of GLI1 N-16 (GLI1 (N-16) sc-6153, Santa Cruz) maps within the range 
of  amino   acid 1-50 of GLI1 of human origin (acc# P08151); this antibody was not 
used in this thesis but in a publication by Ghali L et al. (Ghali et al., 1999) that 
investigated GLI1 expression in BCCs by immunohistochemistry; GLI1 N-16 
antigen is underlined.  
GLSGPPF CHQANLMSGP HSYGPARETN  
 
Amino acids positions 34 to 74 deleted in the tGLI1 isoform described by Lo (Lo et 
al., 2009). 
GLSGPPF CHQANLMSGP HSYGPARETN SCTEGPLFSS PRSAVKLTKK RALSISPLSD 
ASLDLQTVIR TSPSSLVAFI NSRCTSPGGS YGHLSIGTMS 
 
Amino acids positions 34 to 130 deleted in the GLI1N isoform described by 
Shimokawa (Shimokawa et al., 2008); first and last three amino acids are highlighted 
in red and bold font. 
MFNSMTPPPI SSYGEPCCLR PLPSQGAPSV GTEGLSGPPF CHQANLMSGP HSYGPARETN          
SCTEGPLFSS PRSAVKLTKK RALSISPLSD ASLDLQTVIR TSPSSLVAFI NSRCTSPGGS  
YGHLSIGTMS PSLGFPAQMN HQKGPSPSFG VQPCGPHDSA RGGMIPHPQS RGPFPTCQLK  
SELDMLVGKC REEPLEGDMS SPNSTGIQDP LLGMLDGRED LEREEKREPE S  
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Amino acids positions 1 to 231 deleted in the GLI1N isoform described by Altaba 
(Altaba, 1999) first and last three amino acids are highlighted in blue and bold font. 
RGLKLP SLSHTGTTVS RRVGPPVSLE RRSSSSSSIS SAYTVSRRSS LASPFPPGSP 
PENGASSLPG LMPAQHYLLR ARYASARGGG TSPTAASSLD RIGGLPMPPW RSRAEYPGYN 
PNAGVTRRAS DPAQAADRPA PARVQRFKSL GCVHTPPTVA GGGQNFDPYL PTSVYSPQPP 
SITENAAMDA RGLQEEPEVG TSMVGSGLNP YMDFPPTDTL GYGGPEGAAA EPYGARGPGS 
LPLGPGPPTN YGPNPCPQQA SYPDPTQETW GEFPSHSGLY PGPKALGGTY SQCPRLEHYG 
QVQVKPEQGC PVGSDSTGLA PCLNAHPSEG PPHPQPLFSH YPQPSPPQYL QSGPYTQPPP 
DYLPSEPRPC LDFDSPTHST GQLKAQLVCN YVQSQQELLW EGGGREDAPA QEPSYQSPKF 
LGGSQVSPSR AKAPVNTYGP GFGPNLPNHK SGSYPTPSPC HENFVVGANR ASHRAAAPPR 
LLPPLPTCYG PLKVGGTNPS CGHPEVGRLG GGPALYPPPE GQVCNPLDSL DLDNTQLDFV 
AILDEPQGLS PPPSHDQRGS SGHTPPPSGP PNMAVGNMSV LLRSLPGETE FLNSSA 
 
Amino acids positions 515 to 1106 deleted in the GLI1C isoform described by 





P08151 (GLI1_HUMAN), UniProtKB/Swiss-Prot 
 
        10         20         30         40         50         60  
MFNSMTPPPI SSYGEPCCLR PLPSQGAPSV GTEGLSGPPF CHQANLMSGP HSYGPARETN  
 
        70         80         90        100        110        120  
SCTEGPLFSS PRSAVKLTKK RALSISPLSD ASLDLQTVIR TSPSSLVAFI NSRCTSPGGS  
 
       130        140        150        160        170        180  
YGHLSIGTMS PSLGFPAQMN HQKGPSPSFG VQPCGPHDSA RGGMIPHPQS RGPFPTCQLK  
 
       190        200        210        220        230        240  
SELDMLVGKC REEPLEGDMS SPNSTGIQDP LLGMLDGRED LEREEKREPE SVYETDCRWD  
 
       250        260        270        280        290        300  
GCSQEFDSQE QLVHHINSEH IHGERKEFVC HWGGCSRELR PFKAQYMLVV HMRRHTGEKP  
 
       310        320        330        340        350        360  
HKCTFEGCRK SYSRLENLKT HLRSHTGEKP YMCEHEGCSK AFSNASDRAK HQNRTHSNEK  
 
       370        380        390        400        410        420  
PYVCKLPGCT KRYTDPSSLR KHVKTVHGPD AHVTKRHRGD GPLPRAPSIS TVEPKREREG  
 
       430        440        450        460        470        480  
GPIREESRLT VPEGAMKPQP SPGAQSSCSS DHSPAGSAAN TDSGVEMTGN AGGSTEDLSS  
 
       490        500        510        520        530        540  
LDEGPCIAGT GLSTLRRLEN LRLDQLHQLR PIGTRGLKLP SLSHTGTTVS RRVGPPVSLE  
 
       550        560        570        580        590        600  
RRSSSSSSIS SAYTVSRRSS LASPFPPGSP PENGASSLPG LMPAQHYLLR ARYASARGGG  
 330 
 
       610        620        630        640        650        660  
TSPTAASSLD RIGGLPMPPW RSRAEYPGYN PNAGVTRRAS DPAQAADRPA PARVQRFKSL  
 
       670        680        690        700        710        720  
GCVHTPPTVA GGGQNFDPYL PTSVYSPQPP SITENAAMDA RGLQEEPEVG TSMVGSGLNP  
 
       730        740        750        760        770        780  
YMDFPPTDTL GYGGPEGAAA EPYGARGPGS LPLGPGPPTN YGPNPCPQQA SYPDPTQETW  
 
       790        800        810        820        830        840  
GEFPSHSGLY PGPKALGGTY SQCPRLEHYG QVQVKPEQGC PVGSDSTGLA PCLNAHPSEG  
 
       850        860        870        880        890        900  
PPHPQPLFSH YPQPSPPQYL QSGPYTQPPP DYLPSEPRPC LDFDSPTHST GQLKAQLVCN  
 
       910        920        930        940        950        960  
YVQSQQELLW EGGGREDAPA QEPSYQSPKF LGGSQVSPSR AKAPVNTYGP GFGPNLPNHK  
 
       970        980        990       1000       1010       1020  
SGSYPTPSPC HENFVVGANR ASHRAAAPPR LLPPLPTCYG PLKVGGTNPS CGHPEVGRLG  
 
      1030       1040       1050       1060       1070       1080  
GGPALYPPPE GQVCNPLDSL DLDNTQLDFV AILDEPQGLS PPPSHDQRGS SGHTPPPSGP  
 
      1090       1100  





The four known different isoforms of human GLI2 alpha (), beta (), gamma () 
and delta () originate from the combinations of two independent alternative splicing 
sites (Tanimura et al., 1998). The region between amminoacids positions 394 and 
410 is missing in the beta () and delta () isoforms (highlighted in purple) while the 
region between amminoacids positions 1158 and 1586 is missing in the gamma () 
and delta () isoforms (highlighted in green) (according to UniProtKB/Swiss-Prot 
database, GLI2_HUMAN, accession number P10070).  
GLI2 H-300 (GLI2 (H-300): sc-28674, Santa Cruz) recognises an epitope 
corresponding to amino acids 841-1140 of GLI2 of human origin. Reactivity is 
expected with all isoforms of this protein. 
GLI2 Abcam (GLI2, ab26056, Abcam) was produced using a synthetic peptide 
derived from a region between residues 272 - 321 of human GLI2 (600 to 649 
according to GLI2 sequence after the discovery of the N-terminal domain (Roessler 




P10070 (GLI2_HUMAN), UniProtKB/Swiss-Prot  
        10         20         30         40         50         60  
METSASATAS EKQEAKSGIL EAAGFPDPGK KASPLVVAAA AAAAVAAQGV PQHLLPPFHA  
 
        70         80         90        100        110        120  
PLPIDMRHQE GRYHYEPHSV HGVHGPPALS GSPVISDISL IRLSPHPAGP GESPFNAPHP  
 
       130        140        150        160        170        180  
YVNPHMEHYL RSVHSSPTLS MISAARGLSP ADVAQEHLKE RGLFGLPAPG TTPSDYYHQM  
 
       190        200        210        220        230        240  
TLVAGHPAPY GDLLMQSGGA ASAPHLHDYL NPVDVSRFSS PRVTPRLSRK RALSISPLSD  
 
       250        260        270        280        290        300  
ASLDLQRMIR TSPNSLVAYI NNSRSSSAAS GSYGHLSAGA LSPAFTFPHP INPVAYQQIL  
 
       310        320        330        340        350        360  
SQQRGLGSAF GHTPPLIQPS PTFLAQQPMA LTSINATPTQ LSSSSNCLSD TNQNKQSSES  
 
       370        380        390        400        410        420  
AVSSTVNPVA IHKRSKVKTE PEGLRPASPL ALTQGQVSGH GSCGCALPLS QEQLADLKED  
 
       430        440        450        460        470        480  
LDRDDCKQEA EVVIYETNCH WEDCTKEYDT QEQLVHHINN EHIHGEKKEF VCRWQACTRE  
 
       490        500        510        520        530        540  
QKPFKAQYML VVHMRRHTGE KPHKCTFEGC SKAYSRLENL KTHLRSHTGE KPYVCEHEGC  
 
       550        560        570        580        590        600  
NKAFSNASDR AKHQNRTHSN EKPYICKIPG CTKRYTDPSS LRKHVKTVHG PDAHVTKKQR  
 
       610        620        630        640        650        660  
NDVHLRTPLL KENGDSEAGT EPGGPESTEA SSTSQAVEDC LHVRAIKTES SGLCQSSPGA  
 
       670        680        690        700        710        720  
QSSCSSEPSP LGSAPNNDSG VEMPGTGPGS LGDLTALDDT PPGADTSALA APSAGGLQLR  
 
       730        740        750        760        770        780  
KHMTTMHRFE QLKKEKLKSL KDSCSWAGPT PHTRNTKLPP LPGSGSILEN FSGSGGGGPA  
 
       790        800        810        820        830        840  
GLLPNPRLSE LSASEVTMLS QLQERRDSST STVSSAYTVS RRSSGISPYF SSRRSSEASP  
 
       850        860        870        880        890        900  
LGAGRPHNAS SADSYDPIST DASRRSSEAS QCSGGSGLLN LTPAQQYSLR AKYAAATGGP  
 
       910        920        930        940        950        960  
PPTPLPGLER MSLRTRLALL DAPERTLPAG CPRPLGPRRG SDGPTYGHGH AGAAPAFPHE  
 
       970        980        990       1000       1010       1020  
APGGGARRAS DPVRRPDALS LPRVQRFHST HNVNPGPLPP CADRRGLRLQ SHPSTDGGLA  
 
      1030       1040       1050       1060       1070       1080  
RGAYSPRPPS ISENVAMEAV AAGVDGAGPE ADLGLPEDDL VLPDDVVQYI KAHASGALDE  
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      1090       1100       1110       1120       1130       1140  
GTGQVYPTES TGFSDNPRLP SPGLHGQRRM VAADSNVGPS APMLGGCQLG FGAPSSLNKN  
 
      1150       1160       1170       1180       1190       1200  
NMPVQWNEVS SGTVDALASQ VKPPPFPQGN LAVVQQKPAF GQYPGYSPQG LQASPGGLDS  
 
      1210       1220       1230       1240       1250       1260  
TQPHLQPRSG APSQGIPRVN YMQQLRQPVA GSQCPGMTTT MSPHACYGQV HPQLSPSTIS  
 
      1270       1280       1290       1300       1310       1320  
GALNQFPQSC SNMPAKPGHL GHPQQTEVAP DPTTMGNRHR ELGVPDSALA GVPPPHPVQS  
 
      1330       1340       1350       1360       1370       1380  
YPQQSHHLAA SMSQEGYHQV PSLLPARQPG FMEPQTGPMG VATAGFGLVQ PRPPLEPSPT  
 
      1390       1400       1410       1420       1430       1440  
GRHRGVRAVQ QQLAYARATG HAMAAMPSSQ ETAEAVPKGA MGNMGSVPPQ PPPQDAGGAP  
 
      1450       1460       1470       1480       1490       1500  
DHSMLYYYGQ IHMYEQDGGL ENLGSCQVMR SQPPQPQACQ DSIQPQPLPS PGVNQVSSTV  
 
      1510       1520       1530       1540       1550       1560  
DSQLLEAPQI DFDAIMDDGD HSSLFSGALS PSLLHSLSQN SSRLTTPRNS LTLPSIPAGI  
 
      1570       1580  
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